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Introduction 1
1. Introduction 
 
Interest in vaccinating against tumours dates back to the 1890s when the New York 
surgeon William B Coley successfully treated some patients with sarcoma using bacterial 
toxins.  In 1909, Paul Ehrlich successfully carried out immunisation in animals with 
tumour cells and suggested that tumours occur in humans at a high frequency but are kept 
under control by the immune system.  Whereas this hypothesis may be simplistic, it has 
become clear that some tumour cells can indeed be distinguished from corresponding 
normal cells due to the existence of so-called tumour-associated antigens (TAAs) that are 
sometimes recognised by the immune system (reviewed in Dermime S et al. 2002).  Once 
the immune system perceives an antigen as dangerous, it is likely that this antigen and 
antigen-bearing particles or cells will be completely eliminated by the immune system with 
high specificity and efficiency.  Therefore, in situations where well-established approaches 
such as surgery, radiation therapy and chemotherapy fail to help cancer patients, 
therapeutic approaches based on activated effectors of the immune system have the 
potential to be effective alternatives.  
 
 
1.1 Tumour immunoediting and immunosurveillance 
 
The concept that the immune system can recognise and destroy tumour cells was 
postulated in the cancer immunosurveillance hypothesis proposed by Burnet and Thomas 
(Burnet FM 1970).  The logical prediction from this hypothesis is that immunodeficient or 
immunosuppressed humans should show a greater incidence of cancer.  Based on long-
term studies of transplant patients and individuals with primary immunodeficiencies, it is 
clear that some of the observed higher risk was due to the development of tumours of viral 
origin (Penn I 1999).  However, greater risk ratios have also been documented for a broad 
range of tumours with no apparent viral etiology.  For example, one study showed 
increased occurrence of colon, lung, bladder, kidney, ureter and endocrine tumours, as well 
as malignant melanomas, in patients who received renal transplants, as compared with the 
general population (Birkeland SA et al. 1995).  These and other data strongly indicate that 
individuals with severe deficits of immunity indeed have a higher probability of 
developing a variety of cancers.  In addition to supporting epidemiological studies, there is 
accumulating evidence showing a positive correlation between the presence of 
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lymphocytes in a tumour and increased patient survival.  Based on statistical observations 
in one study, it was calculated that patients with tumour infiltrating lymphocytes (TILs) in 
their melanomas survived one and a half to three-fold longer than patients with no TILs 
(Clemente CG et al. 1996). 
 
During tumour formation, the immune system may select for tumour variants that are 
better suited to survive in an immunologically intact environment, very much like it does 
with viruses, bacteria and parasites.  This was demonstrated in many murine studies when 
the repassaging of transplantable tumours through immunocompetent hosts resulted in the 
generation of tumour variants with reduced immunogenicity (Uyttenhove C et al. 1980, 
Urban JL et al. 1982).  In other words, tumours are imprinted by the immunologic 
environment in which they form.  This imprinting process can often result in the generation 
of tumours that are better able to fight the tumour-suppressing actions of the immune 
system by eliminating tumour cells of high immunogenicity but leaving behind tumour 
variants of reduced immunogenicity or that have acquired other mechanisms to evade or 
suppress immune attack.  These cells have a better chance of surviving in the 
immunocompetent host.  The alterations that must occur during the immunologic sculpting 
of a developing tumour are probably facilitated by the genetic instability of tumours 
(Lengauer C et al. 1998).   
 
The term "immunosurveillance" only implies protection of the host by the immune system 
at the earliest stages of cellular transformation.  Therefore, it does not accurately describe 
the whole process.  As argued above, immunosurveillance also shapes tumours by exerting 
selective pressure.  To more appropriately describe the dual host-protecting and tumour-
sculpting actions of the immune system, Dunn and colleagues proposed the use of a 
broader term "cancer immunoediting" (Dunn GP et al. 2002).  They envisage 
immunoediting as a result of processes in three phases: elimination, equilibrium and escape 
(Figure 1.1). 
 
The elimination phase encompasses the original concept of immunosurveillance.  If the 
developing tumour is successfully deleted, this phase represents the complete editing 
process without progression to the subsequent phases.  It is possible that, at first, tumour 
cells appear immunologically as healthy growing cells that do not send out danger signals 
to activate the immune system because they express neither microbial immune-recognition 
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patterns nor release distress signals to alarm the innate immune cells (Restifo NP et al. 
2002).  However, once tumours reach a certain size, they begin to disrupt surrounding 
tissue and stress signals are triggered when oxygen and nutrient supplies become scarce.  
Metabolic disturbance, generation of reactive oxygen species such as OH and H2O2, up-
regulation of protective stress factors and death by apoptosis or necrosis may all act as 
alarm signals to recruit and activate local innate immune cells such as dendritic cells 
(DCs), macrophages, neutrophils and natural killer (NK) cells.  They in turn activate T-
cells to mount an adaptive immune response against tumours.  In the equilibrium phase, all 
tumour cell variants that have survived the elimination phase enter a dynamic equilibrium 
with the host immune system.  Actions of the immune system are the driving force behind 
the Darwinian selective pressure which is enough to contain but not fully extinguish a 
tumour mass containing many genetically unstable and rapidly mutating malignant cells.  
Many of the original escape variants of tumour cells are destroyed, but new variants 
appear, carrying different mutations that provide them with increased resistance to the 
immune attack.  It is likely that equilibrium is the longest of the three phases and may 
occur over a period of many years.  In the escape phase, surviving tumour variants that 
have acquired insensitivity to immunologic detection and/or elimination through genetic or 
Figure 1.1  The three Es of cancer immunoediting. Cancer immunoediting encompasses 
three phases.  Elimination corresponds to immunosurveillance (A).  Equilibrium represents 
the process by which the immune system iteratively selects and/or promotes the generation 
of tumour cell variants with increasing capacities to survive the immune attack (B).  Escape 
is the process wherein the immunologically sculpted tumour expands in an uncontrolled 
manner in the immunocompetent host (C).  In A and B, developing tumour cells (blue), 
tumour cell variants (red) and underlying stroma and nontransformed cells (gray) are 
shown.  In C, additional tumour variants (orange) that have formed as a result of the 
equilibrium process are shown. Different lymphocyte populations are as marked. The small 
orange circles represent cytokines and the white flashes represent cytotoxic activity of 
lymphocytes against tumour cells.  Abbreviations: NK (natural killer) cells, NKT (natural 
killer T-) cells.  From Dunn GP et al. 2002. 
B.  Equlibrium C.  Escape A.  Elimination 
Genetic instability/tumour heterogeneity 
Immune selection 
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epigenetic changes begin to expand in an uncontrolled manner.  Only then does the 
malignant disease become clinically observable. 
 
 
1.2 Tumour immune escape 
 
One study estimated that an average malignancy contains more than 1×104 mutations 
(Stoler DL et al. 1999).  Genomic instability creates a vast repertoire of tumour cells.  
Some of these cells are selected for survival simply because they possess certain genetic 
and epigenetic traits that are beneficial in their environment.  In other words, already 
existing genes and environmental factors define the passive process of natural selection.  
Terms such as "tumour evasion" or "tumour escape" are not really appropriate because 
evasion and escape imply active acquisition of certain characteristics or phenotypes, rather 
than the differential propagation of tumour subclones.  The same concept also applies to 
tumour growth in the face of an effective immunotherapy. 
 
In a review by Khong and Restifo, the following tumour immune mechanisms are 
described (Khong HT and Restifo NP 2002): 
• loss or down-regulation of HLA (human leukocyte antigen) class I molecules 
• loss of tumour antigens and immunodominance 
• defective death receptor signalling 
• apoptosis of activated T-cells 
• lack of co-stimulation 
• secretion of immunosuppressive cytokines 
• presentation of altered peptide ligands 
 
Decreased or absent HLA class I expression is associated with invasive and metastatic 
lesions.  Seven major altered HLA class I phenotypes have been defined in tumour tissues 
(Garrido F et al. 1997) and are explained in Figure 1.2: 
1. HLA class I total loss.  This phenotype is characterised by the absence of any HLA 
class I molecule expression in tumour cells.  One of the mechanisms that underlie this 
loss involves mutations in one copy of the β2-microglobulin gene in combination with 
the loss of heterozygosity involving the second allele (Hicklin DJ et al. 1998).  Other 
detected causes include defects in HLA genes and in the antigen processing and 
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transport pathway, such as down-regulation of proteasome subunits, LMP-2 and LMP-
7 (low molecular protein 2 and 7), and peptide transporters, TAP-1 and TAP-2 
(transporter associated with antigen processing 1 and 2).  However, in these situations, 
HLA class I can often be up-regulated by treatment with IFN-γ (interferon γ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. HLA haplotype loss.  Tumours can partially or entirely lose one of the two HLA 
haplotypes due to the loss of heterozygosity on chromosome 6 (Ramal LM et al. 
2000). 
3. HLA A, B or C locus product down-regulation.  This altered phenotype is found 
when both products of HLA-A, B or C loci are coordinately down-regulated.  It is 
more frequent with HLA-A and HLA-B molecules and is associated with changes in 
Figure 1.2  Normal and altered HLA class I phenotypes found in human 
tumours. Normal cells express 6 HLA class I alleles (2 HLA-A, 2 HLA-B and 2 
HLA-C). HLA molecules can be totally or partially absent from tumour cells 
(Phenotype I-Phenotype V). In addition, tumour cells may not respond to IFNs 
(Phenotype VI), or may also express aberrant HLA-E molecules in cells with low 
expression of HLA-A, B, or C classical class I antigens (Phenotype VII). 
Abbreviations: HLA (human leukocyte antigen), IFN (interferon).  From Garcia-
Lora A et al. 2003. 
Normal HLA Class I Phenotype
Altered HLA Class I Phenotype
Phenotype 1 
HLA total loss 
Phenotype 2 
HLA haplotype loss 
Phenotype 3 
HLA locus loss 
Phenotype 4 
HLA allelic loss 
Phenotype 5 
Compound phenotype 
Phenotype 6 
Unresponsiveness to 
IFNs
Phenotype 7 
HLA class Ia +/- 
HLA class Ib +
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the transcription of corresponding genes (Soong TW and Hui KM 1992, Peltenburg 
LT and Schrier PI 1994). 
4. HLA allelic loss.  This alteration is defined as the loss of a single HLA class I allele 
that might be the result of point mutations, partial deletions of HLA class I genes, 
chromosomal breakage or somatic recombination (Brady CS et al. 2000). 
5. Compound phenotypes.  To produce this phenotype a combination of two different 
alterations is required, for example, an HLA haplotype loss and HLA-B and C locus 
down-regulation (combination of phenotypes II and III).  The final result is a tumour 
cell expressing only one HLA class I allele. 
6. Unresponsiveness to interferons (IFNs).  Some tumour cells express basal levels of 
HLA class I molecules but have lost their capacity to up-regulate them in response to 
different cytokines, including IFN-α and IFN-γ. 
7. Downregulation of classical HLA-A, B and C molecules and appearance of HLA-
E molecules.  HLA-E has a strong NK inhibition capacity (Marin R et al. 2003). 
 
A direct consequence of partial or complete loss of HLA class I is increased susceptibility 
to NK cell lysis.  Therefore, in addition to mechanisms helping them escape recognition by 
T-cells, tumours need other modifications that render them resistant to attacks by NK cells.  
A tumour escape strategy that has yet to be demonstrated in humans is down-regulation of 
MICA and MICB (MHC class I chain-related genes A and B) ligands that engage NK 
activating receptors (Garrido F and Algarra I 2001).  It is also possible that strong NK 
stimulatory factors, such as IL-12 (interleukin 12), IL-2, IL-15 and type 1 IFNs, usually 
associated with microbial infection, are not readily available in tumour environments.  
Furthermore, cross-talk between DCs and NK cells might be lacking (Gerosa F et al. 
2002).  In some situations, tumours may produce immunomodulatory cytokines, such as 
TGF-β (transforming growth factor β) or MIF (macrophage migration inhibitory factor), 
which can directly inhibit NK cell activation and function.   
 
Most examples of antigen down-regulation by tumour cells come from the melanoma 
model.  In one study, cells were observed to be melanoma antigen A (Melan-A)-positive in 
100% of stage I lesions but in only 75% of stage IV lesions (Hofbauer GF et al. 1998).  
Decreased antigen expression was also found in non-regressing tumours after peptide 
vaccination.  Expression of gp100 (glycoprotein 100) was reduced from 47% to 32% after 
vaccination with the corresponding peptide (Lee KH et al. 1998).  In most cases, the exact 
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mechanisms that control down-regulation of tumour antigens are not known.  Nevertheless, 
propagation of such antigen loss variants may be facilitated by epitope immunodominance.  
The theory of immunodominance, as it relates to tumour escape, predicts that antigen-loss 
variants within a tumour are shielded from immune pressure.  Parental tumour cells 
carrying an immunodominant epitope serve as a distraction, thereby diverting attention 
from the tumour variants.  Once the parental cells are eliminated, a new hierarchy is 
established among the variant subpopulations, and formerly immunorecessive epitopes 
become dominant (Schreiber H et al. 2002). 
 
Fas and TRAIL (TNF-related apoptosis inducing ligand) receptors are called "death 
receptors" because they contain cytoplasmic sequences described as "death domains" that 
are essential for the transmission of apoptotic signals into the cells.  Defective death 
receptor signalling is another mechanism that may contribute to the survival and 
proliferation of tumour cells.  Various tumours express cFLIP (cellular FLICE-inhibitory 
protein), a protein that inhibits the Fas signalling pathway, thereby, rendering tumour cells 
resistant to death receptor-mediated apoptosis (Irmler M et al. 1997).  Down-regulation or 
loss of Fas expression and loss of expression of all TRAIL receptors may also contribute to 
tumour escape (Hersey P and Zhang XD 2001 Nature Rev Cancer, Shin MS et al. 1999). 
 
One of the more controversial mechanisms of tumour escape is the expression of death 
receptor ligands by tumour cells.  A variety of cancer cells express the functional Fas 
ligand, which induces apoptosis of Fas-susceptible target cells, possibly including T-cells 
(Niehans GA et al. 1997).  TRAIL is also expressed by tumours but there is no convincing 
evidence that it plays a major role in the induction of tumour-specific T-cell apoptosis in 
human cancers (Cappello P et al. 2002).  
 
Unlike professional antigen-presenting cells (APCs), most cells, including tumour cells, do 
not express the co-stimulatory molecules, CD80, CD86, CD40 and CD70.  Presentation of 
tumour antigens to T-cells without appropriate co-stimulation may lead to T-cell anergy.  
Lack of expression of co-stimulatory molecules by tumours may also hinder optimal NK 
cell activation via CD28 and CD27 pathways (Takeda K et al. 2000).  In an experimental 
setting, insertion of genes encoding CD80, CD86 or both into tumours generally increased 
the immunogenicity of those tumours but did not necessarily lead to regression (Chen L et 
al. 1994). 
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Tumour cells produce a variety of cytokines and chemokines that can negatively effect 
maturation and function of immune cells.  Most tumours secrete VEGF (vascular 
endothelial growth factor), a cytokine known to inhibit DC differentiation and maturation 
(Toi M et al. 1996, Oyama T et al. 1998).  Increased concentrations of IL-10 are frequently 
detected in the sera of cancer patients.  This cytokine negatively influences DCs at many 
different levels.  It interferes with DC differentiation from stem cell precursors 
(Girolomoni G 1997), compromises DC maturation and function, inhibits antigen 
presentation, IL-12 production and induction of T-helper type 1 responses by DCs (Sharma 
S et al. 1999), helps induce spontaneous DC apoptosis (Ludewig B et al. 1995) and 
enhances DC susceptibility to NK cell lysis (Carbone E et al. 1999).  IL-10 has also been 
shown to down-regulate TAP-1 and TAP-2 peptide transporters and HLA class I/II 
antigen-presenting molecules in tumour cells thereby protecting them from recognition by 
cytotoxic T-lymphocytes (CTLs).  The proinflammatory factor PGE2 (prostaglandin E2) is 
another cytokine expressed by tumours.  It increases the production of IL-10 by 
lymphocytes and macrophages and inhibits IL-12 production by macrophages (Huang M et 
al. 1998).  High concentrations of TGF-β are also frequently found in cancer patients and 
are associated with disease progression and poor responses to immunotherapy.  It inhibits 
the activation, proliferation and activity of lymphocytes (Fontana A et al. 1989). 
 
It has been proven that each individual T-cell receptor (TCR) is a very adaptable and 
finely-tunable structure that differentially responds not only to one but to a broad spectrum 
of presented peptides.  Analogues of immunogenic peptides which maintain the capacity to 
induce some TCR-mediated responses, despite changed amino acids at TCR contact sites, 
are defined as altered peptide ligands (APLs).  In vitro studies have shown that APLs can 
mediate a number of different outcomes in interacting T-cells, ranging from anergy and 
partial activation to increased and optimal activation (Kersh GJ and Allen PM 1996 
Nature).  Peptides mimicking the Melan-A immunogenic epitope can be found in peptide 
fractions eluted from melanoma cells and are thought to induce antigen-specific T-cell 
anergy (Rivoltini L et al. 2002).  
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1.3 Dendritic cells 
 
DCs (Figure 1.3) represent a heterogenous cell population, residing in most peripheral 
tissues, particularly at sites of interface with the environment, i.e. skin and mucosae.  Here, 
they represent 1-2% of the total cell number (Banchereau J et al. 2000).  In the absence of 
ongoing inflammatory and immune responses, DCs constitutively patrol through the blood, 
peripheral tissues, lymph and lymphoid organs.  In peripheral tissues, DCs capture self and 
non-self antigens via specific receptors (FcR, MMR, DEC-205 and DC-SIGN), and various 
mechanisms, such as macropinocytosis, receptor-mediated endocytosis and phagocytosis.  
Internalised antigens are then processed into proteolytic peptides, and these peptides are 
loaded onto major histocompatibility complex (MHC) class I and class II molecules.  The 
steps of antigen uptake, degradation, loading and transfer to the cell surface as part of a 
peptide-MHC (pMHC) complex are altogether called "antigen processing and 
presentation".  Constitutively, however, peripheral DCs present antigens quite inefficiently.  
Signals from pathogens or pathogen-induced tissue damage, often referred to as "danger 
signals", induce DCs to enter a developmental program, called "maturation", which 
transforms DCs into efficient antigen-presenting cells and T-cell activators.  Danger 
signals are generated when receptors on DCs recognise an encounter with bacteria, 
bacterial products (DNA and LPS), fungal products (hyphae), viruses, viral products 
(dsRNA), cytokines, molecules on T-cells (CD40L) and molecules derived from self cells 
(tumour cell lysates and heat-shock proteins). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3  Mature monocyte-
derived DCs.  DCs were given 
their name because of the dendrite-
like cytoplasmatic processes pro-
truding from the cell bodies into 
their environment.  Once DCs 
arrive in the secondary lymphoid 
organs, interaction with many T-
cells takes place.  The processes 
increase the surface of DCs thereby 
enabling antigen presentation to an 
increased number of T-cells. 
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During maturation, antigen uptake is down-regulated.  Peptide loading as well as the half-
life and delivery of pMHC complexes to the cell surface are increased.  The expression of 
co-stimulatory molecules (CD80, CD86, CD40 and OX-40L) is also up-regulated.  One 
study demonstrated that mature DCs are up to 1000-fold more efficient in activating 
resting T-cells, compared to other professional APCs, such as monocytes, macrophages 
and B-cells (Bhardwaj N et al. 1993).  Therefore, DCs can be described as the most potent 
APCs.  They are also the only cells capable of activating naïve T-cells and, thereby, of 
initiating adaptive immune responses.  In addition to up-regulation of antigen-presenting 
and co-stimulatory molecules, maturation includes enhancing the ability of DCs to migrate 
out of the tissues and into secondary lymphoid organs, where interactions with T-cells take 
place.  This includes modifications in the expression of chemokine receptors, such as 
CCR7 (chemokine CC motif receptor 27) and adhesion molecules, as well as profound 
changes in the cytoskeleton organisation.  DCs simultaneously become primed to 
synthesise cytokines essential for the development of CTLs and T-helper cells (IL-12, IL-
15 and IL-18) and chemokines which attract naïve and memory cells (Sallusto F and 
Lanzavecchia A 1999).  The maturation state is accompanied by the development of 
resistance to immunosuppressive factors, such as IL-10, and to infection by several 
organisms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4  MHC class I and class II antigen processing and presentation pathways in DCs.
Intracellular proteins (A) undergo degradation by the proteasome complex, are brought into the ER 
where they bind to MHC class I molecules and traffic through the Golgi apparatus on their way to the 
cell surface.  On the cell surface, they are recognised by CTLs (CD8+ T-cells).  Exogenous proteins (B) 
enter the endosome/lysosome vesicles in antigen presenting cells after internalisation by phagocytosis 
or endocytosis.  Here they are degraded into peptides by proteases.  These peptides bind to MHC class 
II molecules in compartments called MIIC, from where they are transferred to the cell surface by 
transport vesicles.  On the cell surface, they are recognised by T-helper cells (CD4+ T-cells). 
Abbreviations: TAP (transporter associated with antigen processing), ER (endoplasmic reticulum), 
MHC (major histocompatibility complex), MIIC (MHC class II rich compartments).  From Ribas A et 
al. 2003. 
A. B.
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Antigenic peptides from exogenously acquired proteins are produced by proteases in 
incoming endosomes (Figure 1.4A).  These endosomes fuse with vesicles carrying MHC 
class II antigen-presenting molecules from the endoplasmic reticulum (ER) to form the so-
called MHC class II rich compartments (MIICs).  Inside MIICs, peptides bind to antigen-
presenting molecules.  Subsequently, pMHC class II complexes are exported to the cell 
surface for activation of T-helper cells.  These complexes are generated only in a narrow 
time-frame after induction of DC maturation but persist with extremely long half-lives of 
several days (Cella M et al. 1997).  Endogenously synthesised antigens, such as self 
proteins and viral proteins, are cleaved by proteasomes into peptides in the cytoplasm and 
transported into the endoplasmic reticulum via TAP transporters (Figure 1.4B).  There they 
are loaded onto MHC class I molecules.  When displayed at the cell surface, pMHC class I 
complexes are recognised by CTLs.  The average pMHC class I complex has a half-life of 
only 5-10 hr at the cell surface and therefore decays reasonably quickly.  Nevertheless, 
these complexes are continuously assembled in the biosynthetic pathway (Cella M et al. 
1999). 
 
 
 
 
 
 
 
 
 
 
 
"Cross-priming" is the term used to describe the ability of DCs to present antigens from 
other cells and mount CTL responses against these antigens.  Since its discovery (Bevan 
MJ 1976), this phenomenon has been implicated in tolerance to self-antigens and in 
immune responses to viruses, transplantation antigens and tumours.  As shown in Figure 
1.5, antigens from multiple extracellular sources can be taken up and presented by DCs 
within MHC class I molecules (Yewdell JW et al. 1999).  How exactly peptides derived 
from exogenous antigens gain access to MHC class I molecules is still being deciphered.  
TAP-dependent cross-priming suggests that exogenous antigens somehow enter the 
Figure 1.5  Exogenously derived 
antigens access the MHC class I 
processing pathway of DCs and are 
presented on MHC class I 
molecules.  Multiple forms of 
exogenous antigens that access the 
MHC class I processing pathway of 
DCs are shown.  Abbreviations: TLR 
(Toll-like receptor), Ig (immuno-
globulin), FcR (Fc receptor), Ag 
(antigen), HSP (heat shock protein). 
From Bhardwaj N 2001. 
Necrotic 
cells 
Pathogens 
e.g. bacteria 
DNA
RNA
TLR FcR
Immune 
complexes 
(Ig + Ag) 
Soluble proteins 
Exosomes 
HSP 
Apoptotic 
cells 
CD36 
Nucleus
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cytoplasm from endosomes following internalisation (Sigal LJ and Rock KL 2000).  
Soluble antigens or antigens within immune complexes appear to access the cytoplasm 
(Rodriguez A et al. 1999).  Only small molecules can traverse the endosomal membrane, 
suggesting the existence of active transporters, pores or leaky junctions that allow 
exogenous antigens to enter the cytoplasm.  It is also possible that antigens processed 
inside endosomes have access to recycling MHC class I molecules that re-appear on the 
cell surface (Yewdell JW et al. 1999).  However, it is not clear whether endosomal 
proteases generate peptides for MHC class I.  In terms of immunotherapy, the exogenous 
pathway is attractive because it can be exploited to introduce antigens in different forms 
into DCs and, thereby, activate a broad repertoire of antigen-specific CTLs and T-helper 
cells.   
 
 
1.4 Danger model 
 
According to the danger model proposed by Matzinger (Matzinger P 1994), the immune 
system does not necessarily respond only to what is foreign but to anything that is 
dangerous.  DCs acquire antigens from the cell debris generated during an inflammatory 
response but do not discriminate between self and pathogen-specific antigens.  They 
process and present both.  Whereas immature and semi-mature DCs induce T-cell anergy 
and activate regulatory T-cells (Lutz MB and Schuler G 2002), only mature DCs are 
capable of efficiently activating T-cells.  The consequence is that antigens are presented in 
a T-cell stimulatory fashion exclusively in the context of danger, which induces the process 
of DC maturation in the first place.  The prerequisite of DC maturation increases the 
probability that a high percentage of antigens presented by the DC is indeed foreign. 
 
The danger model is based on the existence of the so-called second signal, in addition to 
the first signal directed at T-cells.  Whereas the first signal comes from specific recognition 
of antigenic peptides presented within MHC molecules, the second signal is either 
mediated through co-stimulatory molecules on professional APCs or delivered by T-helper 
cells.  The main principle of the model is that the presence or absence of the second signal 
determines immune responsiveness or tolerance.  The main rules to generate an immune 
response or tolerant state are as follows. 
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Naïve T-cells 
• undergo apoptosis if they receive signal one in the absence of signal two 
• second signal may be offered only by DCs 
 
Memory T-cells 
• undergo apoptosis if they receive signal one in the absence of signal two 
• second signal may be offered from all professional APCs, i.e. monocytes, 
macrophages, B-cells or DCs 
 
B-cells 
• undergo apoptosis if they receive signal one in the absence of signal two 
• second signal may be offered only by memory/effector T-cells 
 
Effector T and B-cells 
• perform functions after antigen recognition regardless of the presence or absence of 
signal two 
• undergo apoptosis or revert to a resting state after a reasonably short period of time 
 
In the danger model, it is assumed that the main determinant leading to the initiation of an 
immune response is the presence of an antigen in the context of tissue destruction.  If there 
is no damage and cells are unharmed or they die by apoptosis, no immune response ensues.  
However, if cells are injured, stressed or die by necrosis, an immune response is induced.  
Since an absolute majority of body cells present only signal one, the default reaction of a 
responding T-cell for an antigen should be tolerance.  This kind of behaviour is very 
beneficial to sustain the tolerant state and to avoid auto-aggression against self-tissues 
(Kowalczyk DW 2002). 
 
 
1.5 Tolerance to self-antigens 
 
The establishment of T-cell tolerance to self-antigens has two components: central 
(intrathymic) and peripheral (extrathymic).  In the thymus, T-cells are subjected to the 
rigorous process of negative selection before they are released into peripheral circulation.  
High-avidity T-cells that recognise presented self-antigens are eliminated.  Low-avidity T-
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cells specific for the same antigens and low to high-avidity T-cells specific not only for 
foreign, but also self-antigens that were not presented in the thymus, escape negative 
selection and become part of the mature naïve T-cell population.  Even if their TCRs 
recognise self-antigens, all T-cells that have not been stopped in the thymus are 
functionally competent.  For example, CTLs specific for ubiquitous proteins such as β2-
microglobulin, hemoglobin (Schild H 1990) and kallikrein (Heiser A 2000) are part of the 
peripheral T-cell repertoire and can be activated under appropriate conditions.  In the 
periphery, the immune system either ignores autoreactive T-cells or deals with them before 
activation through mechanisms that include tolerance and regulation (defensive strategies).  
If these approaches are inefficient, the system tries to minimise an autoimmune response 
before it causes too much damage (reactive strategies). 
 
The defensive strategies include passive and active approaches.  Passive maintenance of 
peripheral tolerance is based on simply ignoring existing autoreactive T-cells (Zinkernagel 
RM 1996).  This is possible because their distribution is restricted to hematopoietic and 
lymphoid tissues.  Therefore, T-cells do not circulate throughout the body in search of 
antigens (Mackay CR 1993).  As explained above, somatic cells present their own 
antigens, but lack co-stimulatory molecules and therefore can neither prime naïve T-cells 
nor activate memory T-cells.  Instead, the contact of T-cells with antigens and their 
subsequent activation depend on professional APCs.  The function of APCs is to shuttle 
antigens to the T-cells, most of which are waiting in the lymphoid tissues.  If T-cells 
specific for self-antigens had access to other tissues in the body and if they could be 
activated there without the help of APCs, immunological ignorance would not be possible.  
Indeed, it appears that the majority of self-antigens are not actively tolerised, but ignored 
because they are either expressed at immunologically priviledged sites (Barker CF and 
Billingham RE 1977, Oldstone MB et al. 1991) or they are not expressed above a certain 
threshold required to overcome central or peripheral tolerance (Kurts C 1998).  However, 
not all autoreactive T-cells are ignored in the periphery.  Their potential activation is 
prevented by APC-based and T-cell-based active tolerance mechanisms.   
 
During homeostasis, DCs constantly acquire self-antigens, primarily from somatic tissues 
that are frequently targeted by pathogenic infections.  These immature-like DCs migrate to 
the lymph nodes and present antigens to autoreactive T-cells in a tolerogenic manner 
(Steinman RM 2000).  As a consequence, self-specific T-cells are removed from the 
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circulation.  During infection, DCs originating from the same tissues present self-antigens 
together with pathogenic antigens in a stimulating manner, but not many self-epitopes are 
recognised in the lymphoid organs because most autoreactive T-cells have already been 
eliminated.  Autoreactive T-cells can be, and probably constantly are, activated by APCs 
during infection and would induce autoimmune pathology if it were not for the presence of 
regulatory T-cells.  These CD4+CD25+ cells prevent the activation, expansion and function 
of autoreactive T-cells.  It has been shown in mice that depletion of this T-cell 
subpopulation induces a broad range of autoimmune pathologies (Shevach EM 2001).  
Since they purge the body of autoreactive T-cells that may have escaped elimination by 
tolerising APC, regulatory T-cells seem to be the last line of defence before the onset of 
autoimmunity.  It is still unclear what proportion and which subsets of autoreactive T-cells 
are ignored, tolerised by APCs or regulated by T-cells (Gilboa E 2001). 
 
Reactive strategies are used by the immune system to minimise the effects of already 
existing autoimmune responses.  Activated autoreactive T-helper cells die by neglect 
because most somatic cells do not express MHC class II molecules.  This phenomenon is 
also known as programmed cell death.  CTLs that repeatedly encounter self-antigen on 
somatic cells in the absence of co-stimulation die in a process known as activation-induced 
cell death.  Regulatory T-cells also contribute to the reactive strategies. 
 
Mechanisms in charge of maintaining tolerance are not perfect.  Low-avidity self-specific 
T-cells are able to avoid negative selection in the thymus.  In order to be activated in the 
periphery, such cells need strong stimulatory signals to compensate for their low avidity.  
Evolutionary calibration within the immune system ensures that, in most situations, 
somatic cells and APCs in the periphery do not express stimulatory molecules above the 
threshold of APCs in the thymus.  Whereas low-avidity self-specific T-cells are more 
difficult to stimulate, there are high-avidity autoreactive T-cells that need weaker stimuli 
for activation.  These high-avidity cells can reach the periphery if corresponding epitopes 
are not presented in the thymus.  Most of them are then ignored because the antigens for 
which they are specific are not accessible.  Outside the thymus, multiple mechanisms are in 
charge of eliminating or controlling both low and high-avidity self-specific T-cells, but 
even they can fail.  The consequence is that the repertoire of T-cells in the periphery 
includes cells specific for self-antigens with avidities ranging from low to high.  As 
explained above, DCs needed for T-cell stimulation efficiently present everything they 
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capture, not discriminating between harmless and dangerous.  Therefore, whether an 
antigen is seen as foreign or self, is not really predetermined, but strongly depends on the 
context in which the antigen is presented to the immune system.   
 
Most TAAs are self-antigens.  For example, indirect assays in different studies revealed 
that Melan-A-specific CTLs are present in 20-75% of healthy individuals.  Pittet and 
colleagues (Pittet MJ et al. 1999) used the direct method of tetramer-staining and 
confirmed these findings by detecting CTLs specific for Melan-A in 60% of healthy 
donors.  These cells were of naïve phenotype and had a high frequency of 1 in every 1500 
CTLs.  It was also demonstrated that autoreactive T-cells may even be of high avidity (Yee 
C et al. 1999).  It is thought that active central and/or peripheral tolerance mechanisms 
usually do not exist against these TAAs (Ludewig B et al. 2000).  They seem instead to be 
immunologically ignored.  The idea of attacking tumours with effectors of the immune 
system is to a large extent based on breaking the tolerance to self, and the outcome of 
successful immunotherapy is actually a form of autoimmunity. 
 
 
1.6 RNA-pulsed DCs in tumour immunotherapy 
 
The fact that functionally-competent autoreactive T-cells specific for TAAs have not been 
completely eliminated from the body does not guarantee tumour regression but it is the 
foundation of tumour immunotherapy.  TAAs must be presented to the T-cells in a 
stimulatory manner and, therefore, strategies have to be developed that use the flexibility 
of the immune system in interpreting an antigen as foreign or self.  Vaccination with 
tumour antigen-pulsed DCs was shown to elicit protective immunity in a variety of animal 
models.  This can be explained by the high antigen-presenting and T-cell stimulatory 
capacities of DCs that are the most potent professional APCs and the only APCs able to 
prime naïve T-cells.  It was observed that the cellular arm of the immune system is most 
efficient at specifically recognising tumour cells and eliminating them.  Therefore, the 
emphasis in vaccination has shifted from humoral immunity towards the induction of 
cellular responses, especially CTLs.  The attention CTLs received is not only due to their 
effective killing of malignant cells but also to limitations imposed by available technology.  
Depending on antigen loading methods and the antigen itself, in most cases, engineered 
DCs stimulated CTLs and not T-helper cells.  However, it is becoming increasingly clear 
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that inducing antigen-specific T-helper cells, in addition to CTLs, is necessary to improve 
initiation and maintenance of anti-tumour immunity (Wang RF 2001). 
 
In DC-based tumour immunotherapy, an important decision involves the choice of TAAs 
with which to load the DCs.  Equally important are the composition and the form of the 
antigen in which it should introduced into the DCs.  Different approaches are summarised 
in Table 1.1.  They are thoroughly evaluated and compared in a review by Mitchell and 
Nair (Mitchell DA and Nair S 2000). 
 
 
 
Individual tumour-associated antigens: 
synthetic or eluted peptides 
soluble protein 
cDNA or cRNA encoding the antigen 
Whole tumour antigenic repertoires: 
differentiation of DCs from malignant cells (leukemia) 
tumour lysates 
apoptotic bodies or necrotic cells 
total cellular tumour RNA 
DC-tumour cell hybrids 
peptide-HSP complexes 
DC-derived exosomes 
 
 
 
 
Exogenous loading of a synthetic peptide, representing an antigenic epitope known to be 
immunogenic, onto empty MHC molecules expressed on the DCs is an efficient and very 
often used strategy (Thurner B et al. 1999).  Alternatively, DCs can be pulsed with a 
recombinant protein to induce immune responses against all potentially immunogenic 
epitopes from one antigen (Santin AD et al. 1999).  However, vaccine strategies based on 
synthetic proteins and peptides require the identification of relevant antigens and their 
epitopes.  Unfortunately, the number of described immunogenic TAAs is small, even for 
melanoma which is the best-defined type of tumour in this respect.  Once chosen, it is 
assumed but not guaranteed that these proteins or peptides will be the ones best recognised 
by the immune system of a certain patient.  Peptides also have the disadvantage of MHC-
Table 1.1  Delivery of antigens into DCs
Abbreviations: cDNA (complementary DNA), cRNA 
(complementary RNA), HSP (heat shock protein). 
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restriction, meaning that each peptide binds to molecules of only one specific HLA 
allotype, thereby restricting immunotherapy to patients whose haplotypes include the 
allotype in question. 
 
By using total tumour preparations, DCs can be engineered to present a full spectrum of 
epitopes from different TAAs, even when the identities of the antigens are not known.  
Such approaches include loading of DCs with peptides eluted from tumour cells (Herr W et 
al. 2000), pulsing DCs with tumour lysates (Schott M et al. 2000) and fusing DCs and 
tumour cells into tumour-DC hybrids (Kugler A 2000).  However, these methods are 
highly dependent on the amount of tumour tissue available.  The problem of limited 
tumour material can be overcome by using TAAs in the form of nucleic acids, DNA or 
RNA, because they can be easily amplified in PCR.  Most importantly, if nucleic acids are 
transfected into DCs, all the critical decisions are not made by the scientists but are left to 
the DCs themselves.  DCs choose the antigen(s) and the epitope(s) for presentation by all 
available MHC class I and class II molecules. 
 
Many viral and non-viral gene transfer technologies have been tested on DCs (Kirk CJ and 
Mulé JJ 2000).    While viral vectors have high transduction efficiency (Jenne L et al. 
2001), their clinical applicability may be hampered by safety issues involving viral 
proteins that might be co-expressed with tumour proteins.  Furthermore, 
immunodominance may occur, whereby viral antigens mask or suppress the response to 
less potent tumour antigens.  The consequence of this phenomenon may be that DCs 
expressing both viral and tumour antigens are eliminated by virus-specific CTLs before 
they can activate a tumour-specific response.  Plasmid DNA transfer into DCs has not been 
very efficient (van Tendeloo VF et al. 1998). 
 
Immunisation of mice with RNA was first described in 1995 (Conry RM et al. 1995).  
Shortly after, the first successful attempts to load DCs with tumour antigens in the form of 
RNA and prime T-cells with RNA-transfected DCs were described by the Gilboa group 
(Boczkowski D et al. 1996).  Even though RNA molecules are very unstable and, 
therefore, difficult to work with, RNA transfection into DCs may be advantageous over 
DNA in several respects.  A single cell is sufficient for the establishment of a cDNA 
library.  Subsequent amplification of the total cellular antigenic repertoire in the form of 
DNA is feasible but complicated cloning steps have to be performed.  RNA can also be 
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isolated from a few tumour cells.  The total cellular mRNA amplification technology 
developed by Boczkowski and colleagues is simple and yields unlimited amounts of 
biologically functional RNA (Boczkowski D et al. 2000).  As opposed to transfected DNA, 
which has to be transcribed following entry into the nucleus of DCs, RNA only has to 
reach the cytoplasm where it is directly translated into protein.  Whereas the half-life of 
stable mRNA species in mammalian cells is less than 24 hr, unintegrated DNA can persist 
and function in non-dividing cells for months.  Vaccination with total tumour-derived 
antigens in the form of DNA is, therefore, of greater concern when tumour antigens 
involved in tumourigenesis, such as the products the human papilloma virus E6 or E7 
genes, are introduced into the DCs.  Finally, if cDNA encoding individual TAAs is 
available, corresponding cRNA can be synthesised by in vitro transcription.  Multiple 
cRNA species can easily be transfected into the target cell, leading to the translation of 
several different gene products within the same cell.  In contrast, only one or a few copies 
of a DNA vector are usually incorporated into each cell, thereby limiting expression to 
only a few proteins within each DC.  Whereas additional cloning steps are required with 
DNA, the RNA technology makes it possible to simply add additional RNA species into 
the mixture in order to include a desired antigen in the repertoire of antigens to be 
presented by transfected DCs.       
 
The immune system has learned to deal with self-specific T-cells that were activated 
during infection.  Nevertheless, immunotherapy using effective and repeated vaccinations 
is capable of activating more autoreactive T-cells than the immune system has evolved to 
tolerate.  Depending on the immunotherapeutic approach, other self-antigens are likely to 
be presented alongside TAAs, most of which are self-antigens themselves.  Therefore, by 
trying to manipulate the immune system into specifically recognising and killing tumour 
cells, the thin line between breaking tolerance and inducing autoimmune disease can be 
easily crossed. 
 
 
1.8 Melanoma model 
 
In recent decades, melanoma incidence and mortality rates have been steadily and 
markedly increasing, particularly among Caucasian populations.  Most melanomas are 
thought to be caused by intermittent, not chronic, exposure to UV radiation, especially 
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during childhood.  Nevertheless, exposure in adulthood certainly also plays a role.  In older 
people, melanomas appear to be more related to chronic exposure.  This is suggested by 
the body site distribution of melanomas in the elderly, with more melanomas on 
chronically exposed body sites (de Vries E et al. 2003).  In Europe, the highest melanoma 
incidence rates have been reported in Scandinavia (about 15 cases per 1×105 inhabitants 
and year) and the lowest in the Mediterranean countries (about 5-7 cases per 1×105 
inhabitants and year).  In comparison, both the United States (10-20 cases per 1×105 
inhabitants and year) and Australia (40-60 cases per 1×105 inhabitants and year) have 
higher incidence rates (Garbe C and Blum A 2001).  In 90% of patients with early-stage 
disease, melanoma is curable with surgery alone.  However, the prognosis for patients with 
more advanced disease involving regional lymph nodes or distant metastases is poor, with 
median survival rates of 24 and 6 months, respectively (Kim CJ et al. 2002).  In its 
metastatic stage, melanoma is highly resistant to traditional forms of therapy (e.g. surgery, 
radiation and chemotherapy) and causes substantial mortality (Helmbach H et al. 2001).  
Therefore, clinicians have been more inclined to explore novel approaches, including 
immunotherapy. 
 
Adoptive transfer of TILs in combination with IL-2 resulted in tumour regressions in 
approximately 30% of melanoma patients (Rosenberg SA 1992), suggesting that the 
immune system can play a critical role in the elimination of malignant cells.  To further 
understand the molecular nature of the observed immune responses, much effort has been 
devoted to the characterisation of melanoma-associated antigens (MAAs) with the help of 
T-cells displaying in vitro reactivity against melanoma cells.  Since melanoma is easily 
adapted for laboratory tissue culture, in contrast to most other human cancers, many 
melanoma cell lines were established and used in mixed lymphocyte tumour cell cultures.  
As a result, a wide array of different MAAs have been molecularly identified, which are 
specifically recognised on tumour cells by CTLs in association with MHC class I 
molecules (Boon T and van der Bruggen P 1996).  Even though there is no direct evidence 
that melanoma is more immunogenic than other tumours, identification of these antigens 
has made melanoma the most informative model for understanding cancer immunity.   
 
Given the fact that cancer arises from the host's own tissues, it is no surprise that the large 
majority of TAAs characterised to date are unaltered self-antigens well known to the 
immune system.  In rare cases, mutations can create alterations in individual amino acids 
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or de novo open reading frames yielding new antigens.  The functional genome of 
melanoma cells almost completely reflects the genes expressed by normal melanocytes at 
the same stage of differentiation and similar physiologic context, i.e. proliferation.  As 
shown in Table 1.2, antigens associated with melanoma are divided into three main groups: 
cancer-testis antigens, melanocyte differentiation antigens and melanoma-specific antigens 
(reviewed in Kirkin AF et al. 1998, Turk MJ et al. 2002, Ramirez-Montagut T et al. 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The cancer-testis group of antigens represents proteins expressed in several different 
tumours, including melanoma, but not in normal tissues except for testes.  This appears to 
be due to demethylation of the genes in testes and cancer cells.  Since germ cells in testes 
do not express MHC class I molecules and have no direct contact with the cells of the 
immune system, vaccination against these antigens should cause no side-effects, i.e. 
autoimmunity.  MAGE-1 (melanoma antigen gene) was the first ever tumour-derived 
(melanoma) human gene product to be identified as a CTL target (van der Bruggen P et 
al.1991).  Since then, many cancer-testis antigens and their epitopes have been identified, 
including members of the MAGE, GAGE and BAGE families.  NY-ESO-1 has both class I 
and class II-restricted epitopes and is one of the most immunogenic TAAs, described to 
date.  
Cancer-testis 
antigens 
Melanocyte 
differentiation antigens 
Melanoma-specific 
antigens (mutated) 
MAGE tyrosinase CDK4 
GAGE Melan-A (MART-1) β-catenin 
BAGE gp100 (pmel17) CDC27 
RAGE TRP-1 (gp75) GnT-V 
PRAME TRP-2 (DCT) LDLR 
P15  gp100 (pmel17) 
NY-ESO-1 (CAG3)   
LAGE (CAMEL)   
Table 1.2  Melanoma-associated antigens.  
Abbreviations: CAMEL (CTL-recognised antigen on melanoma), CDC27 (cell 
division control 27), CDK4 (cyclin-dependent kinase 4), GnT-V (beta 1,6-N-
acetylglucosaminyltransferase V), gp (glycoprotein), LDLR (low density lipoprotein 
receptor), MAGE (melanoma antigen gene), Melan-A (melanoma antigen A), 
MART-1 (melanoma antigen recognised by T-cells 1), PRAME (preferentially 
expressed antigen of melanoma). 
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A differentiation antigen is an antigen expressed by both cancer cells and their normal cell 
counterparts.  Such antigens are structurally or functionally associated with a particular 
point in cell differentiation and they are usually found at relatively low concentrations on a 
small subset of normal cells.  In the case of cancer, differentiation antigens are good 
potential targets for the immune system based on clonal expansion of the tumour and its 
abnormal differentiation.  Differentiation antigens relevant to anti-melanoma immunity are 
proteins required for melanin synthesis in cellular compartments called melanosomes.  
This is why they are called melanocyte differentiation antigens.  These antigens are 
normally expressed in melanocytes in the skin and retinal epithelium in the eye.  They 
include tyrosinase, tyrosinase-related protein 1 (TRP-1), tyrosinase-related protein 2 (TRP-
2) and gp100.  Tyrosinase is the rate-limiting enzyme, which catalyses two initial steps of 
the melanin biosynthetic pathway.  TRP-1 stabilises tyrosinase, TRP-2 is a tautomerase 
and gp100 is involved in melanin polymerisation (Prota G et al. 2000).  Melan-A is also a 
differentiation antigen with melanosomal localisation, but its function is currently 
unknown (de Mazière AM 2002). 
 
The process of carcinogenesis is thought to involve accumulation of mutations that act 
collectively to transform normal cells into malignant cells.  These mutations, in addition to 
being oncogenic, may be immunogenic by creating completely new antigenic epitopes or 
by enhancing the binding of poorly reactive or non-reactive epitopes to MHC molecules, 
TCRs or antibodies.  Changes in the genes for CDK4 (cyclin-dependent kinase 4), β-
catenin, CDC27 (cell division control 27) and triosephosphate isomerase are among the 
few examples of mutations that also encode potentially immunogenic epitopes in 
melanoma.  Since they are altered, these antigens are no longer self-antigens but can be 
classified as unique tumour antigens.  In the case of melanoma, they are called melanoma-
specific antigens.  If an immune response is mounted against any of these molecules, only 
malignant cells are targeted and, therefore, damage to normal tissue is unlikely.  The 
problem with these mutated proteins as targets for vaccination strategies is that, in most 
cases, the site of the mutation or rearrangement tends to vary among patients, which results 
in the generation of antigenic epitopes restricted to a few individuals.  In the case of the 
CDK4 antigen, the particular mutation, an arginine (R) to cysteine (C) exchange at residue 
24, was found in only 5% of tested melanomas (Wölfel T et al. 1995).  The CDK4 protein 
is a cell-cycle activator that propagates progression through the G1 phase of the cell cycle.  
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Its mutated form, CDK4-R24C is resistant to inhibition by the cell-cycle inhibitor 
p16/INK4α (Vax VV et al. 2003). 
 
 
1.9 Aims of the study 
 
The goal of this work was to find optimal conditions for producing a DC-based vaccine for 
cancer patients using tumour antigens in the form of RNA.  As explained above, there are 
three main advantages to pulsing DCs with RNA.  Even if only a small amount of tumour 
tissue is available, isolated RNA can easily be amplified in reverse transcription PCR (RT-
PCR).  By using tumour RNA, the identities of TAAs and their T-cell epitopes do not have 
to be known, but one can count on the fact that messages encoding these antigens are part 
of the total cellular RNA pool.  The DC, not the scientist, chooses the antigen(s) and, 
depending on its MHC repertoire, decides which epitope(s) will be presented. 
 
T-cell priming based on in vitro RNA-pulsed DCs was first described in 1996 
(Boczkowski D et al. 1996).  Since then, most publications have concentrated on clinical 
applications, without further exploring cellular events following RNA entry into the DC 
that precede antigen presentation on its surface.  Published protocols for RNA transfection 
into DCs have used different forms of RNA: total cellular tumour RNA, amplified total 
cellular tumour mRNA and single-species tumour-antigen cRNA.  A wide range of RNA 
concentrations have been applied either by lipofection, electroporation or through simple 
DC co-incubation with naked RNA.  No agreement has been reached on how much and 
what kind of RNA should be used and how this RNA should be brought into the DCs.  
Therefore, my studies were designed to quantitate RNA transfer into DCs, to determine 
intracellular stability of transfected RNA in DCs and to analyse the kinetics of protein 
expression and the generation of functional pMHC ligands that can activate effector 
memory CTLs.  Simultaneous activation of CTLs with specificities for different antigens 
minimises the potential for tumour escape through immune selection of tumour variants 
showing loss of individual antigens.  Thus, generation of multiplex pMHC ligands for 
CTLs may improve clinical efficiency.  On the other hand, peptide competition for MHC 
molecules within the DC may limit pMHC ligand generation.  This central immunological 
question was addressed by comparing DCs loaded with total cellular tumour RNA, 
amplified total cellular tumour mRNA and pools of defined single-species tumour-antigen 
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cRNAs versus individual single-species tumour-antigen cRNAs for their capacity to 
display various pMHC ligands and activate CTLs of corresponding specificities. 
 
RNA encoding the enhanced green fluorescence protein (EGFP), an antigen not associated 
with tumours, was used to determine the optimal conditions for RNA transfection into DCs 
using a simple read-out system of flow cytometry.  Subsequent work was based on 
melanoma using a more complicated analysis of effector CTL function.  This tumour 
model was chosen as the most suitable because it is well characterised at both the cellular 
and the molecular levels.  The CTL stimulatory capacity of DCs pulsed with RNA was first 
investigated using one MAA, tyrosinase.  An RNA mixture of three antigens, tyrosinase, 
Melan-A and CDK4-R24C, was compared with total cellular melanoma RNA for 
processing and presentation to antigen-specific CTLs to evaluate the role of antigen 
competition at the level of pMHC generation. 
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2. Materials 
2.1 Instruments and other equipment 
 
Bacteria shaker Certomat H      B. Braun Biotech Int. 
Balance BP 2100       Sartorius 
Balance (analytical) MCI      Sartorius 
Cooling block (for LightCycler®)     Roche 
Cell counting chamber Neubauer     Brand 
Centrifuge Megafuge 2.0      Heraeus 
Centrifuge 5417R       Eppendorf 
Controlled-freezing box      Nalgene 
Electrophoresis chamber      Invitrogen 
Electroporator  Gene Pulser Xcell™     Bio-Rad 
ELISA reader E max       Molecular Devices 
Flow cytometer FACSCalibur™     Becton Dickinson 
Freezer (-20°C) Premium      Liebherr 
Freezer (-80°C) HFU86      Heraeus 
Fridge (4°C)        Bosch 
Gel scanner Fluor-S™ MultiImager     Bio-Rad 
Heating block Thermomixer Comfort    Eppendorf 
Incubator (human cells)      Heraeus 
Incubator (bacteria)       Memmert 
Irradiation chamber Gammacell 40     Atomic Energy 
Liquid nitrogen tank Chronos Biosafe    Messer Griesheim 
Multichannel pipettes (5-50 µL, 25-200 µL)   Dunn Labortechnik 
Micropipettes (0.5-10 µL, 10-100 µL, 20-200 µL, 100-1000 µL) Eppendorf 
Microscope Leica DMIL      Leica 
Microscope (fluorescence) Axiovert 10 with camera  Zeiss    
Microwave oven Micromat      AEG 
Pipetting assistant Easypet      Eppendorf 
Spectrophotometer GeneQuant II     Amersham Biosciences 
Sterile bench         Heraeus 
Thermocycler LightCycler®      Roche 
Thermocycler PTC-200      MJ Research 
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Vortexer        Bender & Hobein 
Water bath SUB       Julabo 
Water purification system Easypure RF    Barnstead 
Vacuum manifold for plasmid preps QIAvac® 6S    Qiagen 
 
 
2.2 Commonly used material 
 
Cryovials        Nunc 
Capillaries (for LightCycler®)     Roche 
ELISA plates Immuno F96 Maxi-Sorp    Nunc 
Filters for cells Cellstrainer      Falcon 
Filters for solutions (0.2 µm and 0.8 µm)    Schleicher und Schüll 
Flasks for cell culture (75 cm2 and 175 cm2)   Falcon 
Gloves (nitrile)       Semperit 
Pasteur pipettes       Peske OHG 
Petri dishes        Falcon 
Pipettes (2, 5, 10 and 25 mL)      Falcon 
Pipette tips (10, 200 and 1000 µL)     Greiner 
Pipette tips (10, 200 and 1000 µL with a filter)   Biozym 
Plates for cell culture (6-well, 24-well and 96-well)   TPP 
Scalpels (Nr. 20)       Feather 
Tubes for cell culture (polystyrene, 15 mL)    Falcon 
Tubes for cell culture (polypropylene, 15 mL and 50 mL)  Falcon 
Tubes for molecular biology (0.5 mL)    Starlab 
Tubes for molecular biology Safelock (1.5 mL and 2 mL)  Eppendorf 
Tubes for FACS™ (1.2 mL)      Peske OHG 
Tubes for FACS™ (5 mL)      Falcon 
 
 
2.3 Chemicals and biological reagents 
 
0.24-95 Kb RNA Ladder      Invitrogen 
Agar         Sigma 
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Agarose        Invitrogen 
AIM V medium       Invitrogen 
Ampicillin        Merck 
β-mercaptoethanol       Sigma 
Blue Juice Gel Loading Buffer     Invitorgen 
Chloroform        Merck 
Carbonate-bicarbonate buffer capsules    Sigma 
DEPC (diethyl pyrocarbonate)     Sigma 
DMSO (dimethyl sulfoxide)      Merck 
Ethidium bromide       Bio-Rad 
Ethanol        Merck 
FACS™ Flow        Becton Dickinson 
FACS™ Rinse       Becton Dickinson 
FACS™ Safe        Becton Dickinson 
Ficoll         Biochrom 
FBS (fetal bovine serum)      Invitrogen 
Formamide        Invitrogen 
HEPES        Invitrogen 
Glycerol        Merck 
GM-CSF (granulocyte macrophage colony stimulating factor) Essex Pharma 
HS (human serum)       LTI 
IL-1β (interleukin 1β)      R&D Systems 
IL-2 (interleukin 2)       R&D Systems 
IL-4 (interleukin 4)       R&D Systems 
IL-6 (interleukin 6)       R&D Systems 
Isopropanol        Sigma 
LB Broth Base       Invitrogen 
L-glutamine        Invitrogen 
MEM         Invitrogen 
One Shot TOP10F´ competent cells     Invitrogen 
OptiMEM I medium       Invitrogen 
Ortho-phosporic acid       Merck 
PBS (phosphate buffered saline)     Cell Concepts 
Peptone        Invitrogen 
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Penicillin/streptomycin      Invitrogen 
PGE2 (prostaglandin E2)      Sigma 
PstI restriction enzyme      Roche 
Ready-Load 1 Kb DNA Ladder     Invitrogen 
RNase A (ribonuclease A)      Roche 
RPMI 1640 medium       Invitrogen 
Sodium chloride       Merck 
Sodium pyruvate       Invitrogen 
SpeI restriction enzyme      New England BioLabs 
Substrate Reagents A and B      Becton Dickinson 
TAE (tris acetate EDTA) buffer     Invitrogen 
TBE (tris borate EDTA) buffer     Ambion 
TransFast™        Promega 
Tri Reagent        Sigma 
Trypan blue        Sigma 
Trypsin/EDTA       Invitrogen 
Tween 20        Merck 
TNF-α (tumour necrosis factor α)     R&D Systems 
XbaI restriction enzyme      Fermentas 
X-vivo 15 medium       Biowhittaker 
Yeast extract        Invitrogen 
Yeast tRNA        Roche 
Zeocin         Invitrogen 
 
 
2.4 Kits 
 
1st Strand cDNA Synthesis Kit for RT-PCR (AMV)  Roche 
Advantage® 2 PCR Enzyme System    Becton Dickinson 
Fix&Perm Cell Permeabilisation Kit     An der Grub 
LightCycler® – FastStart DNA Master SYBR Green I  Roche 
LightCycler® – Primer Set for Human Tyrosinase   Search LC 
mMESSAGE mMACHINE™ T7     Ambion 
OptEIA™ Human IFN-γ Set      Becton Dickinson 
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Poly(A) Tailing Kit       Ambion 
QIAquick® PCR Purification Kit     Qiagen 
QIAwell® 8 Ultra Plasmid Kit     Qiagen 
RNeasy® Mini Kit       Qiagen 
SMART™ PCR cDNA Synthesis Kit    Becton Dickinson 
 
 
2.5 Cell culture media and solutions 
 
Standard tumour medium: 
500 mL RPMI 1640 
50 mL  FBS     = 10% 
5 mL  MEM (100×)    = 1× 
5 mL  L-glutamine (200 mM)  = 2 mM 
5 mL  Sodium-pyruvate (100 mM)  = 1 mM 
 
RPMI III: 
500 mL RPMI 1640 
5 mL  L-glutamine (200 mM)  = 2 mM 
5 mL  Na-pyruvate (100 mM)  = 1 mM 
5 mL  Pen/Strep (104 U/mL)   = 100 U/mL 
 
AIMV III: 
500 mL AIM V 
5 mL  L-glutamine (200 mM)  = 2 mM 
5 mL  Na-pyruvate (100 mM)  = 1 mM 
5 mL  Pen/Strep (104 U/mL)   = 100 U/mL 
 
CTL co-incubation medium: 
16 mL  RPMI III 
4 mL  HS or autologous plasma  = 20% 
8 µL  IL-2 (100 U/mL)   = 40 U/mL 
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B-cell medium: 
45 mL  RPMI III     
5 mL  FBS     = 10% 
 
Trypsin/EDTA 2×: 
20 mL  PBS 
5 mL  Trypsine-EDTA (10×)  = 2× 
 
DMSO 20%: 
40 mL  RPMI III 
10 mL  DMSO    = 20% 
 
Freezing Medium: 
½  FBS 
½  DMSO 20%    = 10% 
 
Dendritic cell medium: 
250 mL X-Vivo 15 
2.5 mL L-glutamine (200 mM)  = 2 mM 
2.5 mL Pen/Strep (104 U/mL)   = 100 U/mL 
 
FACS™ Buffer: 
49 mL  PBS 
1 mL  FBS     = 2% 
 
DEPC water: 
400 mL double distilled water 
400 µL DEPC     = 0.1% 
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2.6 Cells 
 
Name Description Source Reference 
11/33 CTL monoclonal CTL line; HLA-A*0201-restricted; specific for the Melan-A26-35 epitope 
Wölfel T Wölfel T et al. 1993 
14/35 CTL monoclonal CTL line; HLA-A*0201-restricted; specific for the CDK4-R24C23-32 epitope   
Wölfel T Wölfel T et al. 1995 
624.38 MEL melanoma cell line; HLA-A2-positive; CDK4-R24C-negative Panelli MC Rivoltini et al. 1995 
A375 MEL melanoma cell line; HLA-A2-positive; tyrosinase, Melan-A and CDK4-R24C-negative 
ATCC 
(CRL-1619)  
A42 CTL monoclonal CTL line; HLA-A*0201-restricted; specific for the Melan-A26-35 epitope 
Panelli MC Kawakami Y et al. 1994
AK-EBV-B Epstein-Barr virus transformed lymphoblastoid cell line established from a healthy donor Wölfel T Wölfel T et al. 1994 
DC differentitated from monocytes of the healthy HLA-A*0201-positive blood donor PH 
generated in 
the lab  
IL-2 MEL 93.04A12 melanoma cell line; HLA-A2-positive; CDK4-R24C-negative; stable IL-2 transfectant Schrier P  
IVS B CTL polyclonal CTL line; HLA-A*0201-restricted; specific for the tyrosinase369-377 epitope 
Wölfel T Wölfel T et al. 1993 
LAZ388 Epstein-Barr virus transformed lymphoblastoid cell line Schrier P  
RCC26 human renal cell carcinoma cell line; HLA-A2-positive Schendel DJ Schendel DJ et al. 1993 
SK23 MEL human melanoma cell line; HLA-A2-positive Panelli MC  
SK29 MEL human melanoma cell line; HLA-A2-positive; heterozygous for CDK4-R24C Wölfel T Wölfel T et al. 1994a 
T2 hybrid of a T and a B lymphoblastoid cell line; TAP-deficient Panelli MC Salter RD et al. 1985 
TyrF8 CTL monoclonal CTL line; HLA-A*0201-restricted; specific for the tyrosinase369-377 epitope 
Schrier P MJ Visseren et al. 1995 
 
 
2.7 Antibodies 
 
Specificity Clone Isotype Conjugation Application Manufacturer 
CD1a HI 149 IgG1 PE primary Becton Dickinson 
CD11c B-ly6 IgG1 PE primary Becton Dickinson 
CD14 RM052 IgG2a FITC primary Beckman Coulter 
CD40 5C3 IgG1 PE primary Becton Dickinson 
L307.4 IgG1 FITC primary Becton Dickinson 
CD80 
MAB104 IgG1 PE primary Beckman Coulter 
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CD83 HB15e IgG1 PE primary Becton Dickinson 
CD86 FUN-1 IgG1 PE primary Becton Dickinson 
CD206 19 IgG1 PE primary Becton Dickinson 
mouse IgG + IgM  F(ab´)2 FITC secondary Dianova 
HLA-A,B,C G46-2.6 IgG1 FITC primary Becton Dickinson 
HLA-DR Immu-357 IgG1 PE primary Beckman Coulter 
HLA-DP,DQ,DR TÜ39 IgG2a FITC primary Becton Dickinson 
isotype control IgG1 X40 IgG1 FITC and PE primary Becton Dickinson 
isotype control IgG2a G155-178 IgG2a FITC primary Becton Dickinson 
Melan-A A103 IgG1 none primary Dako Cytomation 
 
 
All anti-human antibodies originate from a mouse.  Anti-mouse IgG and IgM F(ab´)2 
fragments originate from a goat. 
 
 
2.8 Molecular biology media, buffers and gels 
 
LB medium: 
10 g  Peptone 
5 g  Yeast extract 
10 g (5 g) Sodium chloride (low salt) 
ad 1 L  Distilled water  
 
LB agar medium: 
10 g  LB Broth Base 
7.5 g  Agar 
ad 500 mL Distilled water 
 
DNA electrophoresis gel: 
27 mL  Distilled water 
3 mL  TAE buffer (10×)   = 1× 
0.36 g  agarose    = 1.2% 
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DNA electrophoresis running buffer: 
180 mL Distilled water 
20 mL  TAE buffer (10×)   = 1× 
8 µL  Ethidium bromide (10 µg/µL) = 0.4 µg/mL 
 
RNA electrophoresis gel: 
27 mL  DEPC water 
3 mL  TBE buffer (10×)   = 1× 
0.36 g  agarose    = 1.2% 
 
RNA electrophoresis running buffer: 
180 mL DEPC water 
20 mL  TAE buffer (10×)   = 1× 
8 µL  Ethidium bromide (10 µg/µL) = 0.4 µg/mL 
 
 
2.9 Plasmids 
 
Plasmid cDNA insert resistance source 
pcDNAI/Amp/Aa1.2 Melan-A ampicillin Wölfel T 
pcDNAI/Amp/C11.1 CDK4-R24C ampicillin Wölfel T 
pGEM4Z/GFP/A64 EGFP ampicillin Su Z 
pZeoSV2+/huTyr tyrosinase zeocin Sutter G 
 
 
2.10 Peptides 
 
Epitope Peptide sequence 
CDK4-R24C23-32 ACDPHSGHFV 
influenza matrix protein58-66 GILGFVTL 
Melan-A26-35 ELAGIGILTV 
tyrosinase369-377 YMNGTMSQV and YMDGTMSQV 
 
All peptides were synthesised at the Genzentrum. 
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2.11 Primers 
 
Sequence 
specificity Primers Sequence 
PCR 
product size Application 
forward 5´  GTTAGCAAGAAACTGAACGTCACA  3´ α-enolase 
reverse 5´  TGAAGGACTTGTACAGGTCAG  3´ 
619 bp real-time PCR 
forward 5´  TAATACGACTCACTATAGGGAGG           AAGCAGTGGTAACAACGCAGAGT  3´
total 
cellular 
mRNA reverse 5´  AAGCAGTGGTAACAACGCAGAGT  3´ 
depends on 
mRNA size 
total cellular 
mRNA 
amplification 
forward 5´  CGATATGAGCCAGTGGCTG  3´ 
CDK4 
reverse 3´  AGGCCTCCTCCACCTCCT 3´ 
134 bp real-time PCR 
forward 5´  GCTACCCCGACCACATGAAG  3´ 
EGFP 
reverse 5´  GTCCATGCCGAGAGTGATCC  3´ 
485 bp real-time PCR 
forward 5´  ACTGCTCATCGGCTGTTG  3´ 
Melan-A 
reverse 5´  CACCTGAGACATGCTGA  3´ 
267 bp real-time PCR 
forward not defined 
tyrosinase 
reverse not defined 
not defined real-time PCR 
 
All primers were synthesised at the Genzentrum except for tyrosinase primers which were 
part of the LightCycler® – Primer Set for Human Tyrosinase. 
 
 
2.12 List of manufacturers and persons 
 
AEG     Nürnberg, Germany 
Ambion    Austin, Texas, USA 
Amersham Biosciences  Piscataway, New Jersey, USA  
An der Grub    Kaumberg, Austria 
ATCC     Rockyville, Maryland, USA 
Atomic Energy   Ottawa, Ontario, Canada 
Barnstead    Dubuque, Iowa, USA 
B. Braun Biotech Int.   Melsungen, Germany 
Beckman Coulter   Palo Alto, California, USA 
Becton Dickinson   Jersey City, New Jersey, USA 
Bender & Hobein   Ismaning, Germany 
Biochrom    Berlin, Germany     
Bio-Rad    Richmond, California, USA 
Biowhittaker    East Rutherford, New Jersey, USA 
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Biozym    Hess. Olendorf, Germany 
Cell Concepts    Umkirch, Germany 
Dako Cytomation   Glostrup, Denmark 
Dianova    Hamburg, Germany 
Dunn Labortechnik   Asbach, Germany 
Eppendorf    Hamburg, Germany 
Essex Pharma    München, Germany 
Falcon     Oxnard, California, USA 
Fermentas    Leon-Rot, Germany 
Genzentrum    Martinsried, Germany 
Greiner    Nürtingen, Germany 
Heraeus    Hanau, Germany 
Invitrogen    Karlsruhe, Germany 
Julabo     Seelbach, Germany 
Leica     Wetzlar, Germany 
Liebherr    Bierbach an der Riss, Germany 
Memmert    Schwabach, Germany 
Merck     Darmstadt, Germany 
Messer Griesheim   Krefeld, Germany 
MJ Research    Watertown, Massachusetts, USA 
Molecular Devices   Sunnyvale, California, USA 
Nalgene    Rochester, New York, USA 
New England BioLabs  Frankfurt am Main, Germany 
Nunc     Naperville, USA 
Panelli MC* National Institutes of Health, Bethesda, Maryland, 
USA 
Peske OHG    München, Germany 
Promega    Madison, Wisconsin, USA 
Qiagen    Chatsworth, California, USA 
R&D Systems    Minneapolis, Minnesota, USA 
Roche     Mannheim, Germany 
Sartorius    Göttingen, Germany 
Schendel DJ*  Institute of Molecular Immunology, GSF, München, 
Germany 
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Schleicher und Schüll   Dassel, Germany   
Schrier P*  Leiden University Medical Center, Leiden, The 
Netherlands 
Search LC    Heidelberg, Germany 
Semperit    Wien, Austria 
Sigma     St. Louis, Missouri, USA 
Starlab     Ahrensburg, Germany 
Sutter G*    Technical University, München, Germany 
Su Z*  Duke University Medical Center, Durham, North 
Carolina, USA 
TPP     Trasadingen, Switzerland 
Wölfel T*    Johannes Gutenberg-University, Mainz, Germany 
Zeiss     Jena, Germany 
 
*  These individuals are thanked for kindly providing cells and plasmids listed above. 
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3. Methods 
3.1 Cell culture 
3.1.1 Cell counting 
 
The cell count and viability was assessed by trypan blue exclusion.  Live cells did not take 
up the trypan blue.  The cell suspension was diluted  1:10 with trypan blue by adding 10 
µL of the cell suspension to 90 µL of trypan blue in a well of a 96-well plate.  A Neubauer 
counting chamber was filled with the trypan blue-diluted cell suspension using a pipette 
and capillary action.  Care was taken not to over or underfill the chamber.  Using an 
inverted microscope, the number of viable (unstained) cells in the four corner squares was 
counted.  Either the cells touching the top and left of the ruled squares or those touching 
the bottom and right were counted, but not both.  Formulas used to calculate cell 
concentrations and total cell numbers are shown in Figure 3.1. 
 
 
 
 
 
 
 
 
 
3.1.2 Cryopreservation of cells 
 
Tumour cell lines and CTL clones were frozen at concentrations between 2×106 and 
5×106/mL in 1 mL volumes.  Peripheral blood mononuclear cells (PBMCs) were frozen at 
40×106/mL in 1.5 mL volumes.  Pelleted cells were first resuspended in an appropriate 
volume of FBS.  The same volume of pre-cooled 20% DMSO was then gradually added to 
the cell suspension.  After thorough mixing, 1 mL or 1.5 mL aliquots of the cell suspension 
were transferred into pre-cooled cyrovials.  The cryovials were placed into controlled-
freezing boxes and stored at –80°C overnight.  The following day, the cryovials were 
transferred into the liquid nitrogen freezer for long-term storage at –196°C. 
 
 
 average number of cells per square × 105 
cell concentration =      ×106 / mL 
 106 
 
 
total cell number = cell concentration × volume of cell suspension 
Figure 3.1  Formulas used to calculate cell concentrations and total cell 
numbers. 
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3.1.3 Thawing of cryopreserved cells 
 
The thawing medium used was FBS.  The cryovials were retrieved from the liquid nitrogen 
freezer and thawed rapidly in a water bath at 37°C.  As soon as only a small ice crystal was 
seen floating inside the cryovial, the contents of a vial were transferred into a 15 mL 
Falcon tube containing 1 mL of FBS.  Additional 2 mL of FBS were slowly added in a 
drop-wise manner with continual mixing.  The tube was immediately centrifuged at 540×g 
for 5 min.  Pelleted cells were then resuspended in the corresponding culture medium pre-
warmed to 37°C. 
 
 
3.1.4 Culture of adherent tumour cell lines 
 
SK23 MEL, SK29 MEL, IL-2 MEL, 624.38 MEL, IL-2 MEL, A375 MEL and RCC26 
tumour cell lines were cultured in the standard tumour medium.  Volume of the medium in 
a middle-sized culture flask (75 cm2 adherence surface) was 10 mL.  Volume of the 
medium in a large-sized flask (175 cm2 adherence surface) was 25 mL.  Approximately 
every 3-4 days cells grew to confluence.  At that time point, their medium was exchanged 
and they were split 1:2 to 1:10, depending on the growth rate of individual cell lines.  The 
medium was removed, cells were washed once with warm PBS and then incubated with 1 
mL (middle-sized flask) or 2 mL (large-sized flask) trypsin/EDTA 2× for 3 min at room 
temperature.  Detached cells were resuspended in fresh standard tumour medium and 
distributed in new culture flasks. 
 
 
3.1.5 Culture of suspension tumour cell lines 
 
LAZ388, AK-EBV-B and T2 tumour cell lines were cultured in the B-cell medium.  
Volume of the medium was 20 mL in a middle-sized culture flask.  Approximately every 4 
days, ¾ of the cell suspension were removed and the same volume of fresh medium was 
added. 
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3.1.6 CTL restimulation and culture 
 
All CTL clones were first expanded in restimulation cultures.  Large stocks were aliquoted 
and frozen.  Each time they were needed for an experiment, CTLs were taken from the 
same stock, thawed, placed into wells of a 24-well plate and restimulated according to one 
of the following standardised protocols. 
 
For restimulation, thawed TyrF8 CTLs (5×105 per well) were mixed with IL-2 MEL cells 
as stimulators (irradiated with 1×104 rad, 8×104 cells per well), LAZ388 cells as feeders 
(irradiated with 1.5×104 rad, 1×105 cells per well) and PBMCs pooled from several donors 
as feeders (irradiated with 5×103 rad, 1.5×106 cells per well) in RPMI III medium (1.5 mL 
per well) supplemented with 7.5% human serum, 7.5% FBS and 100 U/mL IL-2.  Half of 
the medium was substituted with fresh medium approximately every 2 days.  During 
expansion, TyrF8 CTLs were restimulated every 2 weeks.  They were harvested, counted 
and used for co-incubation experiments with DCs or tumour cells on days 7 or 14 after 
thawing and restimulation. 
 
For restimulation, thawed IVS B, A42, 11/33 and 14/35 CTLs (5×105 per well) were mixed 
with SK 29 MEL cells as stimulators (irradiated with 1×104 rad, 1×105 cells per well) and 
AK-EBV-B cells as feeders (irradiated with 1×104 rad, 2×105 cells per well) in AIM V III 
medium (1.5 mL per well) supplemented with 10% human serum and 500 U/mL IL-2.  
Half of the medium was substituted with fresh medium, with the IL-2 concentration 
reduced to 250 U/mL, approximately every 2 days.  During expansion IVS B, A42, 11/33 
and 14/35 CTLs were restimulated once a week.  They were harvested, counted and used 
for co-incubation experiments with DCs or tumour cells on day 7 after thawing and 
restimulation. 
 
 
3.1.7 Isolation of PBMCs from a leukapheresis product 
 
The leukapheresis product was diluted 1:2 with dilution medium pre-warmed to 37°C.  
Using a pipette, 30 mL of the diluted sample were carefully layered onto 20 mL of Ficoll 
in a 50 mL Falcon tubes.  The tubes were centrifuged at 840×g for 30 min without brake.  
Using a Pasteur pipette, the white ring (composed of PBMCs) at the interface between the 
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Ficoll and plasma was removed and transferred into a cell culture flask.  Isolated PBMCs 
were diluted 1:2 with warm dilution medium and aliquoted into 50 mL Falcon tubes.  The 
tubes were centrifuged at 760×g for 10 min.  Pelleted cells were resuspended in 50 mL of 
washing medium pre-warmed to 37°C.  The following centrifugation programme was 
performed to separate cells from platelets: 75×g for 20 min, gradual increase of 15×g/min 
to 540×g, stop without a brake.  Pelleted cells were again resuspended in 50 mL of warm 
washing medium and centrifuged at 540×g.  Pelleted cells were then resuspended in FBS, 
counted and frozen according to the procedure described below. 
 
 
3.1.8 DC generation and culture 
 
A large stock of PBMCs from donor PH was obtained from a leukapheresis product by 
Ficoll density gradient centrifugation.  These PBMCs were aliquoted and frozen.  For each 
DC culture, PBMCs from the same stock were used.  Thawed PBMCs were resuspended in 
RPMI 1640 medium supplemented with 1% autologous plasma at 5-10×106 cells per 2 mL 
per well of a 6-well plate.  The plates were incubated at 37°C and 5% CO2 for 2 hr.  Non-
adherent cells were carefully washed away.  Adhering monocytes were cultured in 2 mL 
per well of dendritic cell medium supplemented with 1% autologous plasma, 800 U/mL 
GM-CSF and 800 U/mL IL-4.  After 3 days of culture, 800 U/mL GM-CSF and 800 U/mL 
IL-4 were added again.  On day 6 of culture, immature DCs were harvested, counted and 
resuspended in fresh dendritic cell medium supplemented with 1% autologous plasma, 800 
U/mL GM-CSF, 500 U/mL IL-4, 5 ng/mL IL-1β, 9 ng/mL IL-6, 9 ng/mL TNF-α and 2 
µM PGE2 at 0.5×106 cells per 1 mL per well of a 24-well plate for maturation.  Mature 
DCs were harvested on day 8 of culture. 
 
 
3.2 Flow cytometry 
 
Flow cytometry was used to measure the cellular expression of chosen molecules.  These 
molecules either fluoresce themselves (e.g. EGFP) or they are specifically stained with 
monoclonal antibodies attached to fluorescent dyes.  Flow cytometric analysis was 
performed in the fluorescence-activated cell sorter (FACS™).  In the FACSCalibur™, the 
suspension of stained cells was forced through a nozzle, creating a fine stream of liquid 
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containing cells spaced singly at intervals.  As each cell passed through a laser beam, it 
scattered the laser light and fluorescent molecules associated with the cell were excited.  
Sensitive photomultiplier tubes detected both the scattered light, which gave information 
about the size and granularity of the cell, and the fluorescence emissions, which gave 
information about the binding of the labelled monoclonal antibodies and, hence, the 
expression of targeted molecules by each cell. 
 
 
3.2.1 Direct staining of cell-surface molecules 
 
In order to measure the expression of cell-surface molecules CD14, CD1a, CD206, CD11c, 
CD83, CD40, CD80, CD86, HLA-A,B,C and HLA-DP,DQ,DR, specific monoclonal 
antibodies conjugated with FITC (fluorescein isothiocyanate) or PE (phycoerythrin) were 
used for the direct staining on the cell surface.  Approximately 5×104 untransfected or 
EGFP cRNA-transfected DCs per well of a 96-well plate were washed twice.  Each 
washing step included resuspension of cells in 150 µL of FACS™ buffer, centrifugation at 
300×g for 3 min and discarding of the supernatant.  After washing, 3 µL of each antibody 
were added separately to the pellets.  After a 30 min incubation on ice and in the dark, cells 
were washed twice.  Finally, cells were resuspended in 200 µL of FACS™ buffer and flow 
cytometric analysis was performed. 
 
 
3.2.2 Indirect staining of intracellular molecules 
 
In order to measure the expression of Melan-A inside RNA-transfected DCs, cells were 
first fixed and permeabilised using Reagents A and B from the Fix&Perm Cell 
Permeabilisation Kit.  Briefly, approximately 3×105 cells were placed into each well of a 
96-well plate and washed twice.  Each washing step included resuspension of cells in 200 
µL of PBS, centrifugation at 300×g for 3 min and discarding of supernatant.  After 
washing, 50 µL of Reagent A (fixation medium) were added to the pellet and mixed 
gently.  After a 15 min incubation at room temperature, cells were washed twice.  
Subsequently, 50 µL of Reagent B (permeabilisation medium) and 17 µL of the Melan-A-
specific primary antibody were added to the pellet and mixed gently.  After a 15 min 
incubation at room temperature, cells were washed three times and then 20 µL of the 
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FITC-conjugated secondary antibody specific for the primary antibody were added to the 
pellet and mixed gently.  After a 20 min incubation at room temperature in the dark, the 
cells were washed three times.  Finally, pelleted cells were resuspended in 200 µL of PBS 
and flow cytometric analysis was performed. 
 
In order to measure the expression of EGFP inside RNA-transfected DCs, no staining was 
necessary, since EGFP itself is a fluorescent molecule.  DCs were washed twice with PBS, 
as described above.  Pellets were resuspended in 200 µL of PBS and flow cytometric 
analysis was performed. 
 
 
3.3 Production of amplified total cellular mRNA 
 
In transfection experiments described below, either total cellular tumour RNA was used or 
amplified total cellular mRNA.  The unspecific amplification procedure included five 
steps: reverse transcription of mRNA into cDNA, amplification of cDNA in PCR, 
purification of amplified cDNA, in vitro transcription of amplified cDNA into cRNA and 
cRNA purification (Figure 3.2). 
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Figure 3.2  The principle of total cellular mRNA amplification.  On the left agarose gel electrophoresis 
picture, total cellular RNA isolated from 624.38 MEL melanoma cells is shown.  The thicker upper band (5 
kb) corresponds to 28S rRNA and the lower thinner band (1.9 kb) to 18S rRNA.  The existence of these two 
bands and the 2-fold higher amount of 28S rRNA, compared to 18S rRNA, indicate that the integrity of 
RNA was not compromised by the isolation procedure.  Only mRNA contained in the total cellular sample 
was reverse transcribed into cDNA.  On the middle picture, a smear of different cellular cDNA species after 
amplification and purification is shown.  This cDNA was in vitro transcribed into cRNA.  On the right 
picture, a smear of different cellular cRNA species after purification i.e. amplified total cellular mRNA is 
shown. 
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3.3.1 Total cellular RNA isolation from tumour cells 
 
Total cellular RNA was isolated from tumour cells using the RNeasy® Mini Kit.  The 
isolation procedure was performed with up to 10×106 cells per column according to 
manufacturer's instructions.  Cellular plasma membranes and organelles were first 
disrupted by vortexing cells with a buffer containing guanidine isothiocyanate.  
Centrifugation through a QIAshredder® column sheared the high molecular weight 
genomic DNA and other high-molecular-weight cellular components to create a 
homogenous lysate.  The lysate was mixed with an ethanol containing buffer and 
transferred onto an RNeasy® column.  Ethanol provided conditions which promoted 
selective binding of RNA to a silica-gel membrane during centrifugation of the solution 
through the column.  Washing buffers were then used to eliminate contaminants while 
RNA remained attached to the membrane inside the column.  Finally, DEPC water was 
used to elute the RNA from the column.  Isolated and purified RNA was stored at –80°C.  
The average yield was 100 µg total cellular RNA from 10×106 cells, depending on the cell 
line.  The integrity and size distribution of isolated RNA were examined by denaturing-
agarose gel electrophoresis and ethidium bromide staining.  Only RNA samples were used 
in further experiment whose relevant ribosomal species, 28S rRNA (5 kb) and 18S rRNA 
(1.9 kb), appeared as bands on the stained gel, as opposed to smears which would have 
indicated RNA degradation (Figure 3.2). 
 
 
3.3.2 Reverse transcription of isolated RNA into cDNA 
 
Reverse transcription of total cellular mRNA into cDNA was performed using the 
SMART™ PCR cDNA Synthesis Kit according to manufacturer´s instructions.  The 
method relied on the ability of reverse transcriptase (RT) to transcribe mRNA into single-
stranded DNA in the so called first-strand reaction.  This reaction was primed by a 
modified oligo(dT) primer that bound to the 3´ poly(A) tail of mRNA species.  When RT 
reached the 5´ end of the mRNA, the terminal transferase activity of the enzyme added a 
few additional nucleotides, primarily deoxycytidine, to the 3´ end of the cDNA.  The 
SMART™ oligonucleotide, with an oligo(G) sequence at its 3´ end, base-paired with the 
deoxycytidine stretch on the 3´ end of cDNA, creating an extended template.  RT then 
switched templates and continued replicating to the end of the nucleotide.  The resulting 
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full-length, single-stranded cDNA contained the complete 5´ end of the mRNA, as well as 
the sequence that was complementary to the SMART™ oligonucleotide.  In cases where 
RT paused before the end of the template, the addition of deoxycytidine nucleotides was 
much less efficient than with full length cDNA-RNA hybrids, thus preventing base-pairing 
with the SMART™ oligonucleotide.  The SMART™ anchor sequence and the poly(A) 
sequence served as universal priming sites for end-to-end cDNA amplification in PCR.  
Therefore, cDNA lacking these sequences, due to prematurely terminated cDNAs caused 
by incomplete RT activity, contaminating genomic DNA or cDNA transcribed from 
poly(A)-negative RNA was not exponentially amplified.  The reverse transcription reaction 
was performed under conditions suggested by the manufacturer.  These are described in 
Figure 3.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.3 Amplification of cDNA 
 
Single-stranded cDNA, synthesised in the reverse transcription reaction with total cellular 
mRNA as a template, was amplified in PCR using the Advantage® 2 PCR Enzyme 
System.  Primers were designed to specifically bind to 5´ (5´ SMART™ + T7 primer) and 
3´ (3´ CDS PCR primer) sequences that were integrated into cDNA during the reverse 
Annealing 
 
3 µL  RNA (1 µg) + deionised water 
1 µL  CDS primer (10 µM)   = final 2 µM 
1 µL  SMART™ oligonucleotide (10 µM) = final 2 µM 
 
5 µL  total 
 
Incubation at 72°C for 5 min followed by incubation on ice for 2 min. 
 
Reverse transcription 
 
5 µL  Annealing reaction mixture    
2 µL  First-Strand Buffer (5×)   = 1× 
1 µL  DTT (20 mM)    = 2 mM 
1 µL  dNTP Mix (10 mM)   = 1 mM 
1 µL  PowerScript Reverse Transcriptase  
 
10 µL  total 
 
Incubation at 42°C for 1 hr followed by incubation on ice for 5 min. 
Figure 3.3  Contents of 
the reverse transcrip-
tion reaction mixture 
and reaction conditions.
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transcription step.  In addition to the sequence that is complementary to the SMART™ 
oligonucleotide sequence, the 5´ SMART™ + T7 primer contained the T7 promoter 
sequence.  Therefore, in PCR performed with this primer, the T7 promoter was integrated 
into every cDNA molecule synthesised during PCR.  This was the prerequisite for 
subsequent in vitro transcription of cDNA into cRNA.  The PCR reaction was performed 
under conditions suggested by the manufacturer.  These are described in Figure 3.4. 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.4 Purification of cDNA 
 
Amplified cDNA was purified using the QIAquick® PCR Purification Kit according to 
manufacturer´s instruction.  The method is based on DNA adsorption to a silica-gel 
membrane in the presence of high salt concentrations.  Briefly, whereas DNA remains 
attached to the membrane, contaminants pass through the column during centrifugation.  In 
a washing step, impurities, such as salts, enzymes, primers and unincorporated nucleotides, 
are removed with a washing buffer.  Finally, DNA is eluted in Tris buffer. 
 
 
3.3.5 In vitro transcription of total cellular cDNA into cRNA 
 
The in vitro transcription of amplified cDNA into cRNA was performed using the 
mMESSAGE mMACHINE™ T7 kit.  Any sufficiently pure DNA with a promoter site can 
serve as a template for an RNA polymerase.  As shown in Figure 3.5, the minimal 
promoter sequence required by the T7 RNA polymerase was part of the 5´ SMART™ + T7 
2 µL  cDNA 
80 µL  PCR-grade water 
10 µL  Advantage 2 PCR Buffer (10×)  = 1× 
2 µL  dNTP Mix (10 mM)   = 0.2 mM 
2 µL  5´ SMART™ + T7 primer (10 µM) = 0.2 µM 
2 µL  3´ CDS PCR primer (10 µM)  = 0.2 µM  
2 µL  Advantage® 2 Polymerase Mix (50×) = 1× 
 
100 µL  total 
 
Initial denaturation at 95°C for 1 min.  Amplification (20 cycles): 95°C for 
15 sec, 65°C for 30 sec and 68°C for 6 min.  Cooling at 4°C. 
Figure 3.4  Contents of 
the PCR reaction 
mixture and reaction 
conditions. 
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primer which was used in the cDNA PCR amplification step.  The mMESSAGE 
mMACHINE™ T7 kit was designed for in vitro synthesis of capped RNA.  Capped RNA 
mimics eukaryotic mRNA found in vivo, because it has a 7-methyl guanosine cap structure 
at the 5´ end.  The cap analogue available in this kit, m7G(5´)ppp(5´)G, was incorporated 
only as the first 5´ terminal G of the transcript because its structure inhibited its 
incorporation at any other position in the RNA molecule. 
 
 
 
 
 
 
 
 
The reaction was performed under conditions suggested in the manufacturer´s instructions 
and described in Figure 3.6.  After in vitro transcription and cRNA purification (described 
below) the measured yield of amplified total cellular mRNA was 20-30 µg per 20 µL of 
the in vitro transcription reaction mixture. 
 
 
 
 
 
 
 
 
 
 
3.4 Production of single-species cRNA 
 
Production of single-species cRNA included four steps: linearisation of the plasmid 
containing a cDNA insert, in vitro transcription based on the promoter sequence and the 
cDNA template in the linearised plasmid, polyadenylation of synthesised cRNA and cRNA 
purification (Figure 3.7).  Since substantial amounts of the cDNA template, i.e. plasmid 
6 µL  cDNA (1 µg) + Nuclease-free water 
10 µL  NTP/Cap (2×)    = 1× 
2 µL  Reaction Buffer (10×)   = 1× 
2 µL  Enzyme Mix 
 
20 µL  total 
 
Incubation at 37°C for 4 hr, followed by DNA digestion by DNase 
(1 µL) at 37°C for 30 min. 
Figure 3.6  Contents of 
the in vitro transcription 
reaction mixture and 
reaction conditions. 
primer:  5´ TAATACGACTCACTATAGGGAGGAAGCAGTGGTAACAACGCAGAGT 3´ 
promoter: 5´ TAATACGACTCACTATAGGGAGA 3´ 
Figure 3.5  The 5´ SMART™ + T7 primer and the minimal sequence of the T7 promoter required for 
recognition by the T7 RNA polymerase.  The primer was used in amplification of total cellular cDNA 
amplification.  Thereby, the T7 promoter was integrated into each cDNA molecule synthesised in PCR. 
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DNA (pDNA), were needed for in vitro transcription reactions, the plasmid had to be 
amplified in competent bacteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.1 Transformation of competent bacteria with plasmid DNA 
 
In order to obtain larger amounts of pDNA that was received from other groups as a kind 
gift, competent bacteria had to be transformed with the pDNA in question and expanded.  
A 50 µL vial of One Shot TOP10F´ competent cells was slowly defrosted on melting ice, a 
small volume of pDNA (Table 3.1) was added and mixed with the bacteria by tapping 
gently.  The cells were incubated on ice for 30 min, then heated at 42°C for exactly 30 sec 
and finally placed on ice to cool for 2 min.  Rich SOC medium, provided together with the 
competent cells, was added and transformed bacteria were plated onto LB medium agar 
plates with the appropriate selection antibiotic (Table 3.1).  Plates were placed into the 
bacterial incubator overnight at 37°C.  Since the antibiotic zeocin is light sensitive and its 
activity is inhibited by high salt concentrations, plates for bacteria transformed with 
pZeoSV2+/huTyr contained low-salt LB agar medium and were stored in the dark. 
 
linearised 
pDNA 
in vitro transcription 
of cDNA into cRNA 
and 
polyadenylation  
of cRNA 
and 
purification 
of cRNA
single-species 
cRNA 
Figure 3.7  The principle of single-species cRNA production.  The left 
agarose gel electrophoresis picture shows the pcDNAI/Amp plasmid with 
the Melan-A cDNA insert after linearisation with the XbaI restriction 
endonuclease.  Linearised pDNA served as a template for in vitro 
transcription of Melan-A cDNA into Melan-A cRNA.  On the right 
picture, the left band corresponds to shorter Melan-A cRNA before 
polyadenylation and the right band to longer Melan-A cRNA after 
polyadenylation and purification.  The same strategy was used to produce 
tyrosinase and CDK4-R24C cRNAs. EGFP cRNA was not polyadenylated 
after in vitro transcription because its poly(A) tail was encoded in the 
plasmid. 
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plasmid cDNA insert 
transf. 
conc. 
transf. 
volume 
resistance to 
antibiotic 
antibiotic 
conc. 
lin. restr. 
enzyme 
pGEM4Z/GFP/A64 EGFP n.d. 2 µL ampicillin 100 µg/mL SpeI 
pZeoSV2+/huTyr tyrosinase 10 ng/µL 3 µL zeocin 50 µg/mL PstI 
pcDNAI/Amp/Aa1.2 Melan-A 50 ng/µL 2 µL ampicillin 100 µg/mL XbaI 
pcDNAI/Amp/C11.1 CDK4-R24C 720 ng/µL 2 µL ampicillin 100 µg/mL XbaI 
 
 
3.4.2 Selection and expansion of transformed bacteria 
 
Only bacteria transformed with pDNA, encoding resistance to an antibiotic, were able to 
grow and form colonies on selection plates despite the presence of the corresponding 
antibiotic in the agar medium.  After overnight growth, colonies were plucked from the 
plates using sterile tooth-picks.  Each individual colony was inoculated into 5 mL of LB 
medium containing the appropriate antibiotic (Table 3.1) in a 15 mL Falcon tube.  If 
previously selected and frozen transformed bacteria were to be expanded, frozen vials were 
transferred from the –80°C freezer onto melting ice.  Approximately 5 µL of the partially 
thawed bacterial suspension were then transferred into a 15 mL Falcon tube containing 5 
mL of LB medium with the appropriate antibiotic.  The tubes were incubated overnight 
(approximately 12 hr) at 37°C with vigorous shaking at 150 rpm for efficient growth of 
transformed bacteria. 
 
 
3.4.3 Freezing of transformed bacteria 
 
Bacteria are the least harmed by the freezing process if the freezing medium contains 15% 
of glycerin.  Therefore, 400 µL of the overnight bacterial suspension were added to 84 µL 
of autoclaved 87% glycerin, vortexed, quickly frozen in liquid nitrogen and transferred to -
80°C. 
 
 
 
Table 3.1  Plasmid information.  Listed are: plasmid names, cDNA inserts, plasmid concentrations used in 
transformation, plasmid volumes used in transformation, antibiotic resistance encoded by the plasmids, 
antibiotic concentrations in culture media for transformed bacteria and restriction enzymes used for plasmid 
linearisation. 
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3.4.4 Plasmid DNA extraction from transformed bacteria 
 
After overnight culture, bacterial suspensions were centrifuged at 5300×g and 4°C for 10 
min.  Plasmid DNA extraction from bacterial cells was performed using the QIAwell® 8 
Ultra Plasmid Kit, according to manufacturer´s  instructions.  Briefly, pelleted cells were 
lysed.  The salt and pH conditions in the lysates ensured exclusive binding of DNA to the 
membrane, while degraded RNA and cellular proteins were not retained.  The membrane 
was then washed with a buffer which disrupts any DNA-protein interactions allowing the 
removal of any nucleic acid-binding proteins and other residual contaminants from the 
pDNA.  Additional washing steps removed salts and other non-DNA constituents.  Purified 
pDNA was finally eluted in Tris buffer.  The yield of extracted pDNA was 4-8 µg per 5 
mL of overnight bacterial culture, depending on the plasmid. 
 
 
3.4.5 In vitro transcription of single-species cDNA into cRNA 
 
Each plasmid was linearised with a restriction enzyme (Table 3.1) in order to produce a 
template suitable for in vitro transcription.  Since all plasmids contained the T7 promoter at 
the 5´ end of cDNA encoding the desired protein, transcription was performed using the T7 
RNA polymerase from the mMESSAGE mMACHINE™ T7 kit according to 
manufacturer´s instructions.  Stability of an RNA molecule and its efficient use as a 
template for translation into protein depend on the presence of a cap at its 5´ end and a 
poly(A) tail at the 3´ end.  A poly(A) tail is always part of a mRNA molecule synthesised 
by a cell.  Therefore, the total cellular mRNA amplification procedure, described above, 
included only the addition of a cap analogue in the in vitro transcription reaction.  
However, single-species cRNA produced using cDNA in a plasmid may or may not 
contain a poly(A) tail, depending on whether the tail is encoded in the construct or not.  
Whereas the EGFP plasmid had a poly(dT) sequence at the 3´ end of the cDNA, the other 
three plasmids did not.  Therefore, in addition to integrating a cap analogue at the 5´ end in 
the in vitro transcription reaction, tyrosinase, Melan-A and CDK4-R24C cRNAs were 
polyadenylated at the 3´ end using the Poly(A) Tailing Kit.  Both reactions were performed 
under conditions suggested by the manufacturer.  These are described in Figure 3.8.  After 
in vitro transcription and cRNA purification (described below), the measured yield of 
EGFP cRNA was approximately 30 µg per 20 µL of the in vitro transcription reaction 
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mixture.  After in vitro transcription, polyadenylation and cRNA purification (described 
below), the measured yield of tyrosinase, Melan-A and CDK4-R24C cRNA was 60-70 µg 
per 100 µL of the polyadenylation reaction mixture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.6 Purification of cRNA  
 
Purification of cRNA, obtained in in vitro transcription reactions using as a template either 
amplified total cellular cDNA or single-species cDNA in a plasmid, was performed using 
the RNeasy® Mini Kit according to manufacturer´s instructions.  The procedure, which 
included RNA binding to a silica-gel membrane, washing and elution, is described above 
in the chapter 3.3.1 (Total cellular RNA isolation).  For purification, the cell lysis and 
homogenisation steps were omitted and the procedure started with the transfer of the in 
vitro transcription reaction mixture onto an RNeasy® column.  RNA was eluted in DEPC 
water and aliquots were stored at –80°C. 
 
 
In vitro transcription 
 
6 µL  pDNA (1 µg) + Nuclease-free water 
10 µL  NTP/Cap (2×)    = 1× 
2 µL  Reaction Buffer (10×)   = 1× 
2 µL  Enzyme Mix 
 
20 µL  total 
 
Incubation at 37°C for 2 hr, followed by DNA digestion by DNase       
(1 µL) at 37°C for 30 min. 
 
Polyadenylation 
 
21 µL  In vitro transcription reaction mixture 
35 µL  Nuclease-free water 
30 µL  E-PAP Buffer (5×)   = 1× 
10 µL  MnCl2 (25 mM)    = 2.5 mM 
10 µL  ATP (10 mM)    = 1 mM 
4 µL  E-PAP enzyme (2 U/µL)   = 8 U 
 
100 µL  total 
 
Incubation at 37°C for 1 hr. 
Figure 3.8  Contents of 
the in vitro transcription 
and polyadenylation re-
action mixtures and re-
action conditions. 
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3.5 Electrophoresis 
3.5.1 DNA agarose gel electrophoresis 
 
Separation of DNA fragments was performed in 0.8-1.2% agarose gels with 0.4 µg/mL of 
ethidium bromide in the running buffer at 5-10 V/cm.  Composition of the DNA containing 
solution that was loaded into gel slots is shown in Figure 3.9.  A 1 Kb DNA ladder  was 
included as a size standard in electrophoresis.  For extraction of DNA fragments from 
agarose gels, the desired fragments were cut from the gel after electrophoresis and purified 
using the QIAquick® Gel Extraction Kit according to manufacturer´s instructions.      
 
 
 
 
 
 
 
 
3.5.2 RNA denaturing-agarose gel electrophoresis 
 
For separation of RNA fragments in agarose gel electrophoresis, DEPC water was used in 
preparation of the gel, running buffer and the RNA sample.  Composition of the RNA 
containing solution that was loaded into gel slots is shown in Figure 3.10.  Prior to adding 
the loading buffer, the solution was incubated at 65°C for 10 min.  The high temperature 
and formamide denatured RNA.  Electrophoresis was performed in 0.8-1.2% agarose gels 
with ethidium bromide (0.4 µg/mL) in the running buffer and 5-10 V/cm.  A 0.24-9.5 kb 
RNA ladder  was included as a size standard. 
 
 
 
 
 
 
 
 
3 µL  RNA (0.5 µg) + DEPC water 
5 µL  formamide (100%)  = 50% 
1 µL  TBE Buffer (10×)  = 1× 
1 µL  Blue Juice Loading Buffer (10×) = 1× 
 
10 µL  total per slot 
Figure 3.10  Composition of the 
RNA containing solution loaded 
into an agarose gel for electro-
phoretic separation of RNA 
fragments. 
8 µL  DNA (0.5 µg) + dist. water = 0.4 µg 
1 µL  TAE Buffer (10×)  = 1× 
1 µL  Blue Juice Loading Buffer (10×) = 1× 
 
10 µL  total per slot 
Figure 3.9  Composition of the 
DNA containing solution loaded 
into an agarose gel for 
electrophoretic separation of 
DNA fragments. 
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3.6 RNA transfection into DCs 
 
The cellular plasma membrane serves the vital function of separating the molecular 
contents of the cell from its external environment.  The membranes are largely composed 
of amphiphilic lipids which self-assemble into a highly insulating bilayer.  On their quest 
to capture as much antigen as possible, immature DCs are well known to take up various 
structures (ranging in size from small molecules to apoptotic bodies) from their 
surroundings, including RNA.  They do so through macropinocytosis and endocytosis.  
Even though simple DC co-incubation with RNA has been shown to achieve T-cell 
priming, more aggressive methods such as lipofection and electroporation proved to be 
better transfection methods.  Lipofection was performed only with EGFP single-species 
cRNA.  In electroporation, both single-species (EGFP, tyrosinase, Melan-A, CDK4-R24) 
and total cellular (A375 MEL, SK23 MEL, SK29 MEL and 624.38 MEL) cRNAs were 
used.  Irrespective of the transfection method, either immature DCs after 6 days in culture 
or mature DCs after 8 days in culture were used. 
 
 
3.6.1 Lipofection 
 
Lipofection reagents usually consist of cationic lipid and neutral lipid components.  The 
positively charged group of the cationic lipid component electrostatically binds to the 
negatively charged RNA.  This interaction results in the formation of bundle-like RNA-
lipid complexes.  The hydrophilic negative charge of the nucleic acid is neutralized inside 
the complex.  The mainly hydrophobic complex with surplus positive charge associates 
with the slightly negatively charged cellular plasma membrane.  Entry of the complex into 
the cytoplasm occurs either via endocytosis or fusion with the plasma membrane.  The role 
of the neutral lipid component is endosomal disruption through which the complex is 
released into the cytoplasm. 
 
To form RNA-cationic lipid complexes, 24 µL of the lipofection reagent TransFast™ were 
mixed with 8 µg of EGFP cRNA (volume to mass ratio 4:1) in a total volume of 200 µL of 
OptiMEM I medium.  This mixture was incubated at room temperature for 15 min in a 15 
mL polystyrene Falcon tube.  Polystyrene does not bind nucleic acids thereby minimising 
the loss of RNA.  At the same time, 2×106 DCs were resuspended in 200 µL OptiMEM I 
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medium.  For transfection, 200 µL of the DC suspension were added to the 200 µL of the 
RNA-lipid complexes solution (total of 400 µL) in the polystyrene Falcon tube and mixed 
gently by pipetting.  The transfection reaction mixture was incubated at 37°C and 5% CO2 
for 1 hr with occasional agitation.  After transfection, the solution was washed once with 
PBS and the cells were resuspended in the dendritic cell medium supplemented with 2% 
autologous plasma, 800 U/mL GM-CSF and 800 U/mL IL-4. 
 
 
3.6.2 Electroporation 
 
Electroporation induces reversible permeability of plasma membranes when cells are 
exposed to short pulses of strong external electric fields.  The formation of hydrophilic 
pores is a result of reorientation of lipids in the bilayer membrane.  The molecular 
mechanism of this phenomenon is still not well understood.   The number of pores and 
their diameter increases with the product of the pulse amplitude and the pulse duration.  
Whereas small molecules simply diffuse through the pores into the cytoplasm, larger 
molecules, like nucleic acids, are driven into the cell by electrophoretic forces.  It has also 
been shown that the presence of nucleic acids facilitates pore formation.  Pores appear 
within a microsecond of exposure to the electric field, but it takes minutes for them to 
reseal. 
 
First, 2-3×106 DCs, resuspended in at least 170 µL OptiMEM I medium, were put into a 
0.4 cm electroporation cuvette and incubated on ice for approximately 3 min.  Cooling the 
suspension before electroporation was advantageous because it slowed down the cellular 
metabolism.  Thereby, overheating due to electricity was prevented.  Furthermore, damage 
caused by the electric shock and by molecules released from dead cells was minimised.  
Subsequently, RNA, resuspended in no more than 100 µL of DEPC water (depending on 
RNA concentration and mass, listed in Table 3.2), was added, giving a total electroporation 
suspension volume of 270 µL.  The suspension was shortly mixed by pipetting and then 
quickly electroporated.  Electroporation was performed with 250 V and 150 µF.  
Immediately after electroporation, cells were transferred into the dendritic cell medium 
supplemented with 2% autologous plasma, 10 mM HEPES, 800 U/mL GM-CSF and 800 
U/mL IL-4.  The cells were counted and the suspension was quickly aliquoted for either 
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FACS™ analyses, RNA isolation or functional assays and placed into the incubator at 
37°C and 5% CO2. 
 
In one experiment, one half of the aliquots was incubated with 5 µg/mL of RNase in the 
medium described above and the other half without RNase.  These DCs were used for 
RNA isolation. 
 
 
 
RNA species RNA mass (µg) 
EGFP cRNA 2, 4 and 8 
tyrosinase cRNA 6, 12, 24 and 48 
Melan-A cRNA 48 
CDK4-R24C cRNA 48 
A375 MEL amplified total cellular mRNA 75 
SK23 MEL amplified total cellular mRNA 80 and 160 
SK29 MEL total cellular RNA 75 
SK29 MEL amplified total cellular mRNA 37.5 and 75 
 
 
3.7 Functional assay 
 
In the functional assay, RNA-transfected DCs, peptide-pulsed DCs, tumour cells or peptide 
pulsed T2 cells served as stimulators.  Antigen-specific CTL clones served as effectors.  In 
order to measure the stimulatory capacities of stimulators, DCs or tumour cells were first 
co-incubated with CTLs.  Unless noted otherwise, CTLs were harvested and used in co-
incubation cultures 8 days after thawing and restimulation.  The amount of IFN-γ secreted 
by activated CTLs was measured in the enzyme-linked immunosorbent assay (ELISA). 
 
 
3.7.1 DC or tumour cell co-incubation with CTLs 
 
Either 2 hr or 25 hr after electroporation, 100 µL of the CTL suspension (2×104 cells in 
CTL co-incubation medium) were added to 100 µL of the transfected-DC suspension 
(5×103, 1×104, 2×104, 4×104 or 8×104 cells in dendritic cell medium supplemented with 
Table 3.2  Amounts of various RNA species used in electroporation. 
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2% autologous plasma and 800 U/mL GM-CSF and 800 U/mL IL-4), giving a total of 200 
µL per well of a 96-well plate and 1:4, 1:2, 1:1, 2:1 or 4:1 stimulator to effector ratios. 
 
Untransfected DCs were exogenously pulsed with peptides by adding 10 µL of the peptide 
solution (100 µL/mL) to 100 µL of the DC suspension (4×104 cells in dendritic cell 
medium supplemented with 2% autologous plasma and 800 U/mL GM-CSF and 800 U/mL 
IL-4).  After a 2 hr incubation at 37°C and 5% CO2, 100 µL of the CTL suspension (2×104 
cells in CTL co-incubation medium) were added,  giving a 2:1 stimulator to effector ratio. 
 
For co-incubation of T2 cells with CTLs, lower cell numbers were taken.  The exogenous 
pulsing was performed with 10 µL of the peptide solution and 100 µL of the T2 suspension 
(1.5×104 cells in dendritic cell medium supplemented with 2% human serum).  After a 2 hr 
incubation at 37°C and 5% CO2, 100 µL of the CTL suspension (3×103 cells in CTL co-
incubation medium) were added, giving a 5:1 stimulator to effector ratio. 
 
After a 24 hr co-incubation of effectors and stimulators, 150 µL of each supernatant was 
harvested and stored at –20°C. 
 
 
3.7.2 IFN-γ ELISA 
 
The measurement of IFN-γ in DC-CTL or tumour-CTL co-culture supernatants was 
performed in ELISA using the OptEIA™ Human IFN-γ Set according to manufacturer´s 
instructions.  Briefly, the ELISA plates were coated with a mouse anti-IFN-γ capture 
antibody and then blocked with an FBS-containing solution.  In some cases, supernatants 
were diluted 1:2.5 in the DC-CTL co-incubation medium.  The same medium was used to 
make serial dilutions of the IFN-γ standard.  After IFN-γ from cell culture supernatants or 
standard solutions bound to the capture antibodies in the plates, the biotinylated mouse 
anti-IFN-γ detection antibody was added together with avidin conjugated to horseradish-
peroxidase.  To visualise the complexes consisting of capture antibody, IFN-γ, detection 
antibody, biotin, avidin and horseradish-peroxidase, H2O2 (a substrate for peroxidase) in 
combination with tetramethylbenzidine (substrate reagents A and B mixed) was added, 
changing the solution colour into blue.  The enzymatic reaction was stopped with 1 M 
ortho-phosphoric acid.  Thereby, the colour of the solution turned yellow, its intensity 
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being directly proportional to the amount of substrate processed, i.e. indirectly proportional 
to the amount of IFN-γ captured.  Light absorption in the reaction solution was measured at 
450 nm.  Unknown IFN-γ concentrations were calculated with the help of a standard curve 
which was drawn based on known concentration of the IFN-γ standard and corresponding 
measured absorbances. 
 
 
3.8 RNA quantitation 
 
Since different samples were to be compared in highly sensitive quantitation experiments, 
great care was given to handling all samples the same way.  RNA from samples prepared 
for transfection and RNA isolated from transfected DCs were first reverse transcribed into 
cDNA.  Amounts of EGFP, tyrosinase, Melan-A and CDK4 message contained in these 
cDNA samples were then precisely determined with the help of real-time PCR using 
sequence-specific primers. 
 
 
3.8.1 Total cellular RNA isolation from transfected DCs 
 
Before RNA isolation, transfected DCs were washed twice with PBS and transferred into 
1.5 mL Eppendorf tubes.  Not many transfected DCs (as few as 1×104 cells) were available 
for RNA isolation, as opposed to unlimited amounts of tumour cells (as many as 10×106).  
To avoid RNA loss in the procedure, the RNeasy® Mini Kit was substituted with the Tri 
Reagent method.  After cells were pelleted, 200 µL of Tri Reagent (containing phenol and 
thiocyanate) were vigorously mixed with the cells to disrupt plasma membranes, inactivate 
released RNases and homogenise the suspension.  In the following step, 20 µg of yeast 
tRNA were added to later enhance RNA pelleting and visualisation.  Incubation at room 
temperature for 5 min allowed the dissociation of nucleoprotein-complexes.  After 40 µL 
of chloroform were added, the suspensions were vortexed for exactly 15 sec, incubated at 
room temperature for 10 min and then centrifuged at 1.2×104×g for 15 min.  The upper 
colourless aequous phase was transferred into new 1.5 mL Eppendorf tubes.  Subsequently, 
100 µL of isopropanol were added.  The solutions were vortexed, incubated at room 
temperature for 10 min and then centrifuged at 1.2×104×g for 12 min.  Supernatants were 
removed and 500 µL of 75% ethanol were mixed with the solutions by pipetting.  After 
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centrifugation at 1.2×104×g for 10 min, supernatants were quantitatively removed and the 
RNA pellets were air-dried at room temperature for 5 min.  RNA was resuspended in 20 
µL of DEPC water. 
 
 
3.8.2 Reverse transcription of in vitro transcribed cRNA and dendritic cell-derived 
RNA into cDNA 
 
In the case of in vitro transcribed amplified total cellular mRNAs and single-species 
cRNAs, stock aliquots were diluted in DEPC water so that all samples had the final 
concentration of 0.093 µg/µL.  Reverse transcription reaction mixtures contained 5 µL of 
each diluted sample.  Therefore, in all reaction mixtures cDNA was synthesised using 0.47 
µg in vitro transcribed RNA as a template. 
 
The transfected DC suspension was aliquoted for RNA isolation at different time points 
and the number of transfected DCs in the suspension was determined.  Since all samples 
contained the same amount of DCs, it was not necessary to measure and normalise the 
concentration of isolated total cellular RNA for reverse transcription or the concentration 
of cDNA for real-time PCR (described below). 
 
Reverse transcription of in vitro transcribed cRNAs and isolated total cellular RNA was 
performed using the 1st Strand cDNA Synthesis Kit for RT-PCR (AMV) according to 
manufacturer´s instructions described in Figure 3.11.  The use of this kit was suggested by 
the manufacturer of solutions used in the following step, real-time PCR.  
 
 
 
 
 
 
 
 
 
 
RNA denaturation at 60°C for 10 min followed by the addition of kit 
reagents. 
 
5 µL  RNA 
3.2 µL  Sterile water 
2 µL  Reaction Buffer (10×)   = 1× 
4 µL  MgCl2 (25 mM)    = 5 mM 
2 µL  Deoxynucleotide Mix (10 mM)  = 1 mM 
2 µL  Oligo-p(dT)15 Primer (0.8 µg/µL)  = 1.6 µg 
1 µL  RNase Inhibitor (50 U/µL)  = 50 U 
0.8 µL  AMV Reverse Transcriptase (25 U/µL) = 20 U 
 
20 µL  total 
 
Annealing at 25°C for 10 min.  Reverse transcription at 42°C for 60 
min.  AMV RT denaturation at 99°C for 5 min.  Cooling at 4°C. 
Figure 3.11  Contents of 
the reverse transcription 
reaction mixture and 
reaction conditions 
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3.8.3 Real-time PCR 
 
The real-time PCR system used SYBR Green I, a fluorescent dye which emitted light only 
when bound to dsDNA.  Therefore, the intensity of fluorescence was proportional to the 
number of dsDNA molecules, i.e. PCR product.  This fluorescence was measured by the 
LightCycler® instrument and recorded after each PCR cycle, in real time.  After the PCR 
run, LightCycler® software drew a typical PCR curve for every sample measured.  As 
shown in Figure 3.12 and Table 3.3, the samples were then compared based on the same 
fluorescence (crossing line) but different cycles numbers (crossing points).  Samples with 
more PCR template reached the same fluorescence "sooner" (lower cycle number) than 
samples with less template (higher cycle number). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2     4     6     8    10    12    14   16   18    20   22   24   26  28   30   32   34 
crossing line 
crossing points 
cycle number 
fluorescence 
intensity 
Figure 3.12  Real-time PCR curves.  The LighCycler® instrument simultaneously measures 
fluorescence intensities of all samples at the end of each cycle during a PCR run.  Fluorescent light is 
emitted by the SYBR Green I dye which fluoresces only when bound to dsDNA, i.e. the PCR product. 
Therefore, the intensity of fluorescence is directly proportional to the amount of the PCR product.  A 
typical PCR curve is drawn for each sample by LighCycler® software after simultaneous PCR runs are 
recorded by the software in real time.  Precise quantitative comparison of samples is possible only in 
the logarithmic phase of a PCR reaction.  Therefore, in analysis, a crossing line is drawn so that it 
crosses logarithmic sections of all PCR curves.  The crossing points between the crossing line and the 
curves reveal at which point i.e. cycle number during the PCR run a sample reached the fluorescence 
intensity marked by the crossing line.  Samples containing more PCR template at the beginning of the 
run reach the chosen fluorescence intensity "sooner" (lower cycle number) than samples with less 
template (higher cycle number).  
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Compositions of PCR reaction mixtures and LightCycler® instrument settings depended 
on the primer pair.  These are listed in Tables 3.3 and 3.4.  The 20 µL of a typical reaction 
mixture were composed of: 2 µL of cDNA, 2 µL of the forward and reverse primer 
solution, 2 µL of the SYBR Green I fluorescent dye and enzyme containing solution, 
sterile PCR grade water and MgCl2.  Volumes of the water and the MgCl2 solution 
depended on the desired final MgCl2 concentration that was optimal for the primer pair.  
All components listed above, except for cDNA and primers, were part of the LighCycler® 
– FastStart DNA Master SYBR Green I kit.  Primer pairs for EGFP, Melan-A, CDK4 and 
α-enolase were designed at the institute.  The solution containing tyrosinase primers and 
MgCl2 as well as the tyrosinase standard were part of the kit LightCycler® – Primer Set 
for Human Tyrosinase.  Sequences of the tyrosinase primers and the exact compositions of 
the solutions in the kit were not disclosed by the manufacturer. 
 
 
 
primer pair final MgCl2 concentration 
primer 
concentration 
annealing 
temperature 
annealing 
duration 
elongation 
duration 
EGFP 3 mM 0.50 µM 63°C 3 sec 20 sec 
tyrosinase unknown unknown 68°C 10 sec 16 sec 
Melan-A 3 mM 0.50 µM 59°C 5 sec 20 sec 
CDK4 4 mM 0.50 µM 55°C 10 sec 15 sec 
α-enolase 5 mM 0.38 µM 60°C 10 sec 25 sec 
 
 
Melting curves plotted by the LightCycler® software were used to control primer 
specificities.  Each peak of the melting curve corresponded to one PCR product of a certain 
size.  More peaks would have indicated lower specificity of primers resulting in 
amplification and quantitation of irrelevant sequences in addition to the targeted sequence.  
With all primer pairs described above, only one peak in the melting curve was observed 
confirming the high primer specificity. 
 
Quantitation was performed with the help of LightCycler® software and its Fit Points 
algorithm.  This algorithm calculated cycle numbers corresponding to the crossing points 
between the crossing line and PCR curves of individual samples (Figure 3.12).   
 
Table 3.3  Real-time PCR conditions optimised for individual primer pairs.  
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 cycles analysis mode temperature temp. trans. rate duration 
acquisition 
mode 
denaturation 1 none 95°C 20°C/sec 600 sec none 
95°C 20°C/sec 10 sec none 
Table3.3 20°C/sec Table 3.3 none amplification 40 quantification 
72°C 20°C/sec Table 3.3 single 
95°C 20°C/sec 0 sec none 
58°C 20°C/sec 10 sec none melting 1 melting curves 
99°C 0.1°C/sec 0 sec continuous
cooling 1 none 40°C 20°C/sec 30 sec none 
 
 
As shown in Table 3.5, relative amounts of PCR templates, i.e. molecules detected by the 
sequence-specific primers, were calculated based on these cycle numbers.  The sample 
with the largest measured amount of the PCR template was taken as a reference.  Template 
quantities detected in other samples were calculated relative to this reference.  The n cycle 
difference between a sample and the reference meant a 2n-fold difference in the number of 
template molecules present in the two samples.  For example, when sample 2 (cycle 
number 19.8) was compared with the reference, sample 1 (cycle number 17.2), the cycle 
difference n=2.6 was used to calculate the 6-fold difference (2n=22.6=6) in the number of 
PCR template molecules between the reference and sample 2 (Table 3.5).  This meant that 
sample 2 contained 6-fold less template than the reference.  This fold-difference was then 
expressed as either per cent of the reference or in relative units.  If the amount of PCR 
template in the reference was expressed as 100% (1/1×100=100%), then sample 2 
contained the amount of the PCR template that was 16.67% of the reference 
(1/6×100=16.67%).  Similarly, if the reference was expressed as 106 relative units 
(1/1×106=106 relative units), then sample 2 could be depicted as 1.66×105 relative units 
(1/6×106=1.66×105 relative units). 
 
The LightCycler® – Primer Set for Human Tyrosinase contained a standard for tyrosinase.  
The standard was included in the real-time PCR run in addition to the samples with 
unknown tyrosinase cDNA quantities.  Based on a standard curve, absolute copy numbers 
of the tyrosinase PCR template in analysed samples were calculated.  These were then 
Table 3.4  LightCycler® instrument settings for a typical real-time PCR run.  
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multiplied by dilution factors (from the reverse transcription and real-time PCR steps) and 
divided by the number of cells from which the RNA had been isolated to express the 
quantity as copy number from 1×104 cells. 
 
 
 
 
 
 cycle number 
relative 
quantity
cycle 
difference calculation
quant. 
difference
(fold) 
quant. 
difference 
(%) 
quant. 
difference 
(relative units)
sample 1 17.2 high  0.0 20=1 1 100.00 1 000 000
sample 2 19.8 middle  2.6 22.6=6 6 16.67 166 666
sample 3 23.9 middle  6.7 26.7=104 104 0.96 9 615
sample 4 28.1 low 10.9 210.9=1 911 1 911 0.05 523
 
 
Different RNA samples contained different copy numbers of tyrosinase mRNA (total 
cellular RNA) or cRNA (amplified total cellular mRNA or single-species tyrosinase 
cRNA), i.e. different amounts of the tyrosinase message.  Furthermore, different quantities 
of these RNA samples were used in electroporation experiments.  In order to define how 
much message for tyrosinase had been introduced into DCs in electroporation with various 
RNA samples, relative units calculated as described above were recalculated to take 
different RNA masses into account. 
 
 
 
 
 
 
 
ru in 
0.46 µg RNA 
(relative to 
sample 1) 
RNA 
mass 
in elp. 
calculation ru in elp. RNA calculation 
ru in 
elp. RNA 
(relative to 
sample 1) 
sample 1 1 000 000 48 µg 48×1 000 000 48 000 000 48.00×106/48×106×106 1 000 000
sample 2 166 666 24 µg 24×166 666 3 999 984 3.99×106/48×106×106 83 333
sample 3 9 615 160 µg 160×9 615 1 538 400 1.53×106/48×106×106 32 050
sample 4 523 160 µg 160×523 83 680 8.36×104/48×106×106 1 743
Table 3.5  Relative quantitation of PCR template molecules in different samples.  Based on 
crossing points calculated by LightCycler® software as shown in Figure 3.12, amounts of the 
PCR template in different samples are calculated relative to the reference (sample 1) and 
expressed either as fold-decrease from the reference, as % of the reference or in relative units.  
Table 3.6  Relative quantities of PCR template molecules recalculated taking masses of RNA 
samples into account.  Relative units (ru) proportional to different numbers of PCR template molecules 
in different RNA samples of the same mass (0.46 µg) are calculated as shown in Table 3.5.  These 
relative units are multiplied by the corresponding RNA mass used in electroporation (elp.) and expressed 
once again relative to the 1×106 units of the sample 1 reference. 
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As shown in the example in Table 3.6, relative units (ru) contained in a sample were 
multiplied by the mass of that RNA sample used in electroporation (elp.).  For better 
overview and easier understanding, the recalculated relative units were once again 
expressed relative to the 1×106 relative units of the sample 1 reference containing the most 
tyrosinase message. 
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4. Results 
4.1 Transfection of DCs with RNA encoding EGFP 
 
While the ultimate goal of this project was to investigate the functionality of DCs 
transfected with tumour-derived RNA, the complexity of an experimental system including 
RNA-pulsed DCs and CTLs (DC-RNA-CTL system) was first reduced to an analysis of 
DCs and RNA in order to find the most efficient method of transferring RNA into DCs and 
to define optimal transfection conditions.  Instead of tumour RNA, in vitro transcribed 
cRNA coding for EGFP was used for these experiments.  The size of EGFP cRNA does 
not differ drastically from that of single-species tumour-antigen cRNAs that were to be 
used in subsequent experiments, allowing the assumption that these single-species cRNAs 
would behave similarly in transfection.    Because of hydrogen peroxide release during 
chromophore formation, EGFP might be toxic, but only when produced in extremely large 
quantities.  Therefore, cells are known to tolerate EGFP well. 
 
EGFP emits green light (507-509 nm) when excited with blue light (488 nm).  The word 
"enhanced" in its name refers to the changes that were introduced into the wild type green 
fluorescence protein (GFP): codon-optimisation and two amino acid mutations.  Optimised 
codon usage means that codons more often found in the genome of jellyfish Aequorea 
victoria (from which wild type GFP was isolated) were replaced by triplets coding for the 
same amino acids, but preferred by mammalian cells.  The consequence of such 
engineering is that the enhanced protein is synthesised quicker in human cells (Yang TT et 
al. 1996).  The F64L mutation helps EGFP fold more easily at 37°C.  The S65T mutation 
affects chromophore formation by accelerating oxidation, and makes EGFP 35-times 
brighter than wild type GFP.  Intracellular formation of the wild type GFP chromophore 
takes up to 95 minutes.  EGFP is ready to emit green light upon excitation within no more 
than 35 minutes (Tsien RY 1998).  Despite the enhanced properties of EGFP, additional 
time is still required after translation for proper folding of the native protein and 
chromophore maturation.  Only then can this molecule be induced to emit green light.  The 
intensity of green fluorescence is proportional to the amount of EGFP.  Therefore, EGFP 
expression upon RNA transfection into DCs was measured in FACS™.  In quantitative 
experiments, amounts of transfected EGFP message were determined by the method of 
real-time PCR using designed EGFP-specific primers. 
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The EGFP system was used to address the following questions: 
• Which transfection method is more efficient, electroporation or lipofection? 
• Which cells take up more RNA, immature or mature DCs? 
• Which cells produce more protein after transfection, immature or mature DCs? 
• Does electroporation change the phenotype of mature DCs? 
• How much single-species RNA should be used for efficient transfection? 
• How quickly is transfected RNA degraded inside the DCs? 
• Is there a correlation between the kinetics of RNA degradation and protein production 
inside the DCs? 
 
 
4.1.1 Generation of DCs 
 
Culture with the cytokines IL-4 and GM-CSF is used to differentiate monocytes into DCs 
within approximately six days.  At this time, the monocyte-derived DCs are in an immature 
state, characterised by intensified antigen uptake.  Maturation of DCs requires the presence 
of additional cytokines, TNF-α, IL-1β, IL-6 and PGE2, also known as the maturation 
cytokine cocktail, for one to two days.  Mature DCs concentrate on exposing processed 
antigens to T-cells.  The transition from antigen-sampling immature to antigen-presenting 
mature DCs can be observed through changes in the expression of several surface 
molecules, comprising what is called the phenotype of DCs.  The typical expression profile 
of in vitro generated DCs consists of the following surface markers: CD14 (receptor for the 
complex of LPS and LPS-binding protein, expressed on monocytes but not on DCs), CD1a 
(involved in presentation of non-peptide lipid and glycolipid antigens), CD206 (mannose 
receptor), CD11c (myeloid DC marker, as opposed to plasmacytoid DCs, involved in 
adhesion and signalling), CD83 (DC maturation marker of unknown function), CD40 (co-
stimulatory molecule), CD80 (or B7.1, co-stimulatory molecule), CD86 (or B7.2, co-
stimulatory molecule), MHC class I (or HLA-A,B,C, antigen-presenting molecules) and 
MHC class II (or HLA-DP,DQ,DR, antigen-presenting molecules). 
 
The phenotypes of 6-day old immature and 8-day old mature DCs were assessed in 
FACS™ after staining with FITC or PE-conjugated antibodies specific for the listed 
surface markers (Figure 4.1).  Measured changes in the percentage of positive cells and/or 
mean fluorescence intensity (MFI), indicating how many cells were expressing the marker 
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and how much of it on average, were in accordance with published observations.  DCs 
were generally CD14-negative.  The relatively high expression of CD1a and CD206 on 
immature DCs was down-regulated upon addition of the maturation cocktail, whereas the 
expression of CD11c remained unchanged.  CD83, CD40, CD80, CD86, MHC class I and 
MHC class II, which were already present on immature DCs, were all up-regulated as part 
of the maturation process. 
 
immature DCs immature DCs mature DCsmature DCs
CD14 
CD1a 
CD11c 
CD83 
CD40
CD80
CD86
HLA-
A,B,C
HLA-DP,
DQ,DR
CD206 
Figure 4.1  Phenotype of immature and mature monocyte-derived DCs.  Immature DCs were 
harvested after 6 days in culture with GM-CSF and IL-4 and stained.  Mature DCs were generated 
from immature DCs in the presence of the maturation cytokine cocktail.  They were harvested after a 
total of 8 days in culture and stained.  FACS™ overlay histograms show fluorescence intensities of 
DCs stained with FITC or PE-conjugated antibodies specific for molecules expressed on the cell 
surface (filled curves) and corresponding isotype controls (black curves).  In analysis, a gate was set 
around isotype controls.  Fluorescence of DCs placed outside the gate was considered specific and 
those DCs positive for the stained surface marker.  Histogram statistics were used to calculate the 
percentage of positive cells and their mean fluorescence intensity (MFI).
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Monocytes used for generating DCs were isolated from PBMCs through plastic adherence.  
In preliminary experiments, PBMCs were obtained from buffy coats or fresh blood of 
different donors.  This resulted in unstable yields of morphologically, phenotypically and 
functionally different DCs and, as a consequence, a low degree of reproducibility in 
experiments.  Keeping in mind that DCs would play an important role in precise 
quantitation experiments, this variability in the system had to be reduced.  Therefore, one 
HLA-A*0201 donor (donor PH) was subjected to leukapheresis in order to obtain large 
numbers of PBMCs.  These cells were aliquoted and frozen.  For each subsequent 
experiment, ampoules from the same stock of PBMCs were thawed, monocytes isolated 
and DCs generated according to the same protocol (unless noted otherwise).  The 
standardisation of DC culture proved to be the right solution, since DCs from donor PH, 
generated on different occasions, displayed the same phenotype (Figure 4.1).   
 
 
4.1.2 Lipofection vs. electroporation and immature DCs vs. mature DCs 
 
It was postulated that in addition to priming CD8+ CTLs, RNA-pulsed DCs could prime 
CD4+ T-helper cells if the transfected RNA was protected by cationic lipids, used as a 
transfection reagent, and was therefore present inside the cells for a longer time (Su Z et al. 
2001).  For this reason, lipofection was the preferred transfection method in preliminary 
experiments.  A comparison of different cationic lipids revealed that TransFast™ was most 
efficient (Strobel I et al. 2000).  Electroporation was then reported to be superior to 
lipofection and passive pulsing (van Tendeloo VF et al. 2001).  Electroporation parameters 
in the following experiments were composed of those suggested in personal 
communication (Steinkasserer A) and found in several publications (Kalady MF et al. 
2002, Milazzo C et al. 2003). 
 
In order to determine which transfection method was more efficient in the standardised DC 
system, and which cells were more susceptible to forced RNA uptake, lipofection and 
electroporation of immature and mature DCs were compared in the same experiment.  
Immature DCs were harvested after 6 days in culture.  One half of these cells was used for 
transfection with EGFP cRNA on the same day, whereas the other half was placed back 
into culture with the cytokine maturation cocktail for an additional two days to produce 
mature DCs.  These mature DCs were then transfected under the same conditions as the 
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immature DCs.  Eight µg of EGFP cRNA were either lipofected or electroporated into 
2×106 DCs.  The percentage of EGFP-positive cells and the mean intensity of green 
fluorescence were measured by flow cytometry in all samples 1, 2, 3.5, 6.5, 12.5, 24.5, 
48.5 and 72.5 hr after transfection.  This kinetics analysis was done to determine how 
quickly protein expression occurred and how stable the transfectants were following 
introduction of RNA by both methods. 
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Figure 4.2  Efficiencies of lipofection and electroporation with EGFP cRNA. 
Same transfection conditions were used for both immature DCs and mature DCs. 
Lipofection (A) and electroporation (B) were performed with 8 µg of EGFP 
cRNA.  The fluorescence of untransfected or EGFP cRNA-transfected DCs was 
measured in FACS™ at different time points after transfection.  Diagrams show 
percentages of EGFP-positive DCs from FACS™ overlay histograms in which a 
gate was set around untransfected DCs.  Fluorescence of DCs placed outside the 
gate was considered to be of EGFP origin and those DCs positive for EGFP. 
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The two transfection methods are best compared by assessment of how many cells 
successfully received the RNA, i.e. by determining of the percentages of EGFP-positive 
cells (Figure 4.2).  The development of green fluorescence seemed to take different courses 
in lipofected and electroporated DCs.  At 48 hr after lipofection, the highest percentage 
(only 15%) of EGFP-positive immature DCs was observed (Figure 4.2A).  This suggested 
that, even though RNA had entered the cytoplasm, it did not immediately make contact 
with the ribosomes on which protein production takes place.  RNA molecules were 
probably gradually released from the complexes with lipids and the amount of EGFP in the 
cells increased at a relatively slow pace, allowing detection of positive cells with a certain 
delay.  At all time points, not as many mature DCs were positive, compared to the 
immature DCs, suggesting that these cells must have taken up fewer RNA-lipid complexes.  
This observation is consistent with the down-regulation of antigen (in this case RNA-lipid 
complexes) capture which is known to occur upon DC maturation. 
 
In electroporated cells, RNA was not slowed down by attached lipids.  Therefore, RNA 
was ready for translation once it arrived in the cytoplasm.  Already within the first 3.5 hr 
after transfection, the percentage of EGFP-positive mature DCs rapidly increased, reached 
a maximum at 12.5 hr and then remained stable at 85-91% for at least two days (Figure 
4.2B).  Similar kinetics were observed with immature DCs.  Nevertheless, electroporated 
RNA seemed to reach fewer immature DCs (73-83%) compared to the mature ones. 
 
MFI is a direct measure of how much EGFP is produced in the cells.  Twenty-four hr after 
either lipofection or electroporation, the MFI of mature DCs was approximately two-fold 
higher than the MFI of immature DCs (Figure 4.3).  Upon DC maturation, internalisation 
of extracellular molecules is reduced, and antigen processing becomes the main task.  One 
can assume that intensified protein synthesis in mature DCs contributes to antigen 
presentation by providing more starting material for peptide production.  This makes 
particular sense if the antigen is introduced into the DC in the form of DNA or RNA.  
Since internalising antigen is primarily a function of immature cells, it is not likely that 
under the same transfection conditions mature DCs would take up more RNA than 
immature DCs.  This observation may indicate that mature DCs synthesised more protein 
than immature DCs transfected with the same amount of RNA. 
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Surprisingly, even though only a few lipofected cells were detected as EGFP-positive 
(Figure 4.3), they fluoresced with a convincingly higher intensity (MFI 147 for immature 
and 299 for mature) compared to their electroporated counterparts (MFI 88 for immature 
and 202 for mature).  It is possible that single cells take up extremely large amounts of 
RNA through lipofection, whereas the RNA is distributed more evenly among the cells 
following electroporation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In a separate experiment performed under the same conditions, even 5 days after 
electroporation, 38% of mature DCs were still EGFP-positive (Figure 4.4).  This 
represented a decrease of only 49% from the maximum, with the intensity of their green 
fluorescence relatively low (down 85% from the maximum).  The compact structure of the 
electroporation lipofection 
mDC 
85.45 %     202.35 MFI 5.51 %     299.34 MFI 
76.25 %     88.21 MFI 9.86 %     147.14 MFI 
iDC 
Figure 4.3  Immature and mature DCs after lipofection and electroporation with EGFP cRNA.  Same 
transfection conditions were used for both immature DCs (iDC) and mature DCs (mDC).  Lipofection and 
electroporation were performed with 8 µg of EGFP cRNA.  Fluorescence microscopy photographs show 
EGFP cRNA-transfected DCs 27 hr after transfection.  The corresponding percentages of EGFP-positive cells 
and EGFP mean fluorescence intensities (MFI) were calculated in overlay histograms based on FACS™ data 
that were obtained 24.5 hr after transfection.  For definition of EGFP-specific fluorescence and EGFP-
positive cells see Figure 4.2. 
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EGFP molecule, which resembles a barrel, makes it very stable under a variety of different 
conditions, including treatment with proteases (Tsien RY et al. 1998), and gives it a half-
life of more than 24 hr (Li X et al. 1998).  Whereas the stability of EGFP surely is largely 
responsible for this observation, it is also possible that the transfected RNA survived inside 
the cell for longer periods of time despite the presence of aggressive intracellular RNases. 
 
These experiments showed that the efficiency of electroporation was undoubtedly superior 
to the efficiency of lipofection.  An advantage was also found in using mature DCs, since 
they produced more protein, based on a given amount of electroporated RNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.3 Phenotype of electroporated DCs 
 
It was important to assure that placing mature DCs into an electric field and forcing foreign 
RNA into them did not change their surface phenotype, comprised of important molecules  
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Figure 4.4  Late kinetics of EGFP expression.  Mature DCs were electroporated 
with 8 µg of EGFP cRNA.  The fluorescence of EGFP cRNA-transfected DCs was 
measured in FACS™ at different time points after electroporation, including the 
relatively late time points 101.5 hr and 124 hr.  In the diagram with two Y-axes, 
mean fluorescence intensities of EGFP cRNA-transfected DCs are depicted on the 
left Y-axis and corresponding percentages of EGFP-positive cells on the right Y-
axis. These were calculated in overlay histograms based on FACS data.  For 
definition of EGFP-specific fluorescence and EGFP-positive cells see Figure 4.2. 
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necessary for interaction with lymphocytes.  Therefore, after 8 days in culture, one aliquot 
of mature DCs was stained with PE-conjugated antibodies for CD80, CD86, CD83 and 
EGFP 
CD80 
CD86 
CD83 
HLA-DR 
day 0: 
before 
electroporation 
day 1: 
24 hr after 
electroporation
day 2: 
48 hr after 
electroporation 
day 3: 
72 hr after 
electroporation
Figure 4.5  DC phenotypes before and after electroporation.  Mature DCs were stained before and at 
several time points after electroporation with 12 µg of EGFP cRNA.  FACS™ histograms for day 0 show 
only fluorescence intensities of stained untransfected DCs.  FACS™ overlay histograms for days 1, 2 and 
3 show fluorescence intensities of both stained untransfected DCs (black curves) and stained EGFP 
cRNA-transfected DCs (filled curves).  Staining was performed with PE-conjugated antibodies specific for 
molecules expressed on the cell surface.  Staining with unspecific PE-conjugated antibodies was included 
as an isotype control (not shown).  For definition of surface marker-specific PE fluorescence and surface 
marker-positive cells see Figure 4.1. 
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HLA-DR in order to define their phenotype before electroporation.  The other aliquot, 
containing 3×106 cells, was electroporated with 12 µg of EGFP cRNA.  Transfected cells 
were divided into three aliquots and put back into culture with IL-4 and GM-CSF.  
Aliquots were harvested 24, 48 or 72 hr after electroporation.  Expression of EGFP, CD80, 
CD86, CD83 and HLA-DR was analysed in FACS™ for each time point. 
 
All transfected aliquots showed stable expression of EGFP (Figure 4.5).  No significant 
shifts in the percentages of CD80, CD86 and HLA-DR-positive cells were observed at any 
of the three time points after electroporation.  The number of CD83-positive cells 
decreased from 89% on day 0 to 55% on day 3, which is most probably an effect caused by 
the lack of maturation cytokines in the medium and not by electroporation.  The only MFI 
shift was observed in the case of CD86 (MFI down from 1111 before electroporation to 
890 a day later), if significant at all, possibly indicating that on average single cells 
expressed somewhat less of this co-stimulatory molecule.  On days 2 and 3, MFI of CD86 
returned to the higher range (MFI 1144 and 1162).  It could be concluded from these 
experiments that electroporation did not alter the expression of several important antigen-
presenting and co-stimulatory molecules on the surface of mature DCs and therefore 
should not be detrimental for their interaction with T-cells. 
 
 
4.1.4 Electroporation with increasing amounts of EGFP cRNA 
 
Since an important goal of these studies was to optimise antigen processing and 
presentation by the DCs following RNA transfer, it was important to determine whether 
changing the RNA concentration would have an impact on the efficiency of transfection 
and the amount of protein produced by the DCs.  Therefore, varying amounts of EGFP 
cRNA (2, 4 or 8 µg) were transfected into 2×106 mature DCs, which were then analysed by 
fluorescence microscopy and flow cytometry at different time points. 
 
More RNA indeed meant more green cells (Figure 4.6).  This difference was detected 
early, only 6.5 hr after electroporation.  Only a few DCs transfected with 2 or 4 µg of 
EGFP cRNA were slightly positive in FACS™, but under a UV-microscope they were 
either not seen to emit green light at all, or only very weakly.  At the same time, many DCs 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
57.07%    60.41 MFI
2 µg EGFP cRNA 4 µg EGFP cRNA 8 µg EGFP cRNA 
25 hr
52.94%     45.89 MFI 56.60%     72.51 MFI 86.60%     190.48 MFI
59.95%     100.6 MFI 87.00%     285.38 MFI
7 hr
Figure 4.6  DCs after electroporation with increasing amounts of EGFP cRNA.  Mature DCs were electroporated with 2, 4 or 8 µg of EGFP cRNA. 
Fluorescence microscopy photographs show EGFP cRNA-transfected DCs 7 hr and 25 hr after electroporation.  The corresponding percentages of EGFP-
positive cells and EGFP mean fluorescence intensities (MFI) were calculated in overlay histograms based on FACS™ data that were obtained 6.5 hr and 
24.5 hr after transfection.  For definition of EGFP-specific fluorescence and EGFP-positive cells see Figure 4.2. 
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transfected with 8 µg were visibly green.  Precise FACS™ analysis at all time points 
confirmed that the difference between 2 and 4 µg was minimal, as in both cases 55-60% of 
the cells measured positive for EGFP.  Doubling the amount to 8 µg resulted in a 
convincingly higher number of cells reached by the RNA, yielding approximately 90% 
positive cells.  As expected, protein levels were also influenced by the amount of 
transfected RNA.  The mean fluorescence intensity at 24.5 hr showed only a 1.6-fold 
difference between 2 and 4 µg (MFI 60 vs. 101), whereas a 2.8-fold difference was found 
between 4 and 8 µg (MFI 101 vs. 285). 
 
The kinetics of EGFP synthesis was the same in the three electroporated samples with the 
maximum MFI reached 24.5 hr after transfection and only a slight decrease over the 
following two days (Figure 4.7).  At all time points, the MFI of DCs transfected with 8 µg 
remained higher than the MFI of DCs transfected with either 4 or 2 µg of EGFP cRNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to achieve better antigen presentation, through generation of more DCs containing 
more transferred RNA, thereby providing more peptides for presentation within their MHC 
molecules, RNA dose-finding seemed to be the right method for enhancing the function of 
Figure 4.7  EGFP expression in DCs transfected with increasing amounts of 
EGFP cRNA. Mature DCs were electroporated with 2, 4 or 8 µg of EGFP cRNA. 
The fluorescence of EGFP cRNA-transfected DCs was measured in FACS™ at 
different time points after electroporation.  In the diagram, mean fluorescence 
intensities of EGFP cRNA-transfected DCs are depicted.  These were calculated in 
overlay histograms based on FACS™ data.  For definition of EGFP-specific 
fluorescence and EGFP-positive cells see Figure 4.2. 
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DCs.  After this experiment it remained to be seen if T-cells would really react more 
strongly to the DCs that were pulsed with higher amounts of tumour RNA.  DCs needed 
some time to recover from the electric shock, and to produce, process and present the 
antigen.  In the case of EGFP, the time needed to recuperate and express the highest 
amount of the protein summed up to approximately 24 hr.  
 
 
4.1.5 Kinetics of EGFP cRNA degradation and EGFP expression 
 
The next issue that was addressed was how transfected RNA behaved inside the cell.  Most 
importantly, how long after electroporation or lipofection could transfected RNA be 
detected and did the kinetics of its degradation correlate with the kinetics of protein 
expression? 
 
To examine these parameters, DCs were aliquoted immediately after electroporation with 8 
µg of EGFP cRNA.  From these aliquots, total cellular RNA, also containing the 
transfected EGFP cRNA, was isolated at 0.5, 1.5, 3, 6, 12, 24, 48 and 72 hr after 
electroporation.  Isolated RNA was reverse transcribed into cDNA.  The quantity of cRNA, 
i.e. cDNA coding for EGFP, was then assessed in all samples using the highly sensitive 
and precise method of real-time PCR.  If samples are compared with a standard, the 
amount of measured RNA can be expressed as the number of molecules.  Unfortunately, a 
standard for EGFP RNA was not available.  Since in an experimental setup without a 
standard a good reference is important, RNA was isolated from the transfected DCs only 
10 and 30 min after electroporation. 
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Figure 4.8  Kinetics of EGFP 
cRNA degradation.  Total cellular 
RNA was isolated from DCs 
transfected with 8 µg of EGFP 
cRNA at different time points after 
electroporation.  Isolated RNA was 
reverse transcribed into cDNA and 
the amount of EGFP messsage was 
assessed by real-time PCR using 
EGFP-specific primers.  The dia-
gram shows the amounts of EGFP 
message expressed relative to the 10 
min value which was taken as the 
100% reference. 
Results 76
The comparison of the 10 min and the 30 min values (Figure 4.8) revealed that within 
those 20 min the amount of EGFP cRNA decreased from 100% (10 min) to 86% (30 min).  
Therefore, the 30 min value was judged to be a suitable reference, since it still 
encompassed most of the RNA that made contact with the cells and provided a time period 
that allowed appropriate technical handling of the samples. 
 
 
 
 
 
 
 
 
 
 
 
 
Small standard deviations showed that RNA had similar degradation kinetics in all 
samples, irrespective of the amount used for transfection (Figure 4.9).  The value at 0.5 hr, 
depicted as the 100% reference, was less than what was put into the electroporation cuvette 
because not all RNA was transported into the cells during transfection.  The value at 1.5 hr 
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Figure 4.9  Kinetics of EGFP 
cRNA degradation – mean values.
Total cellular RNA was isolated 
from EGFP cRNA transfected-DCs 
at different time points after 
electroporation.  Isolated RNA was 
reverse transcribed into cDNA and 
the amount of EGFP message was 
assessed by real-time PCR using 
EGFP-specific primers.  The dia-
gram shows the amounts of EGFP 
message expressed relative to the 0.5 
hr value which was taken as the 
100% reference.  Mean values and 
their standard deviations represent 
seven experiments. 
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Figure 4.10  Detection of 
transfected EGFP cRNA 72 hr 
after electroporation  Total cellular 
RNA was isolated from DCs 
transfected with 2, 4 or 8 µg of 
EGFP cRNA at different time points 
after electroporation.  Isolated RNA 
was reverse transcribed into cDNA 
and the amount of EGFP message 
was assessed by real-time PCR using 
EGFP-specific primers.  The dia-
gram shows crossing points (real-
time PCR raw data) which can be 
used to calculate relative or absolute 
amounts of analysed genetic 
message – the higher the crossing 
point, the less message detected. 
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was stunningly low, indicating that within only an hour the amount of RNA rapidly 
decreased to approximately 17% of that which was associated with the cells in the first 
place.  It seems that a lot of RNA was lost due to the transfection method and to the 
presence of extracellular and intracellular RNases.  The value at 3 hr showed that within 
the following hour and a half another 12% of the RNA was lost, and then between 6 and 72 
hr less than 1% could be detected.  Keeping in mind that all these values were calculated 
relative to the highest amount measured only 30 min after electroporation, it is clear that 
<1% did not necessarily mean that extremely little or no RNA could be found.  Real-time 
PCR raw data (crossing points between 23 and 27) proved that even 72 hr after 
electroporation, EGFP cRNA could still be detected inside the transfected cells (Figure 
4.10).  Higher crossing points do mean less RNA, but only the analysis of those above 35 
is critical because of the technical limitations imposed by the LightCycler® instrument in 
which real-time PCR is performed. 
 
Interestingly, plotting the kinetics of EGFP cRNA degradation against the kinetics of 
EGFP expression showed that RNA and protein behaved very differently (Figure 4.11).  
This raised the question of how protein production could increase while RNA degradation 
eliminated most of the translation substrate from the cell.   
 
In mature electroporated DCs, green fluorescence peaked at 12 hr (Figure 4.11A).  At the 
same time, EGFP cRNA could still be detected, but less than 1% of the amount that had 
been found at 0.5 hr.  The same RNA and protein kinetics experiment was performed with 
lipofected immature DCs (Figure 4.11B).  In these cells, EGFP cRNA degradation took 
place at a slower pace, with 40% of the maximum amount still detectable 12 hr after 
lipofection.  Since lipofected RNA entered the cell as part of an RNA-lipid complex, this 
most likely meant that RNA was better protected from RNases by the lipids used as the 
transfection reagent.  Also with lipofection, the question remained whether the real-time 
PCR studies were detecting extracellular RNA in addition to the intracellular transfected 
RNA. 
 
In order to eliminate the RNA that had not entered the cells and was left floating in the 
culture medium, all cell samples were washed twice before RNA isolation.  Nevertheless, 
it was still possible that the negatively charged RNA remained electrostatically attached to 
the slightly negatively charged cell surface.  Therefore, it was not certain whether the RNA 
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detected by real-time PCR derived only from inside the cells or may also have included 
RNA associated with the cell surface.  Even though extracellular RNA could still be 
internalised by the DC, the origin of RNA is important because most of the potentially 
measured extracellular RNA is not functional and could not contribute to the synthesis of 
EGFP.  The rapid RNA degradation effect that was observed may be an artefact due to 
large amounts of extracellular RNA that are aggressively degraded by RNases in the serum 
containing culture medium. 
 
Contradictory kinetics of RNA degradation and protein synthesis may, to a certain extent, 
be explained by the delayed development of green fluorescence due to the time needed for 
proper folding of the EGFP molecule and its chromophore formation.  While RNA was 
being degraded, EGFP was being produced, but could not be detected.  At the moment 
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A.   electroporation Figure 4.11  Kinetics of EGFP 
cRNA degradation and kinetics 
of EGFP expression.  Mature 
DCs were electroporated (A) and 
immature DCs were lipofected (B) 
with 8 µg of EGFP cRNA.  At 
different time points after 
transfection, the fluorescence of 
EGFP cRNA-transfected DCs was 
measured in FACS™ and total 
cellular RNA was isolated from 
the cells.  Isolated RNA was 
reverse transcribed into cDNA and 
the amount of EGFP message was 
assessed by real-time PCR using 
EGFP-specific primers.  In the 
diagram with two Y-axes, the 
kinetics of RNA degradation is 
plotted against the kinetics of 
EGFP expression.  On the right Y-
axis, the amounts of EGFP 
message are shown (curve). 
These were expressed relative to 
the 0.5 hr value which was taken 
as the 100% reference.  On the left 
Y-axis, corresponding mean 
fluorescence intensities are shown 
(columns).  These were calculated 
in overlay histograms based on 
FACS™ data.  For definition of 
EGFP-specific fluorescence and 
EGFP-positive cells see Figure 
4.2.  
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when it seemed the electroporated RNA levels were extremely low compared to what had 
been measured at the beginning, EGFP started fluorescing. 
 
 
4.1.6 Summary of the data obtained in the EGFP system 
 
If DCs were generated from identical stocks of frozen PBMCs and according to same 
protocol, they displayed an unchanged phenotype.  Standardization of the DC system was 
important for the reproducibility of results in precise quantitation experiments.  The 
highest efficiency of EGFP cRNA transfection into DCs was achieved with 
electroporation.  Lipofection yielded significantly fewer EGFP-positive cells, but 
individual lipofected cells expressed more EGFP based on transfected RNA than 
individual electroporated cells.  Mature DCs expressed more EGFP than immature DCs, 
the maximum being reached 12 hr after electroporation.  DCs remained EGFP-positive for 
at least 5 days.  Expression of important antigen-presenting and co-stimulatory molecules 
on the surface of DCs did not change after electroporation with EGFP cRNA.  EGFP 
cRNA dose-finding showed that more RNA used in electroporation would indeed result in 
higher EGFP expression.  Even though the expression of EGFP in transfected DCs 
increased over the first 12 hr after electroporation, the kinetics of EGFP cRNA degradation 
revealed that the amount of transfected RNA rapidly decreased shortly after 
electroporation.  EGFP cRNA could still be found in transfected DCs 3 days after 
electroporation.  It was unclear whether EGFP cRNA detected in quantitation experiments 
was of intracellular origin or also derived from the cell surface. 
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Experimental model for the study of TAA expression in RNA-transfected DCs 
 
Identification of multiple melanoma-associated antigens was a major achievement in 
tumour immunology within the last decade (reviewed by Castelli et al. 2000).  The 
biochemical approach (peptide extraction from MHC molecules and their mass 
spectrometric analysis) and/or the genetic approach (screening of tumour cDNA libraries 
by anti-tumour T-cells) were used to define twenty different MAAs to date and, at least, 
one MHC epitope has been identified for most of these tumour-associated antigens.  Based 
on their expression patterns in malignant and normal tissues, the antigens have been 
classified into three groups: melanocyte differentation antigens, tumour/testis-specific 
antigens and melanoma-specific antigens. 
 
For these studies, the melanoma model was chosen to quantitatively analyse antigen 
transfection, processing and presentation in DCs because it is well characterised at the 
cellular and molecular levels.  Tyrosinase, Melan-A and CDK4-R24C antigens were 
selected for these experiments. 
 
Tyrosinase is a transmembrane protein of 529 amino acids.  This enzyme is critical for the 
synthesis of melanin in melanocytes and retina cells.  In the case of melanoma, it belongs 
to the melanocyte differentiation antigens group of tumour-associated antigens.  The 
following reagents were available for tyrosinase: 
• cDNA in a plasmid vector (1888 bp insert in pZeoSV2+/huTyr) 
• two HLA-A*0201-restricted peptides (tyrosinase369-377 epitope YMNGTMSQV that 
was predicted based on the cDNA sequence and tyrosinase369-377 epitope 
YMDGTMSQV that was later found to be naturally presented by the cells) 
• two CTL clones specific for these epitopes (TyrF8 CTL and IVS B CTL) 
 
Melan-A, also known as MART-1 (melanoma antigen recognised by T-cells 1), is a 
transmembrane protein of 118 amino acids.  Like tyrosinase, it is expressed in melanocytes 
and retina cells, but its function is still unknown.  It belongs to the melanocyte 
differentitation antigens group of melanoma-associated antigens.  The following reagents 
were available for Melan-A: 
• cDNA in a plasmid vector (656 bp insert in pcDNAI/Amp/Aa1.2) 
• one HLA-A*0201-restricted peptide (Melan-A26-35 epitope ELAGIGILTV) 
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• two CTL clones specific for this epitope (A42 CTL and 11/33 CTL) 
 
CDK4-R24C is a mutated form of CDK4, a protein of 301 amino acids that serves as a 
stimulator in cell cycle progression.  This particular mutation renders CDK4 insensitive to 
its inhibitor, resulting in cell cycle disregulation and, as a consequence, uncontrolled cell 
growth.  CDK4-R24C is unique to melanomas and belongs to the melanoma-specific 
antigens group.  The following reagents were available for CDK4-R24C: 
• cDNA in a plasmid vector (1331 bp insert in pcDNAI/Amp/C11.1)  
• one HLA-A*0201-restricted peptide (CDK4-R24C23-32 epitope ACDPHSGHFV) 
• one CTL clone specific for this epitope (14/35 CTL) 
 
Furthermore, five different melanoma cells lines were used in these studies: 
• 623.38 MEL 
• A375 MEL 
• IL-2 MEL 
• SK23 MEL 
• SK29 MEL 
 
 
4.2 Transfection of DCs with RNA encoding tyrosinase 
 
CTLs are activated through their TCRs that recognise MHC class I molecules presenting 
antigenic peptides.  Activated CTLs secrete IFN-γ, among other cytokines.  In a natural 
situation, IFN-γ directly inhibits viral replication in infected cells, activates macrophages, 
increases expression of MHC class I and other molecules involved in peptide processing 
and presentation, and also increases or even induces MHC class II expression.  In 
immunotherapy against tumours, viruses or other pathogens are not always present, but the 
CTLs react in the same manner after specifically recognising pMHC on tumour cells.  
They can also recognise their pMHC ligands on other cell types, such as APCs, if the 
APCs are provided with either synthetic peptides or genetic information encoding the 
peptide in the form of DNA or RNA.  
 
In functional assays, DCs pulsed with cRNA coding for tyrosinase were co-incubated with 
the tyrosinase-specific TyrF8 CTL clone recognising the tyrosinase369-377 peptide.  IFN-γ 
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secretion by these CTLs was taken as a measure of DC stimulatory capacity and was 
assessed by ELISA.  In quantitative experiments, amounts of tyrosinase message were 
determined in real-time PCR using published tyrosinase-specific primers. 
 
The tyrosinase system was used to address the following questions: 
• How long after their last restimulation should CTLs be added to the transfected DCs 
for efficient stimulation? 
• How much time after electroporation should elapse before the DCs show efficient 
antigen production, processing and presentation? 
• Does exposure of DCs to the electroporation procedure alter their function so that they 
activate CTLs independent of pMHC expression? 
• How much single-species tumour-antigen cRNA must be used for efficient CTL 
stimulation?  
• How many transfected DCs are needed in order to fully engage TCRs on CTLs? 
• How reproducible are the results in a standardised DC-RNA-CTL system? 
• Which RNA concentration is important for electroporation? 
• How quickly is transfected single-species tumour-antigen cRNA degraded inside the 
DCs? 
• How does treatment of transfected DCs with RNase influence RNA degradation 
kinetics? 
 
 
4.2.1 Time in culture needed for  CTLs to most efficiently react to antigen 
presentation  
 
It was observed that the TyrF8 CTL clone was extremely sensitive to cell culture 
conditions and that it had an individual rhythm of proliferation and reactivity, depending 
on how often it had already been restimulated.  Standardising the DC-RNA-CTL system 
meant expanding the TyrF8 CTLs and freezing them in such a quantity that for each of the 
subsequent experiments ampoules from the same stock could be utilised.  Using the same 
source of frozen cells, the same restimulation conditions and the same culture conditions 
provided a hypothetical guarantee that once these CTLs were applied in an assay, they 
would show similar or even identical reactivities against the antigen-presenting cell. 
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According to experience, TyrF8 CTLs needed to be restimulated every two weeks in order 
to survive and proliferate.  If CTLs required time to recover after thawing, and if after two 
weeks they would no longer proliferate, it was essential to determine the optimal time to 
harvest them from restimulation cultures so that their function could be assessed after co-
incubation with test APCs. 
 
To address this point, one ampoule of TyrF8 CTLs was thawed and restimulated.  The 
same was done once again five days later.  On the day of co-incubation with the test DCs, 
one set of the CTLs had already been in culture for thirteen days and the other set for only 
eight days.  Whereas the maximum amount of EGFP cRNA used for transfection had been 
8 µg, the decision was made to use more tyrosinase cRNA.  RNA coding for tyrosinase is 
approximately twice as long as RNA coding for EGFP, therefore a sample of the same 
mass contains less message for tyrosinase than message for EGFP.  Electroporation was 
performed with 12 µg of tyrosinase cRNA and 3×106 DCs.  Twenty-five hours later, either 
13-day or 8-day TyrF8 CTLs were mixed with the transfected DCs.  The number of DCs 
per well was 4×104, 2×104, 1×104 or 5×103.  The number of 2×104 CTLs per well was 
constant, giving stimulator to effector ratios of 2:1, 1:1, 1:2 and 1:4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TyrF8 CTLs that had spent only eight days in culture between the last restimulation and 
co-incubation with the test DCs reacted stronger than the thirteen-day old CTLs, producing 
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Figure 4.12  Reactivities of 8-day 
old and 13-day old TyrF8 CTLs. 
Mature DCs were electroporated 
with 12 µg of tyrosinase cRNA. 
On the day of mixing with 
transfected DCs, TyrF8 CTLs, 
specific for tyrosinase pMHC, had 
been in culture for 8 or 13 days 
after the last restimulation.  The 
diagram shows the amount of 
IFN-γ secreted by 2×104 activated 
CTLs during the 24 hr co-
incubation with 4×104, 2×104, 
1×104 or 5×103 transfected DCs. 
IFN-γ was measured in 
supernatants by ELISA.  Mean 
values and their standard 
deviations represent co-incubation 
triplicates. 
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almost twice as much IFN-γ (e.g. 181 pg/mL IFN-γ vs. 109 pg/mL IFN-γ at 2:1) in 
response to the presented tyrosinase antigen (Figure 4.12).  Better effector cell stimulation 
was also observed with higher numbers of stimulator cells (181 pg/mL IFN-γ at 2:1 vs. 46 
pg/mL IFN-γ at 1:4 when compared using 8-day CTLs).  This showed that taking more 
DCs ensured better engagement of CTLs, resulting in stronger activation. 
 
 
4.2.2 Time needed for transfected DCs to most effectively present the antigen 
 
Data obtained in transfection experiments with EGFP cRNA showed that the maximum 
expression of protein was reached approximately 24 hr after electroporation.  In the EGFP 
system, green fluorescence served as a measure of protein expression.  The tyrosinase 
system was not completely comparable because it was based on RNA coding for a protein 
with different properties and because the measurement of protein expression was indirect 
and required antigen presentation to be assessed in a functional assay.  Nevertheless, it 
seemed fair to assume that electroporated DCs would need time to recover from the 
electric shock and to produce, process and present the antigen on the surface.  The question 
remained whether CTLs would react better if they were present throughout the production 
and the processing phase, or whether they would respond better if they first came into 
contact with the DCs after the pMHC complexes had already been generated.  
 
A kinetic experiment was performed to address this question.  Here, 24 µg of tyrosinase 
cRNA were used in electroporation of 3×106 DCs.  Transfected DCs were divided into two 
aliquots.  One aliquot was used 2 hr later for antigen presentation to the 8-day TyrF8 
CTLs.  The other aliquot was mixed with 9-day CTLs 25 hours after electroporation.  Once 
again 4×104, 2×104, 1×104 or 5×103 DCs and 2×104 CTLs gave the DC:CTL ratios of 2:1, 
1:1, 1:2 and 1:4. 
 
As shown in Figure 4.13, more efficient CTL stimulation was observed with the DCs that 
were given 25 hr to process the transfected RNA before addition of CTLs, compared to 2 
hr (e.g. 499 pg/mL IFN-γ vs. 246 pg/mL IFN-γ at 2:1).  As expected, the highest DC:CTL 
ratio again resulted in the strongest CTL stimulation (499 pg/mL IFN-γ at 2:1 vs. 84 pg/mL 
IFN-γ at 1:4 when compared using CTLs stimulated by DCs 25 hr after electroporation).  
This meant that 4×104 DCs induced the maximum IFN-γ secretion by 2×104 CTLs. 
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In the previous experiment, 12 µg of tyrosinase cRNA were used in electroporation and 
TyrF8 CTLs produced 181 pg/mL IFN-γ when stimulated by the transfected DCs.  In this 
experiment 24 µg of tyrosinase cRNA were introduced into the DCs and they stimulated 
the same CTLs to produce 499 pg/mL IFN-γ.  This comparison indicated that better 
stimulation of an antigen-specific CTL clone could be achieved by transfecting more 
antigen RNA into the DCs.  DCs would in turn express more tyrosinase protein and more 
pMHC at the cell surface.  
 
In general, these experiments showed that TyrF8 CTLs should be used in co-stimulation 
experiments after only 8 days in culture following thawing and restimulation.  After 
transfection and before contact with the TyrF8 CTLs, DCs should also be allowed 
approximately 24 hr to generate pMHC before contact with the TyrF8 CTLs. 
 
 
4.2.3 Controls in the DC-RNA-CTL system 
 
In assessing function in the DC-RNA-CTL system, a number of controls were important.  
Two-hour incubation of PBMCs in plastic cell culture dishes resulted in generation of 
monocyte monolayers adhering to the plastic surface.  Non-adherent PMBCs were 
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Figure 4.13  Stimulatory capa-
cities of tyrosinase cRNA-
transfected DCs 2 hr and 25 hr 
after electroporation.  Mature 
DCs were electroporated with 24 
µg of tyrosinase cRNA.  At the 
moment of mixing with TyrF8 
CTLs, specific for the tyrosinase 
pMHC, transfected DCs had been 
in culture for 2 or 25 hr after 
electroporation.  The diagram 
shows the amount of IFN-γ
secreted by 2×104 activated CTLs 
during the 24 hr co-incubation 
with 4×104, 2×104, 1×104 or 5×103
transfected DCs.  IFN-γ was 
measured in supernatants by 
ELISA.  Mean values and their 
standard deviations represent co-
incubation triplicates. 
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carefully washed away and the remaining monocytes were differentiated into DCs within 
approximately one week.  Despite washing, 10-30% lymphocytes were detected within the 
enriched monocyte population.  These lymphocytes were also present among the mature 
DCs after 8 days of culture and were always part of the cell suspension used in 
electroporation.  Therefore, it was possible that after transfection the contaminating 
lymphocytes could produce IFN-γ in response to the pulsed DCs or even in response to 
their own contact with extremely high amounts of RNA.  If such a response occurred, IFN-
γ would have been produced in the electroporated suspension without the addition of 
antigen-specific TyrF8 CTLs.  This would have required subtraction of the background 
IFN-γ secretion from the reactivity attributed to the TyrF8 CTLs.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It also had to be determined whether TyrF8 CTLs were activated to unspecific IFN-γ 
secretion through their experimental manipulation.  This was assessed after incubation of 
TyrF8 CTLs for 24 hr either alone or with peptide-pulsed DCs or with unpulsed DCs.  
Mature DCs pulsed with exogenous peptides through a simple two-hour co-incubation, 
prior to the addition of CTLs, were generally included in experiments as positive (Tyr 
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Figure 4.14  Controls in the DC-RNA-CTL system.  Mature DCs were electroporated with 24 
µg of tyrosinase cRNA.  One day later, transfected and untransfected DCs were either incubated 
alone or mixed with TyrF8 CTLs, specific for the tyrosinase pMHC.  Untransfected DCs were 
also pulsed exogenously with 10 µg/mL of Tyr peptide YMNGTMSQV or irrelevant Flu 
peptide GILGFVTL for 2 hr prior to the addition of TyrF8 CTLs.  The diagram shows the 
amount of IFN-γ secreted by 2×104 activated CTLs during the 24 hr co-incubation with 4×104
DCs.  IFN-γ was measured in supernatants by ELISA.  Mean values and their standard 
deviations represent co-incubation triplicates. 
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peptide YMNGTMSQV) or negative (Flu peptide GILGFVTL) controls for the antigen-
presenting capacity of the DCs and the specificity of the CTLs. 
 
As shown in Figure 4.14, untransfected and transfected DCs alone secreted small amounts 
of IFN-γ (27 pg/mL and 38 pg/mL respectively).  The addition of TyrF8 CTLs to the 
untransfected DCs did not increase IFN-γ production significantly (46 pg/mL).  The 
irrelevant Flu peptide presented within MHC class I molecules on the surface of DCs was 
not recognised by TyrF8 CTLs (53 pg/mL).  As expected, TyrF8 CTLs were stimulated to 
secrete high amounts of IFN-γ only by specific recognition of the synthetic Tyr peptide 
exogenously pulsed onto the DCs or the natural Tyr peptide produced by the DCs 
themselves after transfection of tyrosinase cRNA (1056 pg/mL and 703 pg/mL, 
respectively). 
 
 
4.2.4 Electroporation with increasing amounts of tyrosinase cRNA 
 
In terms of triggering CTLs through antigen presentation by the DCs, it remained to be 
seen how much RNA should be transfected and how many pulsed DCs should be used in 
order to generate the highest possible stimulatory capacity. 
 
Therefore, 48 µg of tyrosinase cRNA were transfected into 3×106 mature DCs,  in addition 
to the previously tested 24 µg and 12 µg.  One day later, DCs presenting the tyrosinase 
antigen were exposed to the TyrF8 CTLs.  The number of DCs per well was increased to 
8×104, but 4×104 and 1×104 were also taken as a control.  With 2×104 CTLs per well, the 
stimulator to effector ratios were 4:1, 2:1 and 1:2. 
 
As shown in Figure 4.15, with the 4:1 DC to CTL ratio, CTLs were not stimulated above 
the level reached with the 2:1 ratio (e.g. 1036 pg/mL IFN-γ at 4:1 vs. 1039 pg/mL IFN-γ at 
2:1 for 48 µg cRNA).  It can be hypothesised that more DCs did not make a difference, 
since 4×104 DCs were enough to achieve the maximum engagement of TCRs on the 2×104 
CTLs.  The highest tyrosinase cRNA amount of 48 µg indeed resulted in the highest 
stimulatory capacity of DCs (1036 pg/mL IFN-γ for 48 µg vs. 602 pg/mL IFN-γ for 24 µg 
vs. 181 pg/mL IFN-γ for 12 µg at 2:1).  With 48 µg of transfected tyrosinase cRNA, 43% 
more IFN-γ secretion was induced than with 24 µg, and 83% more than with 12 µg. 
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Based on the results of this experiment the decision was made to electroporate DCs with 
48 µg of single-species tumour-antigen cRNA and then to stimulate CTLs with those DCs 
in a stimulator to effector ratio of 2:1, i.e. 4×104 DCs and 2×104 CTLs. 
 
 
4.2.5 RNA and DC concentrations in electroporation 
 
In published studies of RNA electroporation into DCs and in the experiments performed 
here, not only were different amounts of RNA used, but also different cell numbers.  The 
quantity of DCs available for an experiment was usually the limiting factor.  It was 
possible that using fewer DCs would require taking proportionally less RNA in order to 
achieve levels of antigen presentation comparable to those in other experiments.  
Therefore, it was determined whether the number of DCs could be varied in 
electroporation without changing their stimulatory capacity. 
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Figure 4.15  Stimulatory capacity of DCs transfected with increasing amounts of tyrosinase 
cRNA.  Mature DCs were electroporated with 12, 24 or 48 µg of tyrosinase cRNA.  One day later, 
transfected DCs were mixed with TyrF8 CTLs, specific for the tyrosinase pMHC.  The diagram 
shows the amount of IFN-γ secreted by 2×104 activated CTLs during the 24 hr co-incubation with 
8×104, 4×104 or 1×104 DCs.  IFN-γ was measured in supernatants by ELISA.  Mean values and their 
standard deviations represent co-incubation triplicates. 
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The amount of tyrosinase cRNA was kept constant at 48 µg, but either 2×106 or 3×106 
mature DCs were taken for electroporation, which was performed in a total suspension 
volume of 280 µL.  Therefore, the RNA concentration per volume was the same in both 
cases (17 µg RNA per 100 µL), but the RNA concentration per number of DCs was 
different (24 µg RNA per 1×106 DCs and 16 µg RNA per 1×106 DCs). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in Figure 4.16, co-incubation of TyrF8 CTLs with DCs electroporated under 
both conditions did not result in distinct IFN-γ levels (903 pg/mL and 956 pg/mL).  This 
indicated that the important criterion for RNA entry into DCs was the amount of RNA 
present in the suspension volume, and less the number of DCs exposed to this 
concentration of RNA. 
 
 
4.2.6 Reproducibility of results in a standardised system 
 
As noted before, substantial time and effort were made to standardise the complicated DC-
RNA-CTL system so that the results of different fine-tuned quantitation experiments could 
be compared.  In Figure 4.17, IFN-γ secretion by TyrF8 CTLs in three separate 
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Figure 4.16  Stimulatory capacities of DCs electroporated in different concentrations.  The same 
amount of tyrosinase cRNA, 48 µg, was transfected into either 2×106 or 3×106 mature DCs.  One day 
later, transfected DCs were mixed with TyrF8 CTLs, specific for the tyrosinase pMHC.  The diagram 
shows the amount of IFN-γ secreted by 2×104 activated CTLs during the 24 hr co-incubation with 
4×104 DCs.  IFN-γ was measured in supernatants by ELISA.  Mean values and their standard 
deviations represent co-incubation triplicates. 
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experiments was compared in order to assess the reproducibility of results.  As described, 
mature DCs were electroporated with 48 µg of tyrosinase cRNA 24 hr before they were 
mixed with the CTLs.  For comparison, mature DCs were pulsed with the Tyr peptide 
before addition of the CTLs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The comparison showed that if the same conditions were applied in the generation of DCs 
from stock PBMCs, if CTLs were restimulated the same number of times and cultured 
under the same conditions and if the same RNA was used every time in electroporation 
according to the same protocol, then the results of separate experiments displayed a good 
degree of reproducibility (with up to 20% variability). 
 
 
4.2.7 Kinetics of tyrosinase cRNA degradation 
 
The tyrosinase cRNA dose-finding experiment showed that the amount of RNA applied in 
electroporation influenced antigen presentation and CTL stimulation by DCs.  Since the 
presence of transfected RNA in DCs is the prerequisite for antigen expression, it was of 
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Figure 4.17  Stimulatory capacities of DCs electroporated in different 
experiments under the same conditions.  In all three experiments, mature DCs 
were electroporated with 24 µg of tyrosinase cRNA.  One day later, transfected 
DCs were mixed with TyrF8 CTLs, specific for the tyrosinase pMHC. 
Untransfected DCs were pulsed with 10 µg/mL of Tyr peptide YMNGTMSQV 
for 2 hr prior to the addition of TyrF8 CTLs.  The diagram shows the amount of 
IFN-γ secreted by 2×104 activated CTLs during the 24 hr co-incubation with 
4×104 DCs.  IFN-γ was measured in supernatants by ELISA.  Mean values and 
their standard deviations represent co-incubation triplicates. 
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interest to know how long after electroporation and in what quantities tyrosinase cRNA 
could be detected in the DCs.  Furthermore, in comparison to EGFP cRNA, it was of 
interest to determine whether two different RNA species would display distinct 
characteristics in the same experimental setup. 
 
After transfection of 6 µg, 12 µg, 24 µg or 48 µg of tyrosinase cRNA into 3×106 DCs in a 
volume of 270 µL, electroporated cells were aliquoted and incubated until total cellular 
RNA, containing the transfected tyrosinase cRNA, was isolated 0.5, 1.5, 3, 6, 12, 24, 48 or 
72 hr later.  This RNA was reverse-transcribed into cDNA, which was then quantitatively 
analysed in real-time PCR for the presence of tyrosinase message. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A tyrosinase cDNA standard was available, making absolute quantitation possible (Figure 
4.19).  The amount of tyrosinase message was calculated as the number of copies of 
tyrosinase cRNA molecules found in association with a given number of cells.  The most 
interesting observation at the 0.5 hr time point was that the two-fold differences in amount 
of applied tyrosinase cRNA remained almost unchanged after electroporation, incubation, 
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Figure 4.18  Kinetics of tyrosinase cRNA degradation – absolute values.  Total 
cellular RNA was isolated from mature DCs transfected with 6, 12, 24 or 48 µg of 
tyrosinase cRNA at different time points after electroporation.  Isolated RNA was 
reverse transcribed into cDNA and the amount of tyrosinase message was assessed 
by real-time PCR using tyrosinase-specific primers.  The diagram shows the amounts 
of tyrosinase message expressed in absolute numbers of copies detected in samples 
originating from 1×104 cells.  These were calculated from a real-time PCR tyrosinase 
standard curve. 
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RNA isolation and reverse transcription (69.6 vs. 37.6 vs. 20.7 vs. 9.9 million copies).  
Considering the time the cells were given to process the transfected RNA, it was also 
interesting that the two-fold differences changed slightly, but were still detectable one hour 
later, at 1.5 hr (19.3 vs. 11.6 vs. 3.5 vs. 0.9 million copies).  These studies demonstrated 
that through the transfection of DCs it was possible to establish a precise foundation for 
antigen-presentation, which had been established via functional assays, and was hereby 
confirmed at the molecular level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The kinetics of tyrosinase cRNA degradation offered a possible explanation as to why the 
DCs pulsed with higher amounts of RNA developed higher stimulatory capacities.  At all 
measured time points, the most tyrosinase message was detected in the cells that had 
received the most tyrosinase cRNA through electroporation (Figure 4.19).  These data 
indicated that the large quantity of RNA provided not only ample starting material for 
antigen production within a short period of time, but also showed a prolonged presence in 
the DCs. 
 
If the value measured at 0.5 hr was taken as a 100% reference and all other values were 
expressed relatively, it became obvious that tyrosinase cRNA had similar degradation 
kinetics to EGFP cRNA (Figure 4.20).  Already between the 0.5 hr and the 1.5 hr time 
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Figure 4.19  Kinetics of tyrosinase cRNA degradation – absolute values.  Same 
diagram as in Figure 4.17, showing only the lower range of the Y-axis (0-5×106 
copies from 1×104 DCs).
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points, a strong decrease from 100% down to 8-27% was observed, depending on how 
much RNA had been used in electroporation.  Even though the highest amount of 
electroporated RNA (48 µg) ensured the smallest decrease (73%), once again it was 
obvious that much of the applied RNA would not make contact with the DCs during 
electroporation or would be degraded by extracellular and intracellular RNases after 
association with the cells.  Nevertheless, small amounts of tyrosinase cRNA could still be 
detected 72 hr after electroporation and the transfected DCs could activate antigen-specific 
CTLs within 48 hr after receiving the antigenic RNA. 
 
It remained unclear whether RNA detected by the method of real-time PCR had come only 
from inside the cells or was also partly derived from the DC surface, the difference being 
important because extracellular RNA would not be functional in terms of antigen 
expression in the DCs.  After electroporation, one half of tyrosinase cRNA-transfected 
DCs was incubated in the presence of RNase and the other half without RNase.  Aliquots 
were taken from both suspensions to isolate total cellular RNA immediately after 
electroporation and 0.5 hr, 1.5 and 3 hr later.  RNA was reverse transcribed into cDNA.  
The tyrosinase message was then quantitated in all cDNA samples.  A house-keeping gene, 
α-enolase, was quantitated in real-time PCR as an internal control in order to differentiate 
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Figure 4.20  Kinetics of tyrosinase cRNA degradation – relative values.  Total 
cellular RNA was isolated from mature DCs transfected with 6, 12, 24 or 48 µg of 
tyrosinase cRNA at different time points after electroporation.  Isolated RNA was 
reverse transcribed into cDNA and the amount of tyrosinase message was assessed 
by real-time PCR using tyrosinase-specific primers.  The diagram shows the amounts 
of tyrosinase message expressed relative to the 0.5 hr value which was taken as the 
100% reference. 
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between extracellular and possible intracellular actions of added RNase.  If indeed a 
substantial amount of tyrosinase cRNA amplified in the PCR had originated from outside 
the DCs, then the extracellular activity of RNase should result in different kinetics, i.e. a 
larger RNA decrease, compared to the samples incubated without RNase.  
 
 
 
 without RNase with RNase 
 tyrosinase α-enolase tyrosinase α-enolase 
0 hr 15.18 28.04 18.45 28.93 
0.5 hr 15.02 28.35 22.96 33.51 
1.5 hr 18.70 28.77 24.81 33.66 
3 hr 19.89 29.11 26.60 35.76 
 
 
 
 
 
 
 
 
Table 4.1 shows real-time PCR raw data - the higher the crossing point, the less RNA 
detected.  In the presence of RNase, a strong decrease of tyrosinase message was observed 
between 0 hr and 0.5 hr.  Such changes were not seen in the absence of RNase, suggesting 
that real-time PCR was indeed detecting extracellular tyrosinase cRNA, in addition to the 
intracellular tyrosinase cRNA.  On the other hand, a similar behaviour between 0 hr and 
0.5 hr was observed for α-enolase.  This may indicate that RNase acted not only on the 
tyrosinase RNA sticking to the cell surface, but also on the intracellular RNA since α-
enolase was undoubtedly of intracellular origin.  It is not likely that RNase molecules 
crossed the membrane barrier and degraded α-enolase RNA in the cytoplasm.  Even 
though all suspensions were washed twice between incubation with RNase and RNA 
isolation, it is possible that RNase was not fully eliminated and, as a consequence, was still 
present during cell lysis and RNA isolation.  This may have resulted in an artefact seen as a 
decreased amount of α-enolase message.  This problem might be circumvented by 
inactivating RNase with a protease, but on the other hand a protease may influence 
Table 4.1  Degradation of DC-associated tyrosinase cRNA and α-
enolase mRNA in the presence or absence of RNase in the culture 
medium. 
Immediately after electroporation with 48 µg of tyrosinase cRNA, mature 
DCs were resuspended in culture medium containing 5 µg/mL or no 
RNase A.  At different time points after electroporation, tyrosinase cRNA 
transfected-DCs were washed twice and then their total cellular RNA was 
isolated.  Isolated RNA was reverse transcribed into cDNA and the 
amounts of  transfected tyrosinase message and cell-expressed α-enolase 
messsage were assessed by real-time PCR, using tyrosinase-specific and α-
enolase-specific primers.  The table shows crossing points (real-time PCR 
raw data) which can be used to calculate relative or absolute amounts of 
analysed genetic message – the higher the crossing point, the less message 
detected. 
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receptors on the cell surface, sending signals into the cell and resulting in yet another 
artefact.  Unfortunately, adding RNase to the transfected cells did not provide an 
unambiguous solution to the problem of differentiating between RNA outside and RNA 
inside the DCs, leaving this question open for further discussion and research.  
 
 
4.2.8 Summary of the data obtained in the tyrosinase system 
 
Standardization of the DC-RNA-CTL system showed that good reproducibility of results 
could be achieved if DCs and CTLs were cultured according to standardised protocols and 
if electroporation was performed under the same conditions with RNA from identical 
stocks.  The reactivity of tyrosinase-specific CTLs was higher if they had spent not 13 days 
but only 8 days in restimulation cultures prior to co-incubation with tyrosinase cRNA-
transfected DCs.  The stimulatory capacity of transfected DCs was higher if they were 
allowed not only 2 hr but 25 hr to recuperate from electroporation and to produce the 
tyrosinase pMHCs.  In contact with DCs, CTLs reacted by secreting IFN-γ only upon 
recognition of the synthetic peptide or the natural peptide produced by the DCs based on 
transfected RNA.  Contaminating lymphocytes in electroporation DC suspensions did not 
produce IFN-γ above background.  In electroporation, the important criterion for RNA 
entry into DCs seemed to be the amount of RNA present in the suspension volume, and 
less the number of DCs exposed to a certain concentration of RNA.  Tyrosinase cRNA 
dose-finding showed that more RNA used in electroporation would indeed result in higher 
stimulatory capacities of transfected DCs.  Kinetics of tyrosinase cRNA degradation, 
similar to kinetics of EGFP cRNA degradation, revealed that the amount of transfected 
RNA rapidly decreased within only 1.5 hr after electroporation.  The smallest decrease was 
observed with the highest amount of RNA applied in electroporation.  Tyrosinase cRNA 
could still be found in transfected DCs 3 days after electroporation.  It remained unclear 
whether tyrosinase cRNA detected in quantitation experiments was of intracellular origin 
or also derived from the cell surface. 
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4.3 Transfection of DCs with RNA encoding a combination of antigens 
 
In the tyrosinase system, conditions were investigated for optimal transfer of single-species 
RNA into DCs and the subsequent recognition by CTLs.  Nevertheless, only one antigen 
was scrutinised.  A combination of several antigens represents a situation that occurs 
naturally in which peptides have to compete for MHC molecules in order to be presented 
as pMHC ligands on the surface of DCs.  To characterise the parameters for using multiple 
RNA species, three MAAs were studied.  The tyrosinase, Melan-A and CDK4-R24C 
antigens were examined for their individual and combined use in DC-based 
immunotherapy.  These three antigens were compared at the molecular level as single-
species antigen RNA and as components of total cellular melanoma RNA.  In quantitative 
experiments, amounts of tyrosinase, Melan-A and CDK4-R24C message in different RNA 
samples were determined by real-time PCR using published tyrosinase-specific primers 
and designed Melan-A-specific and CDK4-R24C-specific primers.  Expressed genetic 
message being a basis for antigen presentation, the three antigens were further compared 
on the cellular level of presentation as pMHC by melanoma cells and RNA-transfected 
DCs.  Stimulatory capacities of these cells were assessed by IFN-γ ELISA after co-
incubation with antigen-specific CTLs.  This data provided insight into the possibility of 
developing a generic vaccine based on DCs pulsed either with pooled single-species 
cRNAs or amplified RNA derived from malignant cells. 
 
The three-antigen system (tyrosinase, Melan-A and CDK4-R24C) was used to address the 
following questions: 
• How much more antigen message does an RNA sample contain after RT-PCR and in 
vitro transcription of total cellular tumour RNA? 
• How much more antigen message does a single-species tumour-antigen cRNA sample 
contain, compared to total cellular tumour RNA samples?   
• Do different CTL clones specific for the same antigen have different affinities for 
corresponding pMHC? 
• How does the amount of antigen message in tumour cells correlate with the recognition 
of pMHC by antigen-specific CTLs? 
• How efficient is electoporation with single-species tumour-antigen cRNA? 
• How high is the stimulatory capacity of DCs pulsed with total cellular tumour RNA, 
compared to single-species tumour-antigen cRNA? 
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• Is it possible to stimulate CTLs of different specificities with DCs that were pulsed 
with pooled single-species tumour-antigen cRNAs? 
• How does the amount of antigen message transfected into DCs correlate with the 
recognition of pMHC by antigen-specific CTLs? 
 
 
4.3.1 Amount of antigen message in different RNA samples 
 
The whole repertoire of proteins expressed by a malignant cell is encoded in its RNA.  If 
that RNA is isolated from tumour cells and transfected into antigen-presenting cells, a 
basis is established for the expression of a wide variety of tumour-antigens in a non-tumour 
environment.  DCs not only present these antigens more efficiently, but also interact better 
with T-cells due to their high expression of co-stimulatory and adhesion molecules.  The 
strategy of pulsing DCs with total cellular tumour RNA offers a possible solution to the 
problem of insufficient information regarding TAAs.  Relying on the fact that RNA from 
tumour cells likely contains message for several TAAs, the choice of the antigen and its 
presented epitope is left solely to the DC, and the need to know precise peptide sequences 
is eliminated.  Furthermore, total cellular tumour RNA can be isolated from a relatively 
small amount of tumour tissue and then amplified through RT-PCR and in vitro 
transcription, providing enough working material for multiple experiments or vaccine 
production. 
 
As noted before, several TAAs have been identified in the melanoma system and immune 
responses directed against them have been well characterised.  Thereby, it was possible to 
compare total cellular RNA derived from five melanoma cell lines with single-species 
cRNA coding for three different MAAs.  The studies using single-species tyrosinase cRNA  
described above showed that the amount of RNA electroporated into DCs influenced their 
stimulatory capacity.  This raised the question of how much antigen message could be 
found in RNA samples isolated from tumour cells, which had already been used or were to 
be used for transfection into DCs.  
 
To address this issue, various total cellular RNA samples were studied.  These included 
isolated RNA and mRNA amplified after isolation from melanoma cell lines SK29 MEL, 
624.38 MEL, SK23 MEL and IL-2 MEL (melanoma cells transfected with cDNA encoding  
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Figure 4.21  Amounts of antigen message in different RNA samples.  The same 
mass, 0.46 µg, of single-species tumour-antigen cRNAs (tyrosinase, Melan-A and 
CDK4-R24C), total cellular melanoma RNAs and amplified total cellular melanoma 
mRNAs was used for reverse transcription into cDNA.  The amounts of tyrosinase 
(A), Melan-A (B) and CDK4/CDK4-R24C (C) message were assessed in these 
cDNA samples by real-time PCR using tyrosinase, Melan-A and CDK4-specific 
primers.  Only SK29 MEL cells were positive (heterozygous) for CDK4-R24C. 
CDK4-specific primers did not differentiate between CDK4 and CDK4-R24C.  The 
diagram shows the amounts of antigen message expressed relative to the single-
species tumour-antigen value which was taken as the 1×106 relative units reference. 
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IL-2).  RNAs from A375 MEL and RCC26, a renal cell carcinoma cell line, were used as 
negative controls.  Single-species RNA samples included cRNA coding for tyrosinase, 
Melan-A and CDK4-R24C.  The concentration of all samples was adjusted so that the 
amount of RNA in each reverse transcription reaction was 0.46 µg.  The same volume, 2 
µL, of each cDNA sample was then quantitatively analysed in real-time PCR to determine 
the relative amounts of tyrosinase, Melan-A or CDK4-R24C message. 
 
As expected, the highest amount of antigen message was found in the single-species 
samples (Figure 4.21).  These values were expressed as 1×106 relative units and taken as a 
reference.  The least amount of tyrosinase and Melan-A message was detected in total 
cellular RNA isolated from the melanoma cell line SK29 MEL.  IL-2 MEL was found to 
be the cell line producing the most antigenic RNA.  Compared to SK29 MEL, 8-fold more 
tyrosinase RNA and almost 2-fold more Melan-A RNA was found in the IL-2 MEL 
sample.  A375 MEL and RCC26 cells were confirmed to be negative for tyrosinase and 
Melan-A RNA (data not shown). 
 
Primers used to detect the CDK4-R24C message were specific for both the wild type 
protein, CDK4, and its mutated form, CDK4-R24C.  The real-time PCR product, 
synthesised with this primer pair, included the point-mutation site (substitution of C with 
T) in the 24. codon.  Since it was unclear which melanoma cell lines expressed the mutated 
protein, the real-time PCR products were separated in agarose gel electrophoresis, 
extracted from the gel, purified and sequenced.  Sequencing revealed that the only cell line 
positive for CDK4-R24C message was SK29 MEL.  However, these cells were 
heterozygous resulting in co-expression of CDK4 and CDK4-R24C proteins. 
 
The RT-PCR used only poly(A)-positive RNA as a template.  This meant that mRNA was 
amplified whereas rRNA, tRNA and other RNA species were not.  As a consequence, an 
RNA sample obtained after RT-PCR and in vitro transcription was supposed to contain 
higher proportions of message for individual proteins.  Indeed, processing of total cellular 
tumour RNA proved to be advantageous not only because it increased the mass of RNA, 
but also because it resulted in amplification of RNA coding for tumour-antigens (Figure 
4.21 and Table 4.2).  Amplification of total cellular mRNA from all four inspected 
melanoma lines increased  the amount of tyrosinase message in the range 17 to 30-fold, 
with the mean fold increase of 24.  RNA coding for Melan-A was amplified differently, the 
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mean fold-increase of 62 was calculated from the range 58 to 65.  CDK4 RNA was the 
least amplified with a 2.1-fold increase calculated from the range 1.6 to 2.8.  
 
 
Antigen Cell line 
Total cellular 
RNA 
(relative units) 
Amplified 
mRNA 
(relative units) 
fold 
increase 
mean fold increase 
± stand. deviation 
SK29 MEL 9 267 29.67 
624.38 MEL 24 534 22.25 
SK23 MEL 46 766 16.65 
tyrosinase 
IL-2 MEL 74 1994 26.95 
23.88 
± 5.71 
SK29 MEL 18 1099 61.06 
624.38 MEL 29 1689 58.24 
SK23 MEL 24 1511 62.96 
Melan-A 
IL-2 MEL 32 2079 64.97 
61.81 
± 2.86 
SK29 MEL 21 58 2.76 
624.38 MEL 12 25 2.08 
SK23 MEL 13 21 1.62 
CDK4 
IL-2 MEL 14 28 2.00 
 2.12 
± 0.47 
 
 
Single-species tyrosinase and Melan-A cRNA samples were best compared with the IL-2 
MEL amplified mRNA sample because it contained more antigen message than all other 
analysed melanoma RNAs.  The CDK4-R24C cRNA sample was compared with the SK29 
MEL amplified mRNA sample because only this melanoma cell line expressed CDK4-
R24C and the amplified mRNA sample contained more antigen message than the total 
cellular RNA sample.  If the same masses of these RNAs were taken for an experiment, a 
single-species sample would contain 502-fold more message for tyrosinase and 481-fold 
more message for Melan-A when compared with an amplified mRNA sample from the 
optimal tumour cell line (Figure 4.21).  Since CDK4-specific real-time PCR primers did 
not differentiate between wild type CDK4 and its mutated form, CDK4-R24C, co-
expressed in SK29 MEL cells, it was not possible to precisely quantitate the CDK4-R24C 
message.  However, electropherogram of the CDK4 real-time PCR product showed that the 
mutated form had a higher proportion in the sequenced SK29 MEL total cellular RNA 
sample than the wild type form.  Taking these facts into account, it could only be 
concluded that the single-species CDK4-R24C cRNA sample contained <17241-fold more 
Table 4.2  Differential RT-PCR amplification of the tyrosinase, Melan-A and CDK4 message in the 
same melanoma RNA samples.   
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message for CDK4-R24C than the same mass of the SK23 MEL amplified mRNA sample 
(Figure 4.21). 
 
 
4.3.2 Different CTL reactivities upon exposure to synthetic peptides 
 
In order to evaluate the cellular expression of the three antigens, additional CTL clones 
specific for Melan-A and CDK4-R24C had to be integrated into the DC-RNA-CTL 
system.  Two CTL lines, 11/33 and A42 CTLs, were included which recognised Melan-A 
pMHC ligands.  The CTLs 14/35 were used as CDK4-R24C-specific T-cells.  The 
tyrosinase pMHC ligand was recognised by both IVS B CTLs and the previously described 
TyrF8 CTLs.  The use of all five CTL clones was standardised by expanding them to 
produce large batches which were then frozen in aliquots.  For each experiment, cells from 
identical stocks were thawed and cultured according to the standardised protocol. 
 
In order to investigate the affinities of the different CTL clones for their pMHC ligands, 
synthetic peptides were loaded onto T2 cells that express only empty HLA-A2 molecules 
at the cell surface due to a defect in the TAP transporter.  If T2 cells are cultured in the 
presence of exogenous peptides they will express homogenous pMHC ligands comprised 
of HLA-A2 molecules and the provided peptide.  TyrF8 CTLs and IVS B CTLs were 
exposed to two different peptides, representing the same tyrosinase epitope.  
YMNGTMSQV is an HLA-A2-binding peptide sequence predicted from the primary 
structure of the tyrosinase protein.  This peptide was used for in vitro generation of the 
TyrF8 CTL clone.  However, mass spectroscopy of peptides eluted from an HLA-A*0201 
melanoma cell line revealed that the actual sequence of the naturally-presented peptide was 
YMDGTMSQV.  11/33 CTLs and A42 CTLs were tested against the ELAGIGILTV 
peptide from Melan-A and 14/35 CTLs against the ACDPHSGHFV peptide from CDK4-
R24C .  These peptides, at a relatively low concentration of 0.1 µg/mL, were allowed to 
form complexes with MHC molecules on 1.5×104 T2 cells 2 hr before the addition of 
3×103 CTLs (stimulator to effector ratio 5:1).  After 24 hr of co-incubation, supernatants 
were harvested and the amount of IFN-γ secreted by activated CTLs was determined in 
ELISA. 
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As shown in Figure 4.22, TyrF8 CTLs recognised both the predicted and the natural 
tyrosinase peptide, but reacted stronger with the predicted peptide against which it was 
primed (3386 pg/mL vs. 2037 pg/mL).  In contrast, IVS B CTLs secreted significantly less 
IFN-γ than TyrF8 CTLs and seemed to recognise only the natural form of the peptide (338 
pg/mL), the reactivity against the predicted peptide being slightly above background (43 
pg/mL).  These results demonstrated that T-cells were activated only upon highly specific 
recognition of pMHC motifs and that selection of an alternative but highly similar peptide 
resulted in loss of T-cell activation.  11/33 CTLs and A42 CTLs both reacted against the 
Melan-A peptide, but also displayed very different degrees of reactivity.  11/33 CTLs 
produced more IFN-γ than A42 CTLs (2933 pg/mL vs. 280 pg/mL).  The amount of IFN-γ 
secreted by 14/35 CTL upon exposure to the CDK4-R24C peptide fell in the lower range 
(419 pg/mL).  All CTL clones tested with the same peptides in unspecific combinations 
(e.g. TyrF8 CTL with Melan-A peptide) showed no reactivity (data not shown). 
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Figure 4.22  Reactivities of different CTL clones upon presentation of synthetic 
peptides.  T2 cells with empty HLA-A2 molecules at the surface were pulsed 
exogenously with 10 µg/mL of Tyr peptide YMNGTMSQV, TyrD peptide 
YMDGTMSQV, Melan-A peptide ELAGIGILTV or CDK4-R24C peptide 
ACDPHSGHFV for 2 hr prior to the addition of corresponding antigen-specific 
CTLs.  The diagram shows the amount of IFN-γ secreted by 3×103 activated CTLs 
during the 24 hr co-incubation with 1.5×104 peptide-pulsed T2 cells.  IFN-γ was 
measured in supernatants by ELISA.  Mean values and their standard deviations 
represent co-incubation triplicates.  Background IFN-γ secreted by CTLs in 
response to unpulsed T2 cells was subtracted from the values shown. 
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At the level of recognition between stimulator and effector cells, TCR structures defined 
different T-cell affinities for pMHC ligands.  At the intracellular level, distinct signalling 
patterns caused T-cells to secrete different amounts of IFN-γ, which was detected with an 
ELISA experiment.  Therefore, in subsequent experiments, the reactivities of CTL clones 
were taken as a measure of antigen-presenting capacities of other cells.  Even though some 
of the CTLs recognised the same epitope, their reactivities were not directly compared 
because the differences in response to peptides were so great.  Each tumour cell or DC co-
incubation with a CTL clone was perceived as a separate system and a direct comparison 
of antigen-presenting capacities was only allowed within that system. 
 
 
4.3.3 Correlation between amount of antigen message and epitope recognition by 
CTLs 
 
Taking the complicated process of antigen presentation out of the natural context and 
dividing it into separate components was necessary in order to better characterise the 
molecular basis underlying epitope generation, on the one hand, and CTL activation upon 
exposure to pMHC ligands, on the other.  Returning to a more natural environment, the 
antigen processing and presentation machinery of a tumour cell was added as an important 
component of the system.  Here, reactivity of antigen-specific CTLs was no longer directed 
against synthetic peptides bound to MHC molecules, but instead was directed against 
pMHC produced naturally, based on antigen mRNA present in the total cellular RNA pool.  
This raised the question of whether differences in amounts of tyrosinase, Melan-A and 
CDK4-R24C message would influence the pMHC ligand-induced activation of the CTLs. 
 
To address this issue, melanoma cells SK29 MEL, 624.38 MEL, SK23 MEL and IL-2 
MEL were co-incubated with CTLs TyrF8 and IVS B specific for tyrosinase, 11/33 and 
A42 specific for Melan-A, and 14/35 specific for CDK4-R24C for 24 hr at a 5:1 ratio 
(1.5×104 stimulators and 3×103 effectors per well).  A375 MEL and RCC26 were included 
as negative controls.  IFN-γ secreted by activated CTLs was quantitated in ELISA.  These 
values were plotted against the relative amounts of antigen RNA present in the 
corresponding tumour cells (Figure 4.21). 
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A generally good correlation between the amount of antigen message and the degree of 
IFN-γ secretion, representing the pMHC recognition by the CTLs, was consistently 
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Figure 4.23  Amounts of antigen message in melanoma cells and epitope recognition by 
antigen-specific CTLs.  Different melanoma cells were mixed with tyrosinase-specific TyrF8 
and IVS B CTLs (upper row) and Melan-A-specific A42 and 11/33 CTLs (lower row).  In the 
diagrams with two Y-axes, epitope recognition by CTLs is plotted against the amount of antigen 
message in tumour cells.  On the left Y-axis of each diagram, the amounts of IFN-γ secreted by 
3×103 activated CTLs during the 24 hr co-incubation with 1.5×104 melanoma cells are shown. 
IFN-γ was measured in supernatants by ELISA.  Mean values and their standard deviations 
represent co-incubation triplicates.  Background IFN-γ secreted by CTLs alone was subtracted 
from the values shown.  IFN-γ secretion by CTLs in response to negative controls A375 MEL 
(0-25 pg/mL) and RCC26 (0-21 pg/mL) is not shown.  On the right Y-axis of each diagram, the 
amounts of antigen message are shown.  These were expressed in relative units as explained in 
Figure 4.21. 
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observed with the various CTLs (Figure 4.23).  More RNA coding for tyrosinase or Melan-
A present in melanoma cells secured better antigen presentation and CTL activation.  The 
only exception was 624.38 MEL, which stimulated TyrF8 CTLs to produce more IFN-γ 
than SK23 MEL (2566 pg/mL vs. 2050 pg/mL) even though these cells contained less 
RNA coding for tyrosinase (24 relative units vs. 46 relative units).  IL-2 MEL cells were 
found to be the best stimulators, possibly due to the high amounts of antigen RNA.  
Nevertheless, part of their superiority can also be attributed to their capacity to secrete IL-
2, which is well known to support T-cell proliferation and secretion of IFN-γ.  The 
negative controls, A375 MEL and RCC26, did not stimulate CTLs above background 
levels (data not shown).  Interestingly,  A42 CTLs displayed a clearly different behaviour 
following contact with the naturally-produced and presented antigenic peptide.  Co-
incubation with melanoma cells resulted in A42 CTLs secreting significantly more IFN-γ 
than 11/33 CTLs (e.g. 1544 pg/mL vs. 220 pg/mL stimulated by IL-2 MEL), the opposite 
of what was observed with the synthetic peptide loaded onto T2 cells (3047 pg/mL vs. 291 
pg/mL).  This once again confirmed the importance of a naturally-selected epitope for 
efficient T-cell stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Since SK29 MEL cells are the only ones expressing the CDK4-R24C antigen, 14/35 CTLs 
were activated solely by this cell line.  In Figure 4.24, the amount of CK4/CDK4-R24C 
message in SK29 MEL cells is shown not for comparison with CDK4 amounts in other 
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melanoma cells and epitope recognition by CDK4-R24C-
specific CTLs.  Different melanoma cells were mixed with 
CDK4-R24C-specific 14/35CTLs.  In the diagram with two 
Y-axes, epitope recognition by CTLs is plotted against the 
amount of antigen message in tumour cells.  On the left Y-
axis of the diagram, the amounts of IFN-γ secreted by 3×103
activated CTLs during the 24 hr co-incubation with 1.5×104
melanoma cells are shown.  IFN-γ was measured in 
supernatants by ELISA.  Mean values and their standard 
deviations represent co-incubation triplicates.  Background 
IFN-γ secreted by CTLs alone was subtracted from the 
values shown.  IFN-γ secretion by CTLs in response to 
A375 MEL (3 pg/mL) and RCC26 (0 pg/mL) is not shown. 
Unlike other melanoma cells that express only wild type 
CDK4, SK29 MEL cells also express CDK4-R24C, the 
mutated form of the protein. Therefore, on the right Y-axis 
of the diagram, only the amount of antigen message in 
SK29 MEL cells is shown.  This amount was expressed in 
relative units as explained in Figure 4.20. 
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melanoma cells but to indicate that SK29 MEL cells are the only ones expressing the 
mutated form of the CDK4 protein. 
 
 
4.3.4 Efficiency of electroporation with single-species tumour-antigen cRNA 
 
Electroporation of cRNA EGFP into DCs proved to be very efficient, with the percentage 
of EGFP-positive cells reaching the maximum of 90% within only 12 hr after transfection.  
The efficiency of electroporation with a different cRNA species was investigated in two 
experiments.  Electroporation was performed with 48 µg of Melan-A cRNA and either 
1.6×106 mature DCs from donor PH or 2×106 mature DCs from donor RZ.  Transfected 
DCs and untransfected DCs, which served as a control, were harvested either 7 hr or 25 hr 
later.  The relatively early 7 hr time point was chosen because the Melan-A protein has a 
half-life of approximately 3 hr (de Mazière AM et al. 2002) and the 25 hr time point was 
analysed in order to ascertain whether the antigen was still detectable in the DCs at the 
time when CTLs were added in functional assays.  Harvested DCs were fixed, 
permeabilised and stained intracellularly with an antibody specific for Melan-A.  The 
percentages of Melan-A-positive DCs were then assessed in FACS™. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.25  Efficiency of electroporation with Melan-A cRNA. 
Mature DCs were stained 7 hr and 25 hr after electroporation with 48 µg 
of Melan-A cRNA.  FACS™ overlay histograms show fluorescence 
intensities of both stained untransfected DCs (black curves), that served 
as an isotype control, and stained Melan-A cRNA-transfected DCs (filled 
curves).  Intracellular staining was performed after fixation and 
permeabilisation of the cells.  The primary antibody bound to Melan-A. 
The secondary FITC-conjugated antibody was used to detect the primary 
antibody.  For definition of Melan-A-specific FITC fluorescence and 
Melan-A-positive cells see Figure 4.1.
7 hr after electroporation 25 hr after electroporation 
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Melan-A was present in 88% of transfected DCs 7 hr after electroporation (Figure 4.25).  
When protein expression was measured 25 hr after electroporation, 66% of the DCs 
expressed Melan-A, clearly showing that transfected RNA was still functional inside the 
cells, allowing high levels of protein to be produced. 
 
 
4.3.5 Stimulatory capacity of DCs pulsed with single-species tumour-antigen RNA 
and total cellular tumour RNA 
 
Tumour cells are known to often down-regulate their antigen processing and presentation 
machinery in order to escape immune recognition.  The variability in epitope producing 
machineries of melanoma cells was eliminated by transfecting either total cellular tumour 
RNA or single-species antigen RNA into professional APCs.  These experiments were 
performed to determine how efficiently DCs pulsed with a variety of RNA species in 
different amounts would stimulate CTLs.  They were also designed to provide additional 
quantitative insight into the process of antigen presentation that occurs following transfer 
of RNA into DCs. 
 
Single-species cRNAs coding for tyrosinase, Melan-A and CDK4-R24C were 
electroporated into 1-2×106 mature DCs either separately (48 µg and 24 µg) or pooled 
(3×48 µg and 3×24 µg).  Total cellular RNA (75 µg) and amplified mRNA (75 µg and 37.5 
µg) from SK29 MEL cells were chosen because they contained the message for all three 
tumour-antigens.  Electroporation with A375 MEL amplified mRNA (70 µg) was also 
performed as a negative control.  The same DCs, loaded with exogenous peptides 
(YMNGTMSQV from tyrosinase, ELAGIGILTV from Melan-A and ACDPHSGHFV 
from CDK4-R24C) at a high concentration of 10 µg/mL, were included as positive 
controls.  One day after electroporation or 2 hr after loading with peptides, 2×104 TyrF8, 
IVS B, A42, 11/33 or 14/35 CTLs were co-incubated with 4×104 DCs.  Supernatants were 
harvested 24 hr later and the amount of IFN-γ secreted by activated CTLs was assessed in 
ELISA (Figures 4.26, 4.27 and 4.28). 
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Figure 4.26  Stimulatory capacities of tyrosinase-pulsed DCs.  Mature DCs were 
electroporated with different amounts of various RNA species.  One day later, transfected and 
untransfected DCs were mixed with TyrF8 CTLs (A) or IVS B CTLs (B), specific for the 
tyrosinase pMHC.  Untransfected DCs were also pulsed exogenously with 10 µg/mL of Tyr 
peptide YMNGTMSQV for 2 hr prior to the addition of CTLs.  The diagram shows the 
amount of IFN-γ secreted by 2×104 activated CTLs during the 24 hr co-incubation with 4×104
DCs.  IFN-γ was measured in supernatants by ELISA.  Mean values and their standard 
deviations represent co-incubation triplicates.  Background IFN-γ secreted by CTLs in 
response to unpulsed DCs was subtracted from the values shown.  IFN-γ secretion by TyrF8 
CTLs (17±10 pg/mL) and by IVS B CTLs (18±12 pg/mL) in response to the negative control 
A375 MEL amplified mRNA-pulsed DCs is not shown. 
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Figure 4.27  Stimulatory capacities of Melan-A-pulsed DCs.  Mature DCs were 
electroporated with different amounts of various RNA species.  One day later, transfected and 
untransfected DCs were mixed with A42 CTLs or 11/33 CTLs, specific for the Melan-A 
pMHC.  Untransfected DCs were also pulsed exogenously with 10 µg/mL of Melan-A peptide 
ELAGIGILTV for 2 hr prior to the addition of CTLs.  The diagram shows the amount of 
IFN-γ secreted by 2×104 activated CTLs during the 24 hr co-incubation with 4×104 DCs. 
IFN-γ was measured in supernatants by ELISA.  Mean values and their standard deviations 
represent co-incubation triplicates.  Background IFN-γ secreted by CTLs in response to 
unpulsed DCs was subtracted from the values shown.  IFN-γ secretion by A42 CTLs (35±95 
pg/mL) and by 11/33 CTLs (10 pg/mL, single value) in response to the negative control A375 
MEL amplified mRNA-pulsed DCs is not shown. 
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Differential reactivities against the tyrosinase pMHC ligand were observed again with the 
TyrF8 clone producing generally more IFN-γ than the IVS B clone.  As expected based on 
the results of the experiment using T2 cells, the YMNGTMSQV tyrosinase peptide pulsed 
onto the DCs stimulated only TyrF8 CTLs (804 pg/mL).  An important observation in the 
tyrosinase system was that IVS B CTLs reacted very weakly (37 pg/mL) upon exposure to  
the predicted form of the epitope, i.e. synthetic peptide, but strongly recognised the epitope 
naturally processed by DCs after transfection of RNA coding for tyrosinase.  A similar 
situation was found in the Melan-A system.  A42 CTLs reacted less well to the  synthetic 
peptide, ELAGIGILTV, than 11/33 CTLs (598 pg/mL vs. 927 pg/mL), but secreted more 
IFN-γ when stimulated with RNA-transfected DCs.  Despite the common use and 
occasional success of applying peptide-pulsed APCs in immunotherapy, manipulation of 
DCs to express antigens and to produce and present their immunogenic peptides, proved to 
be advantageous with respect to the selection of the correct epitopes for CTL activation. 
DCs transfected with amplified mRNA from the cell line SK29 MEL also specifically 
stimulated T-cells.  All five CTL clones secreted IFN-γ definitely above, but close to, 
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Figure 4.28  Stimulatory capacities of CDK4-R24C-pulsed DCs.  Mature DCs were 
electroporated with different amounts of various RNA species.  One day later, transfected and 
untransfected DCs were mixed with 14/35 CTLs, specific for the CDK4-R24C pMHC. 
Untransfected DCs were also pulsed exogenously with 10 µg/mL of CDK4-R24C peptide 
ACDPHSGHFV for 2 hr prior to the addition of CTLs.  The diagram shows the amount of 
IFN-γ secreted by 2×104 activated CTLs during the 24 hr co-incubation with 4×104 DCs. 
IFN-γ was measured in supernatants by ELISA.  Mean values and their standard deviations 
represent co-incubation triplicates.  Background IFN-γ secreted by 14/35 CTLs in response to 
unpulsed DCs was subtracted from the values shown.  IFN-γ secretion by CTLs in response to 
the A375 MEL amplified mRNA-pulsed DCs (19±4 pg/mL) is not shown. 
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background, in a range where the standard deviation of the values was critical for 
distinguishing between positive and negative results.  The expected differences in 
reactivities were observed only with the more potent clones, TyrF8 and A42 (73 pg/mL vs. 
17 pg/mL upon tyrosinase recognition and 138 pg/mL vs. 67 pg/mL upon Melan-A 
recognition), possibly due to the amount of transfected RNA (70 µg vs. 37.5 µg).  Total 
cellular RNA from SK29 MEL did not cause significant T-cell stimulation.  Amplified 
mRNA from A375 MEL induced only very low IFN-γ secretion (data not shown).  This 
was unspecific, since A375 MEL did not express RNA for any of the three antigens.   
 
Most importantly, single-species cRNAs for tyrosinase, Melan-A and CDK4-R24C 
maintained their functionality after being mixed.  DCs electroporated with pooled RNAs 
were  co-incubated separately with each CTL clone, and managed to stimulate all CTLs by 
simultaneously presenting epitopes from the three antigens.  Two different amounts of 
pooled RNA were used – 3×48 µg that summed up to 144 µg and 3×24 µg that gave a total 
of 72 µg.  Only small differences were observed using DCs for stimulation that had 
received either of the two amounts of RNA.  This indicated that the multiplicity of antigen 
message present in the 144 µg sample exceeded the antigen-presenting capacity of the 
DCs.  In most cases, satisfactory levels of T-cell activation were achieved, similar to or 
only slightly below those reached with 24 µg of a single-species cRNA alone.  Therefore, 
it was clear that even though competition for MHC class I molecules may have occurred, 
CTL responses to pooled RNAs were not inhibited. 
 
In this and other experiments performed under comparable conditions, DCs were 
transfected with various amounts of different RNA species, all containing RNA coding for 
tyrosinase.  Data from these experiments had to be normalised first and then compared in 
order to determine if epitope recognition by TyrF8 CTLs correlated with the amount of 
tyrosinase message transfected into DCs.  In Table 4.2, all message amounts were 
expressed relative to the highest amount used in electroporation, corresponding to 48 µg of 
single-species tyrosinase cRNA and depicted as 1×106 relative units.  Epitope recognition 
was measured as IFN-γ produced by CTLs and was calculated relative to 100% of the 
strongest stimulation, achieved after DC transfection with 48 µg of single-species cRNA.  
It was found above that IFN-γ secretion during CTL co-incubation with melanoma cells 
strongly depended on tumour RNA profiles.  Except for obvious large differences, no such 
correlation was observed with RNA isolated from malignant cells and forced into antigen-
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presenting cells.  The lack of correlation may possibly be due to the variable of 
electroporation that had to be introduced into the DC system.  Nevertheless, this 
comparison clearly indicated that even small amounts of antigen message were sufficient 
to develop DC stimulatory capacity that was specific and above background. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.6 Summary of the data obtained in the three-antigen system 
 
Quantitation experiments showed that total cellular RNA samples from various melanoma 
cells contained different amounts of tyrosinase, Melan-A and CDK4/CDK4-R24C 
message.  In RT-PCR of mRNA from these samples, the Melan-A message was amplified 
more than the tyrosinase message.  The CDK4/CDK4-R24C message was amplified the 
least.  Even after amplification of melanoma mRNA in RT-PCR, in vitro transcribed 
tyrosinase, Melan-A and CDK4-R24C cRNA samples still contained significantly more 
antigen message.  After co-incubation of antigen-specific CTLs with melanoma cells, a 
RNA Species 
RNA mass 
transfected 
(µg) 
Tyr. message 
transfected 
(ru) 
% maximum 
IFN-γ 
secretion 
tyrosinase single-species cRNA 48.0........ 1000000..... 100.00......
tyrosinase single-species cRNA (part of pool) 48.0........ 1000000..... 72.46......
tyrosinase single-species cRNA 24.0........ 500000..... 74.46......
tyrosinase single-species cRNA (part of pool) 24.0........ 500000..... 65.71......
SK23 MEL amplified mRNA 160.0........ 2553..... 6.64......
624.38 MEL amplified mRNA 160.0........ 1810..... 6.17......
SK23 MEL amplified mRNA 80.0........ 1277..... 5.15......
624.38 MEL amplified mRNA 80.0........ 905..... 5.74......
SK29 MEL amplified mRNA 75.0........ 417..... 13.39......
SK29 MEL amplified mRNA 37.5........ 209..... 3.07......
SK29 MEL total cellular RNA 75.0........ 14..... 5.11......
Table 4.2  Amounts of transfected antigen messages in electroporated DCs and epitope 
recognition by TyrF8 CTLs. 
The table shows the mass (µg) of RNA samples applied in different DC electroporation 
experiments, the amount of tyrosinase message (ru) contained in those samples and the level of 
epitope recognition by TyrF8 CTL (% of maximum IFN-γ secretion) during co-incubation with 
the transfected DCs.  The amount of transfected tyrosinase message was calculated from the 
relative units shown in Figure 4.20 and the mass of the RNA applied in electroporation.  It is 
expressed relative to the 48 µg sample which contains the largest amount of tyrosinase message 
and is taken as a 1×106 relative units reference.  The level of epitope recognition is expressed 
relative to the maximum IFN-γ secreted which corresponds to the TyrF8 CTL stimulation by 
DCs transfected with 48 µg of tyrosinase cRNA.  This value was taken as a 100% reference. 
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generally good correlation was observed between the amounts of antigen message present 
in tumour cells and epitope recognition by CTLs.  In two cases, CTLs displayed higher 
reactivites in response to peptides naturally-produced by tumour cells than in response to 
synthetic peptides.  The efficiency of electroporation with Melan-A cRNA was just as high 
as the efficiency of electroporation with cRNA EGFP.  Electroporation of single-species 
tumour-antigen cRNAs into DCs resulted in the highest DC stimulatory capacities.  When 
single-species tyrosinase, Melan-A and CDK4-R24C cRNAs were pooled and then 
transfected into DCs, satisfactory levels of T-cell stimulation were achieved, indicating 
that CTL responses to pooled RNAs were not inhibited even though competition for MHC 
class I molecules may have occurred.  Based on transfected amplified melanoma mRNA, 
DCs also developed stimulatory capacities, but at much lower levels.  Two CTL clones 
once again secreted more IFN-γ upon exposure to epitopes naturally produced by 
transfected DCs than to synthetic peptides.  No correlation was observed between the fine 
differences in the amounts of transfected antigen message and epitope recognition by 
CTLs. 
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5. Discussion 
 
The ultimate goal of these studies is to design a vaccine that can be applied clinically to 
eradicate malignant cells in cancer patients.  The strategy analysed here is based on DCs 
that are manipulated to present TAAs to effector cells of the immune system.  Melanoma is 
the most suitable tumour model because it is well characterised at both the cellular and the 
molecular levels.  Technological innovation has to be combined with knowledge from the 
fields of cellular biology and immunology in order to better understand and manipulate 
biological mechanisms underlying anti-tumour immunity and to ensure the efficiency of 
antigen presentation.  For this reason, in the following text, a relatively new methodology 
is discussed not so much in the clinical context but more in the context of basic science.  
Sequential arguments are presented demonstrating why RNA was chosen as an antigen 
form that is optimal for a DC-based therapy.  Two protocols for RNA transfection into 
DCs of different maturation stages are compared.  The stimulatory capacities of DCs are 
correlated to different amounts of TAA message in various RNA samples that were used 
for transfection.  Furthermore, approaches are considered to improve initiation and 
maintenance of anti-tumour immune responses.  Pooling RNAs encoding several different 
TAAs is suggested as a strategy to overcome tumour immune escape.  Competition 
between antigens and immunodominance are discussed.  Finally, the dangers of 
autoimmunity that are associated with immunotherapy are evaluated. 
   
 
5.1 Efficiency of RNA transfection into DCs 
 
If the preferred approach is to generate TAA-expressing DCs using transfer of genetic 
material, instead of protein, two different antigen forms are available: DNA and RNA.  
Transfection of RNA was shown to be more efficient than DNA transfection (80% vs. 50% 
positive cells) when identical amounts of plasmid DNA and cRNA coding for EGFP were 
used in electroporation.  Furthermore, the level of EGFP expression was slightly higher 
using transfected RNA.  However, the duration of EGFP expression was similar after 
electroporation of either RNA or DNA.  It should be noted that DNA electroporation 
required stronger electric pulsing, since DNA had to cross two membranes in order to 
reach the nucleus.  For this reason, up to 60% mortality was caused by the electric shock 
(Ponsaerts P et al. 2003).  Electroporation of RNA was associated with less toxicity 
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because RNA had to be transferred through only one membrane.  Once in the cytoplasm, 
RNA could be translated directly into protein.  Lundqvist and colleagues (Lundqvist A et 
al. 2002) compared RNA transfection with viral transduction of DCs.  Even though viral 
gene-transfer resulted in a higher transfer efficiency (90% vs. 60% positive cells), 
electroporation of RNA proved to be an adequate alternative, which did not require dealing 
with safety issues usually associated with viral vectors. 
 
The Gilboa group, which initiated the use of RNA-transfected DCs as a vaccine, relied on 
passive pulsing (Heiser A et al. 2000) and lipofection (Su Z et al. 2002) for efficient 
transfer of RNA into DCs.  However, many other groups obtained unsatisfactory results 
with simple co-incubation of RNA and DCs, and chose electroporation over lipofection 
because of significantly higher transfection efficiencies.  Kalady and colleagues directly 
compared passive pulsing, lipofection and electroporation of EGFP cRNA into DCs 
(Kalady MF et al. 2002).  With passive pulsing of immature DCs, they obtained less than 
1% of EGFP-positive cells.  Lipofection had an efficiency of 19% and electroporation 
50%.  In my analysis, 15% immature DCs and 5% mature DCs captured EGFP cRNA-lipid 
complexes and developed green fluorescence (Figure 4.2).  In comparison, van Tendeloo 
reported only 7.5% EGFP-positive immature DCs and 4% mature DCs after lipofection 
(van Tendeloo VF et al. 2001). 
 
It is difficult to directly compare the efficiency of electroporation in my study with that in 
other studies because experiments were performed under different conditions and the 
efficiencies were defined according to different criteria.  Not only the type of electric pulse 
(exponential decay or square-wave) and electroporation parameters (voltage and 
capacitance) but also the number of DCs, amount of RNA and suspension volume in the 
electroporation cuvette influenced the outcome of transfection.  The maturation status of 
DCs (immature or mature) also seemed to make a difference.  The percentage of EGFP-
positive DCs was taken as a measure of electroporation efficiency in all studies, but it was 
assessed at various time points after transfection.  In some cases, total DC populations, 
including dead cells, were analysed whereas in others only viable DCs were taken into 
account.  In my experiments, only 15% of electroporated DCs were found to be dead and 
they were not excluded from the population of cells in which green fluorescence was 
measured.  Groups that performed comparable analyses reported electroporation 
efficiencies with immature DCs in the range of 63%, achieved with 4 µg of EGFP cRNA 
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and 1-4×106 cells in 100 µL (van Tendeloo VF et al. 2001), to 73%, achieved with 10 µg 
of EGFP cRNA and 5×106 cells in 100 µL (Ponsaerts P et al. 2002).  When 0.7×106 
immature DCs were electroporated with 3 µg of EGFP cRNA in a suspension volume of 
100 µL, I found a transfection efficiency as high as 80% (Figure 4.2B).  Up to 90% of 
mature DCs were EGFP positive.  These findings are contrary to the observations of van 
Tendeloo and colleagues.  In their hands, electroporation of DCs matured with LPS and 
TNF-α, instead of the cytokine cocktail used here, yielded only 33% EGFP-positive cells 
(van Tendeloo VF et al. 2001).  When cRNA encoding the Melan-A TAA was transfected 
into mature DCs instead of the reporter protein EGFP, 88% positive cells were measured 
(Figure 4.25).  This showed that electroporation efficiency was reproducible irrespective of 
RNA species using the optimal conditions developed in my studies.  Therefore, 
electroporation of RNA into DCs can be characterised as a simple, efficient, quick and 
low-cost technology with good clinical applicability.  Particularly important was also the 
fact that cryopreserved PBMCs were used as the starting source for DC generation, 
enabling a further step in standardisation to be achieved. 
 
 
5.2 Antigen processing in immature and mature DCs 
 
Whether RNA should be transfected into immature or mature DCs depends on many 
factors.  DCs of different maturation stages may display distinct susceptibilities to RNA 
transfer.  Furthermore, immature and mature DCs are responsible for different steps of 
antigen processing and presentation, meaning that antigen in the form of RNA must be 
introduced into cells with proper functionality.  It is clear that mature DCs most efficiently 
present antigenic peptides due to their up-regulation of MHC expression, improved rate of 
peptide loading into MHC molecules and intensified transport of pMHC complexes to the 
cell surface.  However, at exactly which stage before antigen presentation DCs generate 
the epitope peptides is the matter of considerable controversy. 
 
Peptides are largely produced when cytosolic proteins are degraded by proteasomes.  In 
DCs, changing profiles of MHC-bound peptides are associated with the replacement of 
active proteasome subunits by the so-called immunosubunits (Gileadi U et al. 1999).  Both 
proteasomes and immunoproteasomes seem to have similar efficiencies in degrading 
proteins, but bioinformatic analysis of experimental degradation data showed that they had 
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individual cleavage motifs, yielding a different and less diverse pool of peptides produced 
by immunoproteasomes (Kesmir C et al. 2003).  A less diverse pool of peptides should 
enhance the presentation of relevant antigenic peptides, since they do not have to compete 
for MHC molecules with many other irrelevant peptides.  If proteasomes were restricted to 
immature DCs and immunoproteasomes to mature DCs, the variable quality of generated 
peptides might even serve to prevent autoimmune reactions.  However, data regarding the 
time point of immunoproteasome assembly and activation are somewhat contradictory and 
do not yet allow clear conclusions to be drawn.  One group reported down-regulation of 
mRNA encoding the immunoproteasome subunits upon DC maturation (Li J et al. 2001).  
This might contribute to the higher antigen-processing capability of immature DCs.  
Another group found that immunoproteasomes already represented half of the proteasome 
population in immature DCs.  Quantitative analysis of mRNA showed either very limited 
or moderate induction of immunoproteasome subunit expression in mature DCs.  Given 
that proteasomes are long-lived complexes with half-lives of several days, it was 
postulated that their replacement with immunoproteasomes occurs only gradually over an 
extended period of time.  Therefore, the amount of immunoproteasomes may not be 
significantly different between immature and mature DCs and should not strongly 
influence antigen processing.  However, authors of the study postulated that other, 
unidentified mechanisms involving regulation of (immuno)proteasome activity are 
responsible for the marked differences in antigen presentation between immature and 
mature DCs (Macagno A et al. 2001).  The DC maturation stage at which such regulatory 
mechanisms are active remains unclear. 
 
Obviously, the need is to introduce RNA into DCs at a maturation stage that allows the 
newly synthesised proteins to be degraded by immunoproteasomes and not by 
proteasomes.  Until more precise information is available about when immunoproteasomes 
are activated inside DCs, the decision of whether to transfect RNA into immature or 
mature DCs can only be based on transfection and antigen-presenting efficiencies.  
Unfortunately, relevant data are scarce and also contradictory.  Van Tendeloo and 
colleagues obtained the most potent CTL activation when immature DCs were loaded with 
Melan-A cRNA by electroporation or lipofection, subsequently matured with LPS and 
TNF-α, and then co-incubated with the CTLs.  They attributed the lower stimulatory 
capacity of DCs transfected after maturation to a lower degree of transfectability by either 
lipofection or electroporation (van Tendeloo VF et al. 2001).  My results contribute to the 
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controversy by showing that electroporation of EGFP cRNA was more efficient with 
mature DCs, compared to immature DCs (Figure 4.2B).  Furthermore, mature DCs 
expressed more protein than immature DCs, based on the use of identical amounts of 
electroporated or lipofected EGFP cRNA (Figure 4.3).  This was not a function of 
transfection efficiency because mature DCs were more difficult to lipofect (Figure 4.2B), 
but nevertheless expressed more EGFP than their immature counterparts.  If mature DCs 
translate RNA into more protein, they are likely to generate more peptides.  Therefore, in 
my experimental system tumour-antigen RNA was transfected into mature DCs only, 
resulting in satisfactory levels of CTL stimulation. 
 
As will be discussed below, protein expression decreases relatively quickly after 
transfection due to degradation of transfected RNA by intracellular RNases, thereby 
narrowing the time period in which antigens are produced and processed.  Different 
susceptibilities of proteins to digestion by intracellular proteases also have to be taken into 
account.  The half-life of tyrosinase was estimated to be at least 12 hr (Halaban R et al. 
1997) and that of Melan-A to be approximately 3 hr (de Mazière AM et al. 2002).  The 
relative instability of Melan-A was indicated in this study when Melan-A cRNA-
transfected DCs were stained with a Melan-A-specific antibody and analysed in FACS™ 
(Figure 4.25).  Melan-A was expressed in 88% of the cells from one donor 7 hr after 
electroporation.  However, 24 hr after electroporation, Melan-A was detected in 66% of 
transfected DCs from a second donor.  Additional staining experiments, to assess precise 
kinetics and quantify mean fluorescence intensity, are required to confirm the observed 
decrease in Melan-A expression.  In terms of antigen presentation, different stabilities of 
TAAs could lead to a situation in which peptides originating from one antigen, e.g. Melan-
A, are generated and presented sooner than peptides derived from another antigen, e.g. 
tyrosinase.  Considering the fact that an average pMHC class I complex has a half-life of 
5-10 hr on the cell surface (Cella M et al. 1999), choosing the right time-frame for DC-
CTL interaction may be critical for efficient T-cell activation.  Whereas selection of an 
optimal time point may not be possible for all antigens encoded by total cellular RNA, it 
might prove to be advantageous with single-species tumour-antigen cRNAs.  Therefore, an 
additional argument in favour of electroporating mature DCs might be that the expression 
of their co-stimulatory, adhesion and antigen-presenting molecules is already up-regulated.  
This phenotype is not changed by electroporation (Figure 4.5).  If mature DCs are 
transfected, there is no need to wait an additional 1-2 days in order for their maturation to 
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take place.  Theoretically, they can be used for CTL stimulation immediately after 
transfection.  Practically, however, DCs need time to recuperate from the shock of 
electroporation and to produce, process and present the antigen.  This was demonstrated by 
my finding that tyrosinase cRNA-pulsed DCs developed a higher stimulatory capacity 
when they were cultured one day before contact with the CTLs, as opposed to only two 
hours (Figure 4.13).  This 24 hr time period might be used for simultaneous maturation, if 
immature DCs were electroporated, however, if RNA encoding a short-lived antigen is 
used, it may be necessary to initiate co-incubation of DCs and CTLs sooner, thereby 
limiting the time available for DC maturation. 
 
Keeping in mind that all steps performed in vitro are merely attempts to simulate in vivo 
situations, a strong argument in favour of RNA transfection into immature DCs is made by 
the Gilboa group (Nair S et al. 2003).  Instead of maturing DCs in vitro through culture 
with various agents that mimic the conditions encountered at a site of inflammation, 
immature DCs were electroporated and then injected into adjuvant-pretreated skin.  
Thereby, transfected DCs were matured in situ and displayed migratory capacities, 
immunostimulatory properties and anti-tumour activity that were comparable to, or even 
better than, those achieved using DCs matured ex vivo.  Mature DCs injected into adjuvant-
treated sites migrated more efficiently, but their immunostimulatory capacities remained 
lower than those of immature DCs that matured in situ.  In the end it will probably be 
necessary to evaluate these various parameters using labeled DCs in comparative clinical 
trials in order to define the best clinical strategy. 
   
 
5.3 Quantitation of antigen presentation on RNA-pulsed DCs 
 
In the vast majority of studies evaluating the ability of RNA-pulsed DCs to prime or 
activate CTLs, uncloned lines were used in which the CTLs were only one component of a 
complex pool of lymphocytes.  The function of polyclonal CTLs specific for repertoires of 
unknown tumour epitopes or even for defined individual epitopes was mostly tested in 
cytotoxicity assays.  In my experimental system only antigen-specific CTL clones were 
analysed because the goal of the study was to detect fine quantitative differences based on 
DCs pulsed with various amounts of different RNA species.  Considering that the 
efficiency of CTL activation depends on the quantity of pMHC complexes expressed on 
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the surface of DCs and that the number of peptides generated is proportional to the amount 
of protein synthesised, it was important to know whether higher protein expression and 
stronger CTL stimulation could be achieved with increased doses of RNA.  The kinetics of 
transfected RNA degradation and protein expression were investigated to determine the 
time-frame in which the most antigen was produced.  Furthermore, quantitation of RNA 
samples was performed in order to precisely define how much antigen message was 
introduced into the DCs.  Finally, the correlation between the amount of transfected 
antigen message and CTL stimulation was analysed. 
 
Varying amounts of RNA transferred into the DCs could indeed be used to manipulate 
levels of protein expression and subsequent peptide presentation.  The dependence of 
protein expression on the quantity of transfected RNA was demonstrated in the EGFP 
cRNA dose-finding experiment (Figures 4.6 and 4.7).  Pulsing DCs with increased 
amounts of tyrosinase cRNA resulted in improved stimulation of CTLs (Figure 4.15), 
indicating that, given more RNA, more proteins were produced in DCs and, consequently, 
more peptides were processed and presented at the cell surface.  Whereas a total of 8 µg 
(or 3 µg per 100 µL electroporation suspension) was the maximum dose of EGFP cRNA 
applied in electroporation, 48 µg (or 19 µg per 100 µL) was the highest amount of cRNA 
used encoding tyrosinase, Melan-A or CDK4-R24C.  Total cellular melanoma RNA and 
amplified melanoma mRNA samples contained less message for individual antigens, 
therefore, 75 µg (or 30 µg per 100 µL) were used.  These amounts were similar to or even 
exceeded those described in the literature.  For comparison, 20 µg per 100 µL of Melan-A 
cRNA (Kalady MF et al. 2002) and 10 µg per 100 µL of myeloma RNA (Milazzo C et al. 
2003, Grünebach F et al. 2003) were among the highest electroporation RNA doses 
reported by other groups.   
 
The kinetics of EGFP cRNA degradation (Figures 4.8, 4.9 and 4.10) and tyrosinase cRNA 
degradation (Figures 4.18, 4.19 and 4.20) in the DCs showed that transfected RNA was 
rapidly lost within the first several hours after electroporation.  Nevertheless, RNA could 
still be detected inside the cells three to five days later.  The behaviour of RNA after 
electroporation was also investigated by Eppler and colleagues.  When DCs were 
electroporated with fluorochrome-labelled RNA and then immediately analysed in 
FACS™, a pronounced increase of fluorescence was observed, compared to control DCs 
that were mixed with the RNA, but were not transfected.  Four hours after electroporation, 
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fluorescence decreased to control levels (Eppler E et al. 2002).  In my analyses, large 
amounts of RNA applied by electroporation allowed prolonged antigen expression, but 
most antigen was probably produced within a relatively short time after transfection.  The 
intensity of EGFP fluorescence reached a maximum 24 hr after electroporation and then 
slowly decreased over the following four days (Figures 4.4 and 4.7).  Although EGFP 
molecules have a long half-life of more than 24 hr (Li X et al. 1998), kinetic measurements 
clearly demonstrated that after the initial surge of EGFP expression, based on high 
amounts of freshly transfected RNA, the EGFP translation rate was reduced due to 
elimination of the RNA template.  Another group reported similar kinetics in luciferase 
cRNA-lipofected DCs.  Luciferase activity reached a maximum 3-8 hr after transfection 
and decreased significantly by 24 hr (Weissman D et al. 2000). 
 
In the studies of others, it was demonstrated that total cellular tumour RNA could be 
amplified in RT-PCR without the loss of biological function (Boczkowski D et al. 2000).  
Using this technology, one important advantage is that unlimited RNA stocks can be 
produced from a limited number of tumour cells.  Another advantage is that the 
proportions of antigen message in amplified RNA were found to be higher than in native 
RNA.  This was due to the fact that only mRNA is reverse transcribed and amplified in 
RT-PCR whereas rRNA, tRNA and other RNA species are not.  Interestingly, in my 
analysis of melanoma-derived RNA samples, the Melan-A message was amplified 62-fold, 
the tyrosinase message 24-fold and the CDK4 message only 2-fold (Figure 4.21).  These 
differences may reflect variations in the expression levels of the message for the three 
antigens in melanoma cells from which the RNA samples were obtained.  Whereas CDK4-
R24C may have a lower expression level, tyrosinase and Melan-A may have higher 
expression levels in melanomas.  Therefore, the polymerase could associate sooner with 
tyrosinase and Melan-A cDNA templates and their amplification started in earlier PCR 
cycles.  The amplification of CDK4 molecules may have taken place later during the PCR 
run because they were not so easily detected by the polymerase.  The same approach 
helped to define quantitative differences between single-species tumour-antigen RNA 
samples and total cellular melanoma RNA samples.  Approximately 17240-fold more 
CDK4-R24C message, at least 500-fold more tyrosinase message and at least 480-fold 
more Melan-A message was found in corresponding single-species cRNAs compared to 
amplified melanoma mRNAs. 
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A good correlation was observed between the quantity of antigen message in various 
melanoma cells and the CTL recognition of antigenic epitopes presented on their surfaces.  
In other words, antigen-specific CTLs consistently reacted better to tumour cells that 
contained more RNA encoding the specific antigen (Figure 4.23).  When RNA was 
transfected into DCs, such fine quantitative differences in epitope recognition were not 
detected (Table 4.3).  Nevertheless, the elucidation of parameters affecting antigen 
presentation on RNA-transfected cells (Figure 4.21) made it possible to better understand 
the stimulatory capacities of differently-pulsed DCs.  The amount of CDK4-R24C message 
remained low in the RNA sample even after RT-PCR.  Therefore, DCs developed no 
stimulatory capacity for CDK4-R24C-specific CTLs when electroporation was performed 
with either total cellular melanoma RNA or amplified melanoma mRNA (Figure 4.28).  In 
extrapolation, it is likely that total cellular tumour RNA-transfer will not allow DCs 
displaying a repertoire of mutated peptides to efficiently prime specific CTLs, unless the 
mutations lead to over-expression of the template message.  In contrast, successful 
amplification of tyrosinase and Melan-A message resulted in the activation of both 
tyrosinase-specific CTL clones and one of two Melan-A-specific CTL clones by DCs 
transfected with amplified mRNA (Figures 4.26 and 4.27).  DCs pulsed with native tumour 
RNA did not stimulate CTLs specific for tyrosinase above background.  The Melan-A 
epitope, however, was recognised even on DCs transfected with native tumour RNA when 
a CTL clone with high avidity was used.  As expected, CTLs responded significantly 
stronger to electroporation with single-species tyrosinase, Melan-A or CDK4-R24C cRNA.  
Compared to transfection with tyrosinase cRNA, levels of CTL stimulation with amplified 
melanoma mRNA-pulsed DCs were 8-fold and 18-fold lower, depending on the CTL 
clone.  This means that amplified mRNA yielded 13.4% and 5.5% , respectively, of the 
stimulation levels found with single-species tyrosinase cRNA.  In the case of Melan-A, 
stimulation with amplified melanoma mRNA was 6-fold lower or 17.5% of the maximum 
reached with single-species cRNA. 
 
Clearly, it is technically feasible to force extremely large quantities of RNA into many 
DCs.  Whereas this leads to reproducibly high stimulation of antigen-specific CTL clones, 
it seems that less antigen presented on fewer DCs will suffice for T-cell priming.  
Theoretically, this may lead to preferential expansion of high-avidity T-cells.  Heiser and 
colleagues observed specific killing when CTLs were stimulated after 1×106 DCs were 
passively pulsed with as little as 10 ng of PSA (prostate-specific antigen) cRNA.  
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Increasing the dose resulted in augmented responses that reached a plateau at 1.5 µg 
(Heiser A et al. 2000).  The Weissman group lipofected only 0.2 µg of HIV (human 
immunodeficiency virus) gag cRNA into 1×105 DCs and induced antigen-specific CTLs 
when these DCs were co-incubated with PBMCs (Weissman D et al. 2000).  However, 
differences between electroporated and passively pulsed or lipofected DCs have been 
investigated so far only at the functional level of CTL priming or activation.  In terms of 
protein expression, my fluorescence microscopy and corresponding FACS™ data (Figure 
4.3) clearly showed that each of the few lipofected DCs produced more EGFP than any of 
the many electroporated DCs.  This observation and other quantitation data now provide 
the basis for evaluating the efficiency of T-cell priming using only a few or many DCs 
expressing low, intermediate or high levels of antigen. 
 
 
5.4 Correct and incorrect peptide sequences 
 
The HLA-A2-restricted tyrosinase368-376 epitope YMNGTMSQV, predicted from the 
amino acid sequence of the protein (Wölfel T et al. 1994b), was found to be slightly 
different from the tyrosinase368-376 epitope YMDGTMSQV, identified by mass 
spectroscopy of peptides eluted from an HLA-A*0201 melanoma cell line (Skipper JC et 
al. 1996).  The difference between the primary sequence and the sequence of the presented 
peptide is due to a posttranslational conversion of asparagine (N) into aspartic acid (D) at 
position 3.  The newly defined peptide was recognised much more efficiently by a CTL 
clone than the predicted peptide, indicating that the post-translationally modified peptide in 
fact is the natural epitope.  Whereas this difference is of central importance for peptide 
recognition by melanoma CTLs, it has no impact on peptide binding to the MHC molecule.  
Based on this discovery, a novel mechanism was suggested for the generation of peptides 
from transmembrane and secreted proteins.  These proteins are associated with the ER as 
they are synthesised and, thus, they have no physical contact with the proteasome in the 
cytosol.  However, peptides are produced from transmembrane and secreted proteins.  It 
was hypothesised that either their proteolysis takes place in the ER (Lee SP et al. 1996) or 
that such proteins are mistranslated in the cytosol (Wang RF et al. 1996).  A mechanism 
responsible for the generation of the tyrosinase peptide was postulated by Engelhard and 
colleagues (Engelhard VH et al. 2002).  Tyrosinase is a transmembrane protein and it is, 
therefore, synthesised on ER-bound ribosomes.  Once properly folded, the tyrosinase 
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molecule, anchored in a lipid-bilayer, is sorted to the melanosomal compartments.  The 
conversion of YMNGTMSQV into YMDGTMSQV is not based on a simple deamination 
of N into D, but involves constitutive glycosylation of N in the ER during synthesis.  After 
translation and glycosylation, some tyrosinase molecules, possibly the misfolded ones, are 
reverse translocated into the cytosol where deglycosylation of N is accompanied by its 
deamination into D.  Tyrosinase is then degraded by the proteasome and generated 
peptides are transferred into the ER by the TAP transporter. 
 
The only epitope displayed on tyrosinase expressing cells was indeed found to be 
YMDGTMSQV (Skipper JC et al. 1996, Mosse CA et al. 1998).  Even though the 
sequence YMNGTMSQV does not adequately represent this epitope, it is a good example 
of a peptide that, in a natural system, is most probably perceived as unnatural, contrary to 
the best knowledge of scientists at the time.  As discussed below, in this case, "unnatural" 
also means "incorrect".  However, heteroclitic peptides demonstrate that in nature "the 
unnatural" peptide can sometimes be recognised and possibly mount an even stronger 
immune response than "the natural" epitope (Dyall R et al. 1998).  Heteroclitic peptides 
differ from their natural counterparts in amino acids that are responsible for binding to 
MHC molecules and/or interaction with TCRs on CTLs.  The slightly different sequences 
ensure a higher stability of pMHC complexes and sometimes a higher immunogenicity of 
the peptides.  These peptides should be recognised by the same CTLs that react upon 
presentation of natural peptides.  If heteroclitic peptides are used for priming, it can be 
expected that the resultant CTLs will react strongly to the naturally-produced peptides 
during secondary challenge. 
 
In this study, TyrF8 CTLs and IVS B CTLs were used to recognise the tyrosinase368-376 
epitope presented on RNA-transfected DCs.  TyrF8 CTLs were cultured from PBMCs of a 
healthy donor.  After priming and expansion with autologous YMNGTMSQV-pulsed 
antigen-presenting cells, TyrF8 CTLs were cloned by standard limiting dilution procedures 
(Visseren MJ et al. 1995).  Whereas the predicted peptide was used in the generation of 
TyrF8 CTLs, IVS B CTLs were established from mixed lymphocyte tumour-cell cultures 
which included autologous melanoma cells, presenting the natural YMDGTMSQV 
peptide.  IVS B CTLs were not cloned, but subsequently produced clones were tested and 
had lytic activities identical to that of IVS B.  This line is, therefore, referred to as a clone 
(Wölfel T et al. 1993).  When the two tyrosinase peptides were separately loaded onto T2 
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cells, TyrF8 CTLs reacted stronger to the predicted epitope, but recognised both peptides 
(Figure 4.22).  IVS B CTLs showed almost no reactivity against the predicted peptide, but 
did react to presentation of the natural epitope.  The specificity of the IVS B clone for the 
naturally processed peptide was confirmed in co-incubation experiments with different 
melanoma cells (Figure 4.23).  Since tumour cells always present the natural tyrosinase 
peptide, IVS B CTLs were successfully activated.  Most importantly, when DCs were 
either pulsed exogenously with the predicted peptide or produced the natural peptide based 
on transfected tyrosinase cRNA, IVS B were stimulated to a significantly higher level by 
the RNA-pulsed DCs than by the peptide-pulsed DCs (Figure 4.26B). 
 
A similar situation was observed with A42 CTLs recognising the Melan-A26-35 epitope.  
A42 CTLs were cloned by limiting dilution of tumour infiltrating lymphocytes from a 
melanoma patient.  Autologous tumour cells, presenting the natural peptide, served as 
stimulators in the culture of this clone.  A42 CTLs were reported to successfully recognise 
the EAAGIGILTV peptide, among several others (Kawakami Y et al. 1994).  The 11/33 
clone was also used in this study to detect presentation of the Melan-A epitope.  Since 
11/33 CTLs were obtained by limiting dilution from mixed cultures of PBMCs and 
autologous melanoma cells, this clone is also specific for the naturally processed peptide 
(Wölfel T et al. 1993).  Even though both A42 and 11/33 CTLs were generated against the 
same Melan-A epitope, avidities of their TCRs for pMHC complexes were likely to be 
different.  This was confirmed by the use of a slightly changed peptide.  The heteroclitic 
peptide ELAGIGILTV, used in this analysis, is an analogue of the peptide with the natural 
sequence EAAGIGILTV.  The substitution of alanin (A) with leucine (L) was shown to 
result in stable binding of the peptide to MHC molecules and more efficient recognition by 
CTLs (Valmori D et al. 1998).  Activation of the 11/33 clone was also positively 
influenced by this change.  11/33 CTLs reacted stronger to the synthetic peptide 
exogenously pulsed onto both T2 cells (Figure 4.22) and DCs (Figure 4.27B) than to 
melanoma cells (Figure 4.23) and Melan-A cRNA-pulsed DCs (Figure 4.27B) which 
produced the natural peptide.  In contrast, the A42 clone was stimulated to much higher 
levels by tumour cells (Figure 4.23) than by peptide-pulsed T2 cells (Figure 4.22).  
Furthermore, co-incubation with RNA-transfected DCs resulted in slightly stronger 
activation of A42 CTLs, compared to peptide-pulsed DCs (Figure 4.27A). 
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The outcome of loading DCs with a certain peptide strongly depends on the repertoire of 
CTLs.  As was seen with TyrF8, CTLs may recognise unnatural peptides in addition to the 
natural ones representing the same epitope.  The 11/33 example showed that some CTLs 
can even react significantly stronger to synthetic rather than peptides produced by the cells.  
On the other hand, peptides with sequences different from those in primary structures of 
proteins may cause lower reactivity or no immunity at all.  Experiments performed with 
IVS B and A42 CTLs demonstrated the advantage of DC-pulsing with RNA, as opposed to 
loading with peptides.  The use of RNA technology eliminated the need to know the 
correct sequences of immunogenic peptides.  Unfortunately, not even RNA-transfected 
DCs can be counted on to generate and present the same peptides as tumour cells.  For 
example, virally-infected murine DCs were shown to differentially present the same MHC 
class I epitopes compared to infected fibroblasts, even though both cell types produced 
similar levels of infectious virions and individual viral proteins (Butz EA and Bevan MJ 
1998). However, in most cases, a DC is likely to better choose antigens and their epitopes 
for presentation than the scientist.  When DCs are loaded with RNA, this choice is not 
restricted to only one HLA allotype, but takes into consideration all MHC class I and class 
II molecules expressed by the DC.  Immunotherapy based on pulsing with synthetic 
peptides usually has the disadvantage of restricted presentation by only one HLA allotype, 
which automatically eliminates the possibility of treating patients whose repertoires do not 
include the allele in question. 
 
Furthermore, peptides intracellularly associated with MHC molecules may have an 
advantage over peptides that bind extracellularly to empty MHC molecules expressed on 
the cell surface.  Proteins fused with a cell-penetrating peptide were shown to rapidly and 
efficiently enter intact cells (Rojas M et al. 1998).  In a study performed by Wang, DCs 
were pulsed with a construct consisting of an epitope from TRP-2 and the cell-penetrating 
peptide, resulting in successful internalisation of the construct (Wang RF and Wang HY 
2002).  These DCs were observed to present the TRP-2 epitope over longer periods of time 
in vitro and, after injection into mice, a much more efficient elimination of a melanoma 
challenge occurred in vivo, when compared to DCs pulsed with the TRP-2 peptide alone.  
Even though the mechanism of prolonged antigen presentation is not clear (it may involve 
gradual release of peptides from endosomes into the cytoplasm), the difference between 
peptides endogenously bound to MHC molecules and peptides exogenously loaded onto 
MHC molecules strongly indicates that the endogenous pathway yields higher stimulatory 
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capacities of antigen-pulsed DCs.  Following transfection of RNA, peptides are produced 
and associated with antigen presenting molecules inside the DCs, again supporting the use 
of RNA technology to create pMHC complexes on DCs. 
 
 
5.5 Priming T-helper cells in addition to CTLs 
 
Most tumours express MHC class I molecules on their surface, but are negative for MHC 
class II.  CTLs recognise antigenic peptides presented within class I molecules.  They are 
very effective in terms of lysing malignant cells directly upon recognition of pMHC class I 
complexes.  Therefore, tumour immunotherapy has focussed on the induction of CTL 
responses.  This is exemplified by an increasingly larger list of identified MHC class I-
restricted TAA epitopes.  Immunisation of patients with antigens known to provide these 
epitopes and, thereby, to stimulate CTLs, was shown to generate anti-tumour immunity 
leading to tumour regression.  However, in the majority of vaccinated patients, overall 
immune responses were too weak and short-lasting to eradicate all cancer cells.  
Fortunately, a growing body of evidence suggests that including T-helper cells in 
immunotherapeutic strategies can improve initiation and maintenance of CTL responses 
(Wang RF 2001). 
 
T-helper cells play an important role in priming CTLs.  One proposed mechanism is that 
they recognise antigens presented within MHC class II molecules on the DCs and, in turn, 
activate antigen-bearing DCs.  Molecules responsible for the interaction between T-helper 
cells and DCs are CD40 and CD40 ligand (CD40L).  CD40L is a membrane molecule 
expressed by antigen-stimulated T-helper cells which triggers CD40, a surface receptor on 
DCs.  CD40 activates DCs, resulting in increased production of cytokines, especially IL-12 
that is a well-known CTL activation factor (Cella M et al. 1996).  Therefore, after 
interaction with T-helper cells, DCs become competent to prime CTLs.  Inflammatory 
cytokines and bacterial products that up-regulate MHC and co-stimulatory molecules 
increase the ability of DCs to stimulate CTL responses (Sallusto F and Lanzavecchia A 
1994) and may be even sufficient to activate DCs to a state where they can autonomously 
do so, even in the absence of T-helper cells (Lanzavecchia A 1998).  However, T-helper 
cells are essential for the maintenance of CTL effector functions by secreting cytokines 
such as IL-2, which are necessary for CTL growth and proliferation (Greenberg PD 1991).  
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These findings have important implications in cancer therapy because complete tumour 
elimination requires prolonged anti-tumour immunity (Ossendorp F et al. 1998).  
Furthermore, T-helper cells can also mediate tumour regression in the absence of CTLs 
(Greenberg PD 1991).  Mechanisms underlying this phenomenon are not clear but several 
studies suggested that IFN-γ, secreted by T-helper cells, might be involved in anti-tumour 
and anti-angiogenic activities (Qin Z and Blankenstein T 2000, Mumberg D et al. 1999).  
Other studies proposed that T-helper cells eliminate tumours through activation and 
recruitment of effector cells, including macrophages and eosinophils (Hung K et al. 1998 J, 
Greenberg PD 1991).  It was shown that IFN-γ sensitises tumour cells to CTLs via up-
regulation of MHC class I molecules (Dighe AS et al. 1994).  T-helper cells also activate 
B-cells to become antibody-secreting plasma cells.  Tumour-specific antibodies might, in 
turn, contribute to therapeutic anti-tumour immunity (Glennie MJ and Johnson PW 2000). 
 
The prerequisite of using antigens in the form of RNA is that transfected RNA has to reach 
the cytoplasm in order for proteins to be synthesised.  Endogenously expressed antigens 
are presented within MHC class I molecules.  Consequently, CTLs and not T-helper cells 
are activated.  However, the RNA technology can be modified to prime both CTL and T-
helper cell responses.  It has been shown that MHC class II presentation of antigens can be 
greatly enhanced when they are fused with a sorting signal of LAMP-1 (lysosome-
associated membrane protein 1), which directs endogenoulsy expressed proteins into 
lysosomal compartments and, to a lesser extent, into late endosomes (Wu TC et al. 1995).  
The Gilboa group produced cRNAs encoding chimeric proteins, consisting of the LAMP-1 
sorting signal and either telomerase or CEA (carcinoembryogenic antigen).  When these 
RNAs were used in T-cell priming, good CTL responses, significantly higher antigen-
specific T-helper cell proliferation and higher numbers of IFN-γ secreting T-helper cells 
were detected, compared to priming with native telomerase or CEA proteins (Nair S et al. 
1998).  The same group tried another approach.  A short incubation of cRNA-transfected 
DCs with invariant chain antisense oligonucleotides suppressed the expression of the 
invariant chain, resulting in enhanced presentation of class II epitopes, activation of T-
helper cells and more potent and longer lasting CTL responses in vaccinated mice (Zhao Y 
et al. 2003).  One of the functions of the invariant chain is to block peptide-binding sites of 
MHC class II molecules while they are being assembled in the ER and transported into 
endosomal compartments where they are loaded with peptides derived from internalised 
exogenous proteins.  If the invariant chain is not expressed and the class II peptide-binding 
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sites are unprotected, i.e. open, endogenous peptides can be associated with MHC II 
molecules in the ER.  Thereby, the repertoire of presented endogenous peptides is 
expanded and corresponding T-helper cells are activated, in addition to CTLs. 
 
 
5.6 Overcoming tumour immune escape 
 
One of the strategies used by tumours to escape from immune surveillance is to down-
regulate TAA expression.  This phenomenon has been observed especially in melanoma, 
where tumour progression is often associated with reduced expression of melanocyte 
differentiation antigens such as gp100, Melan-A and tyrosinase (de Vries T et al. 1997).  In 
most cases, molecular mechanisms involved in the down-regulation of tumour-antigens are 
unknown.  However, Kurnick and colleagues discovered that some melanoma cells 
produce soluble factors which actively, but reversibly, down-modulate transcription of the 
Melan-A gene (Kurnick JT et al. 2001). 
 
In order to avoid tumour immune escape, immunotherapy can target multiple TAAs 
simultaneously.  Polyclonal responses of CTLs specific for more than one antigen are 
likely to result in more efficient elimination of malignant cells, and the killing should not 
be hampered by the down-regulation of one of the targeted molecules.  Such an approach is 
complicated with DNA vectors, but can be easily developed with RNA.  Heiser and 
colleagues transfected DCs with total cellular RNA from renal cell carcinoma (RCC) and 
used them for in vitro priming of CTLs.  Unlike the melanoma model, immunogenic 
antigens associated with RCC have not been identified.  Nevertheless, CTLs against 
telomerase were found to be a component of the CTL pool primed against RCC.  When 
compared, tumour-specific CTLs were consistently superior to CTLs stimulated with 
telomerase RNA-transfected DCs in their ability to recognise and lyse tumour cells (Heiser 
A et al. 2001a).  In addition to telomerase, PMBCs from patients vaccinated with  RCC 
RNA-transfected DCs displayed reactivity to the oncofetal antigen and G250 (Su Z et al. 
2003).  The same group also worked with prostate cancer.  Once again, DCs transfected 
with amplified tumour RNA stimulated T-cell responses directed against multiple TAAs.  
Only a fraction of these CTLs were activated against PSA and telomerase.  Therefore, 
polyclonal tumour-specific CTLs were superior in recognising and killing tumour targets 
to CTLs specific for PSA only (Heiser A et al. 2001b).  Similarly, epitopes derived from 
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MUC1 and Her-2/neu antigens were shown to contribute to the cytotoxic activity of CTLs 
primed with breast cancer RNA-pulsed DCs (Müller MR et al. 2003).  MUC1-specific 
CTLs were also detected within the presumably polyclonal CTL pool primed with 
myeloma RNA-pulsed DCs (Milazzo C et al. 2003).  All these studies prove that 
immunotherapeutically-induced tumour-specific CTLs indeed represent polyclonal 
responses and demonstrate the efficiency of strategies that prime CTLs against multiple 
antigens.   
 
Another mechanism possibly contributing to immune escape is presentation of APLs.  As 
explained above, the synthetic peptide ELAGIGILTV is an optimised analogue of the 
naturally presented Melan-A26-35 peptide EAAGIGILTV.  The altered amino acid sequence 
is a basis for quantitatively and qualitatively improved CTL responses (Valmori D et al. 
1998, Rivoltini L et al. 1999).  Therefore, when their impact on a CTL clone were 
compared, the natural peptide was described as an agonist and the synthetic peptide as a 
superagonist.  At the other extreme, some APLs were observed to act on the same CTLs as 
partial agonists or antagonists rendering T-cells only partially activated or even anergised 
(Rivoltini L et al. 2002).  Interestingly, EAAGIGILTV embodies a general sequence motif 
frequently occurring in a variety of endogenous peptides and proteins (Loftus DJ et al. 
1996, Dutoit V et al. 2002).  Since interaction with APLs with partial agonist or antagonist 
activities potentially plays a role in the functional impairment of self-reactive T-cells, 
presentation of APLs may be one of the mechanisms of maintaining peripheral tolerance to 
self-antigens, in this case Melan-A.  Furthermore, given the genetic instability of tumour 
cells, it is conceivable that modifications of antigen structure, processing and/or 
presentation may lead to the expression of APLs by cancer cells and that the existence of 
partial agonist and antagonist peptides derived from TAAs may contribute to the 
development of peripheral tolerance to these antigens.  Indeed, suboptimal activation of 
antigen-specific CTLs was detected in response to melanoma cells expressing endogenous 
Melan-A26-35-like peptides.  However, the phenomenon was overcome when CTLs were 
generated with the superagonist peptide (Carrabba MG et al. 2003).  The RNA technology 
also benefited from these observations.  DCs electroporated with Melan-A cRNA carrying 
an A27L amino acid substitution displayed higher stimulatory capacities than DCs pulsed 
with unmodified Melan-A cRNA (Abdel-Wahab Z et al. 2003).  
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When total cellular RNA is used as a source of TAAs for T-cell priming, identities of these 
antigens do not have to be known.  If antigens associated with a certain tumour have been 
identified, single-species tumour-antigen cRNAs can be combined in DC-based 
immunotherapy to minimise effects of tumour escape.  By concentrating on several well 
defined antigens, as opposed to the whole cellular repertoire, quantitatively better 
presentation of relevant antigenic epitopes and, thereby, more efficient T-cell activation 
can be achieved (Figures 4.26, 4.27 and 4.28).  If necessary, components of the transfected 
cRNA pool can be manipulated so that peptides with optimised sequences are presented 
within both MHC class I and class II molecules. 
 
 
5.7 Antigen competition and immunodominance 
 
The use of multiple antigens in DC-based vaccination, either in the form of pooled single-
species tumour-antigen cRNAs or in the form of amplified mRNA from tumour cells, 
automatically raises the question of immunodominance.  If only one epitope will induce 
strong immune responses, there is no sense in developing a vaccine for several different 
antigens.  However, advantages of simultaneous immunisation against multiple epitopes 
are becoming increasingly obvious with immunotherapeutic strategies applying more 
profound mechanisms to break tolerance against self-antigens and to fight tumour escape. 
 
Grossman and colleagues (Grossmann ME et al. 2001) favour the use of strategies that 
utilise not only dominant, but also subdominant epitopes in the design of tumour vaccines.  
Whereas the immune system is likely to be tolerant to dominant epitopes from self-
antigens, it may be easier to mount immune responses against subdominant epitopes.  
CTLs specific for subdominant epitopes more often bypass negative selection in the 
thymus and in the periphery.  Pulsing with antigens in the form of RNA, allows DCs 
themselves to choose epitopes from antigens that are probably both dominant and 
subdominant.  Unlike with antigenic peptides, the identity of epitopes and their ranking in 
the hierarchy of immunodominance do not have to be known if RNA coding for full 
antigens is used. 
 
Which epitope will dominate an immune response is decided on two levels.  The number 
of pMHC complexes expressed on the surface of a DC molecule may, to a certain extent, 
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be influenced by the competition of that peptide with other peptides present inside a DC at 
the same time.  However, competition between CTLs specific for different epitopes seems 
to be the most important factor contributing to the phenomenon of immunodominance. 
 
In my studies, combining tyrosinase, Melan-A and CDK4-R24C antigens was investigated 
to determine whether it is possible to activate epitope-specific CTLs with DCs that 
received large amounts of RNA coding for several different antigens (Figures 4.26, 4.27 
and 4.28).  Whereas the primary conclusion was that successful stimulation can be 
achieved, the experiments inspire a discussion about the quantities of peptides produced by 
DCs and their importance for vaccination strategies.  In my experimental DC-RNA-CTL 
system, the variable of competition between CTLs with different specificities and different 
affinities for pMHC complexes was eliminated, since DCs transfected with either pooled 
tyrosinase, Melan-A and CDK4-R24C cRNAs or amplified melanoma mRNA were 
separately co-incubated with each of the five antigen-specific CTL clones.  Therefore, 
arguments can be reduced to the competition of peptides inside the DC, even though CTLs 
were used to assess the immunogenicity of those peptides upon presentation. 
 
The highest stimulation of CTLs was achieved within the system when DCs transfected 
with 48 µg of a single-species cRNA alone were utilised.  As expected, 24 µg of a single-
species cRNA alone led to lower but not proportional CTL stimulation.  When 48 µg of 
each of the three single-species cRNAs were pooled, giving a total of 144 µg, and 
transfected into DCs, stimulations of individual CTL clones never reached their 
maximums, but were approximately in the range associated with 24 µg of each single-
species cRNA applied alone.  Responses to DCs transfected with 24 µg of each of the three 
single-species cRNAs, summing up to a total of 72 µg combined RNA, were similar or 
equal to the upper limit reached with 144 µg of pooled cRNAs.  Since the CTLs had the 
capacity to secrete more IFN-γ, the argument can be made that the limiting factor in CTL 
activation was not the number of 2×104 CTLs, but rather the quantity of pMHC class I 
complexes expressed on the surface of 4×104 DCs.  After transfection with either 144 µg 
or 72 µg of pooled cRNAs, so many antigenic peptides were produced that, in the context 
of a total cellular peptide pool, the antigen-presenting capacity of each DC was fully used.  
Tyrosinase, Melan-A and CDK4-R24C peptides possibly competed for free antigen-
presenting molecules to some extent, but enough pMHC class I complexes were formed in 
all three cases for successful stimulation of epitope-specific CTL clones. 
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In comparison with single-species cRNA samples, amplified mRNA from a melanoma cell 
line contained much lower amounts of combined message for tyrosinase, Melan-A and 
CDK4-R24C.  DCs transfected with 75 µg of this RNA seemed to produce significantly 
fewer peptides, as assessed by CTL recognition of pMHC class I complexes.  It is possible 
that, the total cellular mRNA pool also contained factors that changed antigen processing 
and presentation in the DCs.  However, since potential intracellular competition between 
peptides was not observed to strongly influence CTL stimulation when high doses of 
pooled single-species cRNAs were used, it is difficult to imagine that this kind of 
competition occurred upon transfection of total cellular mRNA.   
 
If used as a vaccine, DCs pulsed with various RNA species will have the task of 
simultaneously activating CTLs of different specificities.  For this reason, potential 
immunodomination, i.e. suppression of T-cell responses to subdominant epitopes by 
dominant epitopes, has to be taken into account.  It has been hypothesised that competition 
between CTLs of different specificities occurs if peptides produced inside the same DC are 
not very abundant (Kedl RM et al. 2003).  On the other hand, very high amounts of various 
peptides should result in expression of many pMHC class I complexes and eliminate the 
basis for CTL competition.  As concluded above, DCs transfected with large quantities of 
pooled single-species tumour-antigen cRNAs produced large quantities of relevant 
peptides.  These peptides possibly compete with irrelevant peptides and also among 
themselves, but nevertheless they do stimulate corresponding CTLs in the range where 
more RNA does not mean higher IFN-γ secretion by CTLs.  This indirectly indicates that 
MHC class I molecules on the DCs are saturated with peptides, with possibly a high 
percentage of them presenting antigenic epitopes.  Therefore, according to Kedl, these DCs 
should not cause immunodominance of an epitope from one antigen to epitopes from other 
antigens when used as a vaccine.  Nevertheless, for DCs transfected with amplified mRNA 
from melanoma cells, a different set of rules may apply.  Since antigenic peptides do not 
necessarily outnumber other peptides produced inside a transfected DC, fewer relevant 
complexes are expressed.  According to Kedl, this may result in competition between 
CTLs of different specificities. 
 
It was shown in numerous experiments that increasing the quantity of DCs used in 
vaccination, diminished or even abolished immunodominance.  Furthermore, if separate 
DC populations were engineered to present single antigens and were pooled for 
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immunisation, immunodominance does not occur (Wolpert EZ 1998, Sandberg JK 1998, 
Grufman P 1999a, Grufman P 1999b).  In other words, more DCs and more pMHC 
complexes expressed on their surfaces, meant less competition between responding CTLs, 
particularly if individual peptides were presented on separate DCs.  Amplified mRNA 
from tumour cells is used when immunogenic antigens are unknown.  In this case, message 
for different antigens can not be separated and the only way to avoid potential 
immunodominance seems to be administration of higher numbers of transfected DCs.  If 
TAAs have been identified, as in the case of melanoma, two vaccination strategies can be 
considered.  Each single-species tumour-antigen cRNA can be transfected into DCs 
separately and these DCs can be mixed before administration as a vaccine.  According to 
experience of several groups, pooling pulsed DCs instead of antigens should eliminate 
immunodominance.  Technically, it is easier to transfect pooled single-species tumour-
antigen cRNAs into DCs.  Whereas simultaneous presentation of different antigenic 
peptides may lead to immunodominance, the quantitation experiments performed with 
pooled tyrosinase, Melan-A and CDK4-R24C cRNAs demonstrated that peptides are 
abundant enough and should therefore minimise immunodominance. 
 
 
5.8 Dangers of autoimmunity associated with immunotherapy 
 
Some autoimmnune phenomena seem to be associated with certain tumours.  In some 
cases, antigen-specific immune responses have been described as the connection between 
malignancies and autoimmunity. 
 
Paraneoplastic neurologic disorders are autoimmune neuronal degenerations that develop 
in some patients with systemic cancer.  Such disorders are believed to be initiated when 
solid tumours (e.g. breast, ovarian, small-cell lung) present outside of the nervous system 
express neuronal proteins.  Darnell  proposed the following model (Darnell RB 1996).  
Antigens in question are normally expressed exclusively in neurons, both during 
development and adulthood.  Because of the blood-brain barrier and/or the 
immunologically privileged state of neurons, the immune system most probably ignores T-
cells specific for neuronal proteins.  When these proteins are expressed elsewhere in the 
body, i.e. in tumour cells, they are recognised by the immune system and specific T-cells 
are activated.  Anti-tumour responses based on these onconeural antigens may be followed 
Discussion 135
by the disruption of the blood-brain barrier or a change in the nature of the immune cells 
themselves.  This establishes autoimmune neurologic degeneration and brings patients to 
clinical attention.  There is a report regarding three patients with paraneoplastic 
neurological syndromes who experienced spontaneous regressions of small-cell lung 
carcinoma (Darnell RB and DeAngelis LM 1993). 
 
Wegener's granulomatosis is a systemic disease of unknown origin.  Autoimmune 
mechanisms and infection are suggested to play a role in its pathogenesis.  It is 
characterised by a necrotising vasculitis involving lungs, upper airways and kidneys.  
Autoantibodies against proteinase 3, also known as Wegener´s autoantigen, are closely 
associated with this disease (Kallenberg CG et al. 2002).  The close temporal association 
between RCC and Wegener´s granulomatosis suggests that the malignancy is, in some 
cases, a trigger for the development of the disease.  However, proteinase 3 was not found 
in malignant tissues of patients suffering from both RCC and Wegener´s granulomatosis 
(Tatsis E et al. 1999). 
 
Vitiligo is an autoimmune condition characterised by the loss of epidermal melanocytes.  
Otherwise healthy patients suffering from this disorder were examined for the presence of 
immunity against antigens associated with melanocytes.  Tyrosinase-specific autoanti-
bodies were detected in 77% of individuals with vitiligo (Song YH et al. 1994).  Another 
study showed that 77% had circulating CTLs specific for Melan-A (Ogg GS et al. 1998).  
This demonstrated that vitiligo is caused by autoimmune responses directed at the same 
antigens that are often used as targets in immunotherapy of melanoma.  Indeed, vitiligo is 
more frequent in melanoma patients where its development may be associated with an 
ongoing spontaneous or therapeutically induced immune response against this type of 
cancer.  Romero and colleagues found that Melan-A specific CTLs were expanded in 
tumour-infiltrated lymph nodes of melanoma patients with extremely high frequencies of 1 
in every 30 to 400 CTLs (Romero P et al. 1998).  Some of these patients had not received 
immunotherapy before the study was performed, indicating spontaneous T-cell priming.  
These Melan-A-specific CTLs displayed mostly an antigen-experienced phenotype and 
were capable of efficiently killing autologous tumour cells in vitro, providing direct 
evidence that an antigen-specific immune response had been triggered by the tumour.  
Similar results were obtained for the tyrosinase antigen.  The same group also examined 
Melan-A-specific CTLs in the circulation (Pittet MJ et al. 1999).  These cells were 
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detected in 77% of examined melanoma patients.  Their frequency of approximately 1 in 
every 1500 CTLs was somewhat lower, compared to that measured in tumour-infiltrated 
lymph nodes, but still significantly high.  Interestingly, just as many Melan-A specific 
CTLs were found in 60% of healthy controls.  Circulating CTLs specific for Melan-A 
displayed a naïve phenotype in healthy individuals and 70% of melanoma patients, 
whereas an experienced CTL phenotype was observed in the remaining 30% of patients.  
Vitiligo developed in 23% of the patients, probably not as a spontaneous response, but 
occurring after antigen-unspecific immunotherapy with different combinations of the 
cytokines IL-2, IFN-α and TNF-α.  The frequency of Melan-A-specific CTLs in patients 
with melanoma and vitiligo was 1 in every 430 CTLs.  Another study found no vitiligo in 
melanoma patients who remained unresponsive to IL-2 immunotherapy (Rosenberg SA 
and White DE 1996).  However, vitiligo was seen in 26% of melanoma patients who did 
react to the same therapy.  These findings provided evidence that the presence of growing 
melanomas can sensitise patients to melanocyte differentiation antigens and that the 
immune response against these antigens is associated with cancer regression in patients 
undergoing immunotherapy. 
 
Although paraneoplastic neurologic disorders, Wegener´s granulomatosis and vitiligo are 
unwanted side-effects or even harmful diseases, their association with tumours shows that 
the immune system is indeed capable of mounting strong responses against TAAs.  The 
responses can even be spontaneous or caused by antigen-unspecific immunotherapy.  
Unfortunately, these autoimmune conditions also indicate that efficient immune reactions 
to tumours can be dangerous because of autoimmune diseases that may accompany them.  
DC-based tumour immunotherapy is likely to generate immune responses more powerful 
than those induced spontaneously.  Depending on the approach, either total cellular 
antigenic repertoires or well-defined individual self-antigens are used.  This justifies the 
question, whether an improved efficiency of immunotherapy results in an even higher risk 
of autoimmunity. 
 
Highly tumourigenic and poorly immunogenic mice were vaccinated with irradiated GM-
CSF-transduced melanoma cells and antibodies blocking CTLA-4 (cytotoxic T-
lymphocyte associated protein 4).  The treatment was effective, but 56% of the animals 
developed vitiligo, starting at the site of vaccination and in most cases progressing to 
distant locations.  Depigmentation occurred in T-helper cell-depleted mice, strongly 
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suggesting that the effect was mediated by CTLs (van Elsas A et al. 1999).  Bondanza and 
colleagues also demonstrated potentially dangerous effects of vaccination against self-
antigens (Bondanza A et al. 2003).  DCs that phagocytosed autologous apoptotic cells 
were injected into healthy mice, genetically predisposed or not to the development of 
autoimmunity.  In all vaccinated mice, high titres of anti-nuclear and anti-dsDNA 
autoantibodies were found.  In normal mice, these antibodies progressively disappeared 
and did not cause autoimmune disease or tissue damage.  In contrast, predisposed animals 
developed progressive and eventually lethal autoimmunity.  In the study, DCs were pulsed 
with total cellular preparations that contained whole repertoires of expressed antigens, an 
approach similar to transfecting total cellular RNA into DCs.  Whereas the existence of 
autoimmune reactions was confirmed, it was also observed that these reactions were 
transient in healthy mice.  Therefore, the group concluded that autoantibody responses in 
treated patients may go undetected and that it should be relatively safe to use DCs pulsed 
with total cellular antigenic repertoires in vaccination.  Potent anti-tumour immunity was 
observed in the absence of detectable autoimmunity in mice vaccinated with only 
irradiated GM-CSF tranduced melanoma cells (Dranoff G et al. 1993), with DC-derived 
exosomes (Zitvogel L et al. 1998) and with DCs pulsed with total cellular RNA from 
ovalbumin-expressing tumour cells (Boczkowski D et al. 1996).  
 
In humans, autoreactivity of CTLs primed with total cellular RNA-pulsed DCs was 
investigated thoroughly by Heiser and colleagues (Heiser A et al. 2001a).  In their RCC 
model in vitro, DCs transfected with renal tumour RNA stimulated CTLs capable not only 
of killing autologous tumour cells, but also recognising antigens expressed by tumour cells 
from other RCC patients.  The same CTLs did not react against autologous DC-targets that 
were transfected with either autologous or allogeneic RNA derived from normal tissue. 
This demonstrated that primed CTLs were indeed tumour-specific.  Furthermore, foreign 
RNA, which included message for non-matched HLA molecules, did not induce 
alloreactive CTL responses after transfection into autologous DCs.  In the context of 
vaccination strategies, antigens in the form of allogeneic tumour RNA may represent an 
attractive alternative because well-characterised and generic vaccines could substitute for 
expensive and time-consuming individual approaches.  As a control, the group transfected 
DCs with RNA from normal tissues.  CTLs primed by these DCs lysed neither tumour nor 
normal tissue targets.  These data indicated that harmful autoimmunity with pathological 
consequences may not be a serious issue with this approach, even though self-antigens 
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might be presented in a highly stimulatory manner.  After vaccination of RCC patients 
with total cellular tumour RNA-pulsed DCs, enhanced reactivity against RCC antigens was 
reported (Su Z et al. 2003).  Even though there was minor reactivity of vaccine-induced T-
cells against benign renal tissue, neither deterioration of renal function nor increases of 
autoimmune parameters were observed in the patients. 
 
A similar study was performed with prostate cancer.  DCs transfected with total cellular 
RNA from this tumour stimulated CTLs which not only recognised tumour-antigens, but 
also antigens expressed by normal prostatic tissue.  Interestingly, these responses were 
exclusively directed against PSA shared between malignant and nonmalignant tissue.  
Other shared antigens were either insufficiently expressed by normal prostate cells or they 
contained only epitopes subdominant to PSA.  In this particular case, the group evaluated 
the risk of autoimmunity as acceptable since prostates are nonessential for life (Heiser A et 
al. 2001b).  When prostate cancer RNA-pulsed DCs were applied in a clinical trial, modest 
anti-tumour effects were suggested in the patients and no dose-limiting toxicity or adverse 
effects, including autoimmunity, were observed (Heiser A et al. 2002).  
 
Even if DCs are pulsed with mixtures of self-antigens, the rules of immunodominance 
ensure that not all antigens will be efficiently presented and that their presentation will not 
necessarily generate strong T-cell responses, depending on the frequency and the avidity of 
antigen-specific T-cells and their competition for different factors associated with DCs 
pulsed with antigenic mixtures.  However, quantitative differences in expression between 
usually over-expressed or re-expressed TAAs versus other self-antigens that are not over-
expressed may permit more successful activation of TAA-specific T-cells.  Mutated TAAs, 
that can no longer be classified as self-antigens, might have the advantage of winning the 
competition and becoming immunodominant, while still allowing the development of 
somewhat weaker responses against some subdominant TAAs.  Based on these 
considerations, Gilboa concluded that most self-antigens should be underrepresented in a 
tumour-specific T-cell population.  Furthermore, contrary to popular belief, vaccination 
with patient-specific tumour-derived antigenic mixtures may not only be more effective 
than vaccination with single shared tumour self-antigens, but may also entail a reduced risk 
of autoimmunity (Gilboa E 2001). 
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Immunotherapeutic approaches directed at multiple TAAs are likely to be more effective 
than strategies targeting individual TAAs.  However, using a single antigen eliminates 
competition and potentially increases the strength of the immune response against this 
antigen, compared to simultaneous responses against different antigens.  Depending on the 
antigen chosen, this may cause not only stronger tumour immunity, but also autoimmunity. 
 
Immunisation of rats with a viral vector expressing human PAP (prostatic acid 
phosphatase), an antigen uniquely expressed in prostatic tissue and prostate cancer, 
generated a CTL response and destructive autoimmune prostatitis.  A vector expressing rat 
PAP induced no immunity (Fong L et al. 1997).  The study performed by Ludewig and 
colleagues (Ludewig et al. 2000) is also often cited in discussions about autoimmunity 
caused by immunotherapy against tumours.  The mice they vaccinated developed life-
threatening autoimmune diabetes and cardiovascular disease.  It has to be noted that this 
immunotherapy targeted antigens that were selectively expressed in essential organs based 
on transgenes.  Therefore, conclusions about the connection between immunotherapy and 
autoimmunity were drawn from a highly artificial model situation in which antigens with 
known distribution were chosen.  Nevertheless, this study is a good example of a worst-
case scenario, stressing the necessity of careful antigen selection in immunotherapy.  In 
other transgenic mouse models, no autoimmune phenomena were detected.  After 
vaccination, tumour cells expressing high levels of influenza virus hemagglutinin were 
rejected in mice, but pancreatic cells engineered to selectively express the same antigen 
were not destroyed (Morgan DJ et al. 1998).  Even though skin eptihelial cells in 
transgenic mice expressed the viral E7 antigen, the skin remained unaffected after 
immunisation with the E7 peptide.  These mice were protected against subsequent 
challenge with tumour cells expressing a transfected E7 gene (Melero I et al. 1997).  When 
CTLs specific for a viral envelope protein were adoptively transferred into mice with 
lymphoid cells selectively expressing this protein, tumour cells positive for the same 
antigen were eradicated, but no detectable autoimmune damage to the lymphoid tissue was 
induced (Hu J et al. 1993).  The tumour suppressor protein p53 is over-expressed in close 
to 50% of all human malignancies.  Mice immunised with murine p53-overexpressing 
tumour cells completely rejected this tumour upon challenge.  No demonstrable damage to 
normal tissue was observed (Vierboom MP et al. 1997). 
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Based on some data, the development of vitiligo was associated with vaccination against 
individual MAAs.  However, there are other studies that found no such correlation.  
Immunisation of mice with purified murine TRP-1, a melanocyte differentiation antigen, 
failed to induce antibody or CTL responses, but when human TRP-1 was used, mice 
rejected metastatic melanomas and developed vitiligo (Naftzger C et al. 1996).  Skin 
depigmentation and melanocyte destruction were also observed in mice inoculated with a 
viral vector encoding murine TRP-1 (Overwijk WW et al. 1999).  However, mice 
vaccinated with either a plasmid or a viral vector encoding murine TRP-2 rejected the 
melanoma tumour and did not develop generalised vitiligo (Bronte V et al. 2000).  
Vaccination of mice with TRP-2 peptide-loaded DCs also resulted in protective antitumour 
immunity, but only minor depigmentation restricted to the vaccination site was seen, 
despite the observed CTL-mediated melanocyte destruction in vitro (Schreurs MW et al. 
2000).   
 
In vitro, CTLs usually kill isolated normal cells with the same efficiency that they kill 
tumour cells.  Nevertheless, experimental data presented above strongly indicate that 
structured normal tissues and tumour masses in vivo display different susceptibilities to 
effector cells of the immune system.  Therefore, Gilboa concluded that vaccination against 
individual self-antigens expressed in tumour cells should be capable of inducing 
therapeutic immunity in the absence of devastating autoimmune consequences.  However, 
increasing the effectiveness and/or intensity of vaccination with a self-antigen could result 
in mild to serious autoimmune pathology.  Careful selection of TAAs is the safest solution 
to this problem.  Good candidates can be found in the group of antigens that are expressed 
in immunoprivileged sites and are reactivated in cancer cells (e.g. MAGE) and in the group 
of fetal and embryonic antigens that are re-expressed in cancer cells (e.g. CEA and 
oncofetal antigen).  Most importantly, since tumour cells themselves are not able to shuttle 
their own antigens to the secondary lymphoid organs, professional APCs are necessary to 
activate the naïve and the memory T-cells.  For that reason, it should be possible to control 
unwanted autoimmune reactions by simply stopping vaccination (Gilboa E 2001). 
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5.9 Conclusions and prospects 
 
Even though RNA is rapidly degraded and, therefore, difficult to work with, 
electroporation of RNA encoding TAAs was confirmed to be a highly efficient method of 
introducing antigens into DCs in order to improve their presentation to the immune system.  
It is unclear whether RNA should be electroporated into DCs of an immature or mature 
stage.  Whereas these studies indicated that in vitro mature DCs express more antigen than 
immature DCs, allowing transfected DCs to mature in situ may prove to be a good  
compromise between initial manipulation ex vivo and subsequent adaptation in vivo.  
Kinetic studies demonstrated that after electroporation there is an initial surge in antigen 
expression which subsequently decreases, depending on transfected RNA degradation and 
protein half-life.  Therefore, considering the right time-frame for T-cell activation by 
engineered DCs might be advantageous in designing immuntherapeutic strategies.  
Quantitation experiments explained the significantly different stimulatory capacities of 
DCs pulsed with total cellular tumour RNA and single-species tumour-antigen cRNAs.  
Transferring more antigen message into DCs indeed resulted in higher antigen expression, 
better epitope presentation and stronger T-cell stimulation.  Amplification of total cellular 
RNA samples increased the proportions of TAAs that have higher expression levels in the 
tumour and, thereby, enhanced their presentation, but a normally-expressed mutated TAA 
was hardly amplified in RT-PCR and, consequently, only weakly presented.  If 
immunogenic TAAs are not known in a tumour model, total cellular RNA is the only 
source of antigenic material than can be utilised.  Single-species RNAs encoding identified 
TAAs not only guarantee stronger T-cell stimulation, but also allow fine-tuning of immune 
responses by adjusting antigenic sequences and combining antigens.  RNA coding for a 
protein fused with a signal sequence was described to induce tumour epitope presentation 
not only to CTLs but also to T-helper cells.  Priming of T-cells against more than one 
antigen is necessary to minimise the effects of potential tumour escape from immune 
surveillance.  Electroporation with a combination of RNAs encoding different TAAs was 
shown to stimulate CTLs on levels only slightly lower than those achieved with individual 
RNAs alone, indicating that possible competition of antigens inside the DCs did not inhibit 
T-cell responses.  It remains to be seen whether pooling RNAs before transfection or 
mixing individually-transfected DCs before vaccination helps avoid immunodominance 
due to competition between T-cells.  Having established and discussed approaches to 
enhance TAA presentation and T-cell activation, the risk of autoimmunity associated with 
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immunotherapy requires attention.  Examples from the literature indicate that vaccination 
against TAAs, most of which are self-antigens, may not be as dangerous as previously 
postulated. 
 
The described methodology was optimised and thoroughly explained in the context of 
immunology and cellular biology.  This was only possible in a well-defined system with 
highly sensitive antigen-specific CTL clones.  Further research should show if the 
observed quantitative differences in antigen presentation have an impact on priming of 
immune responses in vitro and subsequently in vivo, as another small step is made in 
mobilising the immune system to fight cancer. 
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6. Summary 
 
In situations where well-established approaches such as surgery, radiation therapy and 
chemotherapy fail to help cancer patients, immunotherapy has the potential to be an 
effective alternative.  Tumour cells can sometimes be distinguished from corresponding 
normal cells due to their expression of tumour-associated antigens (TAAs), most of which 
are unaltered self-molecules.  These molecules must be presented to the immune system in 
the context of danger in order to achieve their specific recognition.  If dendritic cells 
(DCs), the most potent professional antigen-presenting cells, are loaded with RNA, they 
will translate the RNA into protein, process the protein into peptides and present the 
peptides within MHC molecules (pMHC) on their surface to cytotoxic T-lymphocytes 
(CTLs) and T-helper cells in a stimulatory manner.  These effector cells can, in turn, 
recognise tumour cells.  The goal of these studies was to find optimal conditions for 
producing a DC-based vaccine for cancer patients using TAAs in the form of RNA.  The 
studies were designed to quantitate RNA transfer into DCs, to determine the intracellular 
stability of transfected RNA in DCs and to analyse the kinetics of protein expression and 
the generation of functional pMHC ligands that could activate effector memory CTLs.  
Simultaneous activation of CTLs with specificities for different antigens minimises the 
potential for tumour escape through immune selection of tumour variants showing loss of 
individual antigens.  Thus, generation of multiplex pMHC ligands for CTLs may improve 
clinical efficiency.  On the other hand, peptide competition for MHC molecules within the 
DC may limit pMHC ligand generation.  This central immunological question was 
addressed by comparing DCs loaded with total cellular tumour RNA, amplified total 
cellular tumour mRNA and pools of defined single-species tumour-antigen cRNAs versus 
individual single-species tumour-antigen cRNAs for their capacity to display various 
pMHC ligands and activate CTLs of corresponding specificities.   
 
Experiments performed with RNA encoding the enhanced green fluorescence protein 
(EGFP), a reporter protein, showed that the highest efficiency of RNA transfection into 
DCs was achieved with electroporation, reaching levels of 90% positive cells.  The fact 
that mature DCs expressed more EGFP than immature DCs suggests that this stage of DC 
maturation will be optimal for vaccine development.  Importantly, electroporation and 
RNA transfer did not alter the expression of antigen-presenting and co-stimulatory 
molecules on the surface of DCs. 
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The melanoma model was chosen for extensive analyses because its characterisation at the 
cellular and molecular levels has made it a very informative model for understanding 
cancer immunity.  In addition to total cellular melanoma RNA, single-species cRNAs were 
used encoding the melanoma-associated antigens, tyrosinase, Melan-A and CDK4-R24C.  
Antigen presentation was detected with the help of effector memory CTL clones specific 
for each of these antigens.  The CTL stimulatory capacity of RNA-transfected DCs was 
higher if they were allowed one day to recuperate from electroporation and to produce 
pMHC complexes.  Tyrosinase cRNA dose-finding showed that more RNA would indeed 
result in higher stimulatory capacities of transfected DCs.  Kinetics of tyrosinase cRNA 
degradation, similar to kinetics of EGFP cRNA degradation, revealed that the amount of 
transfected RNA rapidly decreased inside the DCs within 1.5 hr after electroporation.  The 
smallest decrease was observed with the highest amount of RNA applied in 
electroporation.  The kinetics of RNA degradation and protein half-life will be important 
parameters to consider in defining the right time-frame for T-cell activation by engineered 
DCs.  When reverse transcription PCR (RT-PCR) was performed with total cellular 
melanoma RNA samples to generate amplified mRNA, the Melan-A, tyrosinase and 
CDK4/CDK4-R24C message was amplified 62-fold, 24-fold and 2-fold, respectively.  
These differences likely reflect variations in the expression levels of the corresponding 
antigen message in melanoma cells from which the RNA was isolated.  Approximately 
17240-fold more CDK4-R24C message, at least 500-fold more tyrosinase message and at 
least 480-fold more Melan-A message was found in single-species cRNAs when the same 
masses of single-species cRNA and amplified melanoma mRNA samples were compared.  
This explained why electroporation of single-species cRNAs into DCs yielded the highest 
DC stimulatory capacities.  Combinations of tyrosinase, Melan-A and CDK4-R24C 
cRNAs were studied for their capacity to induce satisfactory levels of T-cell stimulation 
when presented by DCs.  Here it was demonstrated that antigen competition was not a 
critical factor, since CTL responses to pooled RNAs were not inhibited even though 
competition for MHC class I molecules may have occurred within the DCs.  DCs also 
developed CTL stimulatory capacities, but at much lower levels, using amplified 
melanoma mRNA.  Two antigen-specific CTL clones displayed higher reactivities upon 
exposure to pMHC produced naturally by RNA-transfected DCs than to synthetic peptides 
pulsed onto DCs.  In one case, this could be explained by a post-translational modification 
of the peptide, which normally occurs within cells.  Since this particular modification was 
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not represented in the synthetic peptide, which was chosen from the protein sequence, the 
synthetic peptide was not well recognised.  This demonstrated that the use of RNA 
technology eliminates the need to know the correct sequences of immunogenic peptides.  
Thereby, DCs are better than scientists at choosing antigens and their epitopes for 
presentation to T-cells. 
 
These data provided a better understanding of antigen presentation by DCs based on the 
use of RNA, giving insight into antigen competition and paving the way for the use of 
pooled RNAs of defined species for the development of a multiplex vaccine.  They also 
allowed a precise protocol for efficient T-cell activation to be defined.  Further 
experiments will demonstrate whether quantitative differences detected in antigen 
presentation between DCs loaded with total cellular tumour RNA and amplified total 
cellular tumour mRNA versus single-species tumour-antigen cRNAs have an impact on de 
novo T-cell priming in vitro and in vivo. 
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8. Abbreviations 
 
Ag   antigen 
APC   antigen-presenting cell 
APL   altered peptide ligand 
bp   base pair 
CAMEL  CTL-recognised antigen on melanoma 
CCR   chemokine (CC motif) receptor 
CD   cluster of differentiation 
CD40L  CD40 ligand 
CDC27  cell division control 27 
CDK4   cyclin-dependent kinase 4 
cDNA   complementary DNA 
CEA   carcinoembryogenic antigen 
cFLIP   cellular FLICE-inhibitory protein 
cRNA   complementary RNA 
CTL   cytotoxic T-lymphocyte 
CTLA-4  cytotoxic T-lymphocyte associated protein 4 
DC   dendritic cell 
DC-SIGN  DC-specific ICAM-grabbing nonintegrin 
DEPC   diethyl pyrocarbonate 
DNA   deoxyribonucleic acid 
DNase   deoxyribunuclease 
DMSO  dimtehyl sulfoxide 
dsDNA  double-stranded DNA 
dsRNA  double-stranded RNA 
EDTA   ethylendiamino-tetra-acetate 
elp.   electroporation or electroporated 
ER   endoplasmic reticulum 
EGFP   enhanced green fluorescence protein 
ELISA   enzyme-linked immunosorbent assay 
Fab   fragment antigen binding 
FACS™  fluorescence-activated cell sorter 
Fc   fragment crystallisable 
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FcR   Fc receptor 
FITC   fluorescein isothiocyanate 
GFP   green fluorescence protein 
GM-CSF  granulocyte macrophage colony stimulating factor 
gp   glycoprotein 
GnT-V  beta 1,6-N-acetylglucosaminyltransferase V 
HIV   human immunodeficiency virus 
HLA   human leukocyte antigen 
HSP   heat-shock protein 
iDC   immature DC 
IFN   interferon 
Ig   immunoglobulin 
IL   interleukin 
LAMP-1  lysosome-associated membrane protein 1 
LDLR   low density lipoprotein receptor 
LMP   low molecular protein 
LPS   lipopolysaccharide 
MIIC   MHC class II compartment 
MAA   melanoma-associated antigen 
MAGE  melanoma antigen gene 
MART-1  melanoma antigen recognised by T-cells 1 
mDC   mature DC 
Melan-A  melanoma antigen A 
MFI   mean fluorescence intensity 
MIC   MHC class I chain-related gene 
MIF   macrophage migration inhibitory factor 
MMR   macrophage mannose receptor 
mRNA  messenger RNA 
NK   natural killer 
NKT   natural killer T 
OX-40L  OX40 ligand 
PAP   prostatic acid phosphatase 
PBMC   peripheral blood mononuclear cells 
PBS   phosphate buffered saline 
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PCR   polymerase chain reaction 
pDNA   plasmid DNA 
PE   phycoerythrin 
PGE2   prostaglandin E2 
pMHC   peptide-MHC 
PRAME  preferentially expressed antigen of melanoma 
PSA   prostate-specific antigen 
RCC   renal cell carcinoma 
RNA   ribonucleic acid 
RNase   ribonuclease 
rpm   rotations per minute 
rRNA   ribosomal RNA 
RT   reverse transcriptase 
RT-PCR  reverse transcription PCR 
ru   relative unit 
TAA   tumour-associated antigen 
TAE   tris acetate EDTA 
TAP   transporter associated with antigen processing 
TBE   tris borate EDTA 
TCR   T-cell receptor 
TGF   transforming growth factor 
TIL   tumour-infiltrating lymphocyte 
TLR   Toll-like receptor 
TNF   tumour necrosis factor 
TRAIL  TNF-related apoptosis-inducing ligand 
tRNA   transfer RNA 
TRP   tyrosinase related protein 
UV   ultraviolet 
VEGF   vascular endothelial growth factor 
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